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Abstract 
Natural products have traditionally played an important role in drug discovery 
research.  They have been particularly important in the search for therapies for 
neurodegenerative diseases.  Although there are numerous forms of neurodegenerative 
diseases, the disorders associated with protein misfolding (e.g. Alzheimer’s, Parkinson’s, 
Huntington’s and prion diseases) represent a unique area for natural products drug 
discovery as these diseases share many pathological features, suggesting that therapies 
developed for any one of these diseases may have applications for the others.  There have 
been many reports of secondary metabolites with biological activities related to 
neurodegeneration associated with protein misfolding, and emerging drug targets for 
these diseases are fueling interest in finding natural products which can serve as leads for 
therapeutic development.  The literature surrounding the topic of natural products and 
neurodegenerative disease has been summarized in the first chapter of this dissertation. 
Although there have already been many natural products identified as potential 
therapeutic leads for neurodegenerative diseases, there is still a significant need for the 
enhancement of methodologies used for bioassay screening of secondary metabolites.  
Metabolomic approaches to drug discovery have the potential to combine the advantages 
of phenotypic disease models and molecular target assays.  The metabolomic 
examination of a phenotypic disease model can provide detailed information concerning 
the molecular target and/or the mechanism of action of a compound while simultaneously 
revealing its phenotypic effects.  The third chapter of this dissertation describes the 
metabolomic examination of a phenotypic model of Huntington’s disease.  This detailed 
exploration of the metabolic changes associated with mutant huntingtin toxicity has 
xiii 
 
revealed many intriguing new insights into the specific processes which are involved in 
the cellular response to protein aggregation.  The results in this chapter show that the 
metabolic response of cells to mutant huntingtin can be detected using a metabolomic 
approach and that these metabolic changes can be used to identify potential therapeutic 
targets for Huntington’s disease.  These results also show the importance of the 
metabolites alanine, glutamine, glycerol and valine in the metabolic response to mutant 
huntingtin in multiple species.  This work provides the foundation for the future 
development of a metabolomic-based drug discovery platform for natural products. 
In the fourth chapter of this dissertation, the use of metabolic profiling to examine 
the protective role of the metabolite trehalose is described.  Trehalose is a disaccharide 
that has been previously identified as having therapeutic implications for 
neurodegenerative diseases.  In order to explore the role that trehalose plays in the yeast 
model of Huntington’s disease, a series of yeast strains with gene deletions for each step 
in the metabolic cycle of trehalose were engineered to express normal and mutant 
huntingtin protein fragments.  One of these gene deletion strains, deficient in the 
production of the acid trehalase protein, exhibited a prounouced reduction in the toxicity 
associated with mutant huntingtin, the aggregation of mutant huntingtin and the 
elimination of the metabolic aberrations associated with mutant huntingtin expression. 
This investigation of the role of trehalose in the yeast model of Huntington’s disease 
provides evidence for the therapeutic potential of the manipulation of chemical chaperone 
systems in mammalian cells. 
The final chapter of this dissertation diverges from the topic of neurodegeneration 
and instead describes the isolation and characterization of a series of briarane diterpenes 
xiv 
 
from a Briareum sp. of octocoral.  The ichthyotoxic properties of these compounds are 
described as well as their metabolic transformation by fish.  The scientific merits of this 
study make it an important and significant part of my doctoral research and demonstrate 
the multidisciplinary nature of my research. 
1 
Chapter 1 The emerging role of natural products for the treatment of 
neurodegenerative diseases associated with protein misfolding 
1.1 Introduction 
Neurodegenerative diseases caused by misfolded proteins have become a 
significant problem in developing countries as life expectancies continue to rise.  Today 
millions of people suffer from neurodegenerative diseases such as Alzheimer’s, 
Parkinson’s, Huntington’s and prion diseases (Farooqui and Farooqui 2009; Stefani 
2007). These disorders share many common pathological features, including the 
formation of protein aggregates in the brain, dysregulation of cell signaling, oxidative 
stress, inflammation, and apoptosis (Amor, et al. 2010; Davies, et al. 2006; Skovronsky, 
et al. 2006).  The search for new therapies for these conditions is urgent since there are 
currently no effective treatments available to halt or reverse their progress (Scatena, et al. 
2007).   
The United States National Institute of Neurological Disorders and Stroke 
(NINDS) estimates that over 4.5 million people suffer from these diseases in the U.S. 
alone (NINDS 2010), and there are many millions more suffering in other countries 
around the world (Figure 1.1).  Alzheimer’s disease is the most common of these 
neurodegenerative conditions, with an estimated 4 million diagnosed cases in the U.S.  
Parkinson’s disease is the second most common with around half a million diagnosed 
cases.  Huntington’s disease and prion diseases are much rarer, but the crippling and fatal 
effects of these diseases are no less severe for those suffering from them.  Because of the 
millions of people affected by these diseases, there is considerable work underway to 
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search for new therapies for 
patients with these disorders 
(Cornelis, et al. 2007; Gilgun-
Sherki, et al. 2006; Gold and 
Villafranca 2003; Lleo 2007; 
Planells-Cases, et al. 2006; 
Scatena, et al. 2007; Van der 
Schyf, et al. 2006; Van der 
Schyf, et al. 2007). 
Natural products are expected to play a significant role in the search for 
neurodegenerative disease therapeutics since historically secondary metabolites have 
been an excellent source for the development of small molecule therapeutics (Butler 
2004; Newman 2008; Newman and Cragg 2007).  The unique combination of novel 
chemical space occupied by natural products coupled with their potent bioactivities has 
made them an attractive resource for drug discovery.  Neurodegenerative diseases pose a 
particularly difficult problem for drug discovery efforts since the mechanisms of many of 
these diseases are still not clearly understood.  The exceptional properties of natural 
products make them excellent tools for answering the difficult problems posed by drug 
discovery efforts for neurodegenerative disorders.  Two molecules have already 
demonstrated the potential of natural products for treating neurodegenerative disease: 
galanthamine (1) and huperzine A (2).  Both of these compounds inhibit the enzyme 
acetylcholinesterase and are in clinical use for the treatment of Alzheimer’s disease 
(Dong, et al. 2009; Heinrich and Lee Teoh 2004).   
Alzheimer’s
4,000,000
Parkinson’s
500,000
Huntington’s
15,000
Prion
300
Prevalence of neurodegenerative 
disorders in the United States
Figure 1.1 Estimated prevalence of neurodegenerative 
diseases associated with protein misfolding in the United 
States. Data from the United Stated National Institutes of 
Health, National Institute of Neurological Disorders and 
Stroke. 
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A small number of review articles have 
appeared previously summarizing discoveries in 
natural products limited to Alzheimer’s and 
Parkinson’s disease (Houghton and Howes 2005) or 
the very broad topic of biological activity in the 
central nervous system with little space given to 
neurodegenerative diseases  (Clement, et al. 2004; 
Gomes, et al. 2009).  Somewhat more common have 
been reviews of natural products discoveries related to 
a single biological target for neurodegenerative 
disease, such as acetylcholinesterase (Barbosa Filho, 
et al. 2006; Jung and Park 2007; Loizzo, et al. 2008; 
Orhan, et al. 2009; Viegas Jr, et al. 2005) or neurotrophins (Ohizumi, et al. 2004; Tohda, 
et al. 2005).  There have also been reviews of specific classes of compounds such as the 
flavonoids and polyphenols and their biological activities pertaining to neurodegeneration 
(Bastianetto, et al. 2007; Patel, et al. 2008; Vafeiadou, et al. 2007).  However, there has 
never been a comprehensive review of the natural products literature that summarizes the 
data concerning protein aggregation related neurodegenerative diseases.  This review 
summarizes the literature pertaining to bioactive natural products and their primary 
application to neurodegenerative diseases associated with protein misfolding.  
Compounds with very broad or non-specific bioactivities, such as antioxidants, have been 
excluded since their therapeutic applications are limited.  Instead this review is focused 
on summarizing the role of natural products in drug discovery efforts for established as 
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well as emerging targets for neurodegenerative diseases.  The following sections will 
provide a brief introduction to each disease followed by a summary of natural products 
discoveries related to therapeutic targets specific for each disease. 
1.2 Alzheimer’s disease 
Alzheimer’s disease (AD) is characterized by the presence of insoluble amyloid 
plaques in the extracellular region between neurons; these plaques consist primarily of 
the β-amyloid (Aβ) peptide, the aggregation-prone agent that is central to AD 
neuropathology (Pallas and Camins 2006).  The misfolding and aggregation of Aβ is 
believed to lead to disruption of normal neuronal functions, including decreased 
production and altered regulation of neurotransmitters and neurotrophins, mitochondrial 
dysfunction, oxidative stress, inflammation, and tau hyperphosphorylation (Pallas and 
Camins 2006; Querfurth and LaFerla).  The combined effects of these problems lead to 
the degeneration of cholinergic neurons, especially in the hippocampus, which results in 
the primary symptom of AD (i.e. memory loss) (Pallas and Camins 2006; Querfurth and 
LaFerla). 
Because AD is caused by such a multi-faceted collection of disrupted cellular 
processes, there are many potential therapeutic targets for this disease.  It has even been 
proposed that drug discovery efforts would benefit from a polypharmacological approach 
that modulates multiple targets (Van der Schyf, et al. 2006; Van der Schyf, et al. 2007).  
In the following sections, the reported activities of natural products against a variety of 
AD targets have been summarized.  In some cases these targets are specific enzymes, in 
others the target is simply the general alleviation of toxic agents associated with AD.  The 
relevant biological activity and structural features are discussed in each case. 
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1.2.1 Acetylcholinesterase inhibitors.  Natural products with inhibitory activity 
against cholinesterases, such as physostigmine (3), have been known since the 1920’s 
(Triggle, et al. 1998), although it wasn’t until later in the 20th century that these 
compounds began to receive attention as potential therapeutics for AD (Orhan, et al. 
2009).  The therapeutic effect of these compounds for AD is due to the increase in 
concentration of the neurotransmitter acetylcholine at the synapse, which is normally 
deactivated by the enzyme acetylcholinesterase (Lleo 2007).  Acetylcholinesterase 
inhibitors are commonly used to treat AD; the natural product galanthamine (1), 
originally isolated from Galanths spp. of plants, is an approved therapy for AD in the 
United States and Europe as well as many other countries (Heinrich and Lee Teoh 2004).  
Huperzine A (2) is another well known acetylcholinesterase inhibitor which was 
originally isolated from Huperzia serrata, a plant with traditional use in Chinese folk 
medicine (Yuan, et al. 2008).  It has entered clinical use in China and is being developed 
for use in other countries (Dong, et al. 2009).  The activity of 2 and other naturally 
occurring inhibitors of acetylcholinesterase have been thoroughly reviewed elsewhere 
(Barbosa Filho, et al. 2006; Jung and Park 2007; Loizzo, et al. 2008; Orhan, et al. 2009; 
Viegas Jr, et al. 2005; Yuan, et al. 2008; Zangara 2003). 
1.2.2 Kinase inhibitors (Cdk5 and Gsk3).  Two protein kinases have been 
implicated in AD, cyclin dependent kinase 5 (Cdk5) and glycogen synthase kinase 3 
(Gsk3), both of which are promising targets for the development of new therapies against 
AD.  Although Gsk3 has multiple functions, it is known to play an important role in the 
phosphorylation of tau and in the production of Aβ; inhibition of Gsk3 has also been 
shown to decrease the production of Aβ in a mouse model of AD (Giese 2009; 
6 
Hernandez and Avila 2008).  Cdk5 is essential for neuronal development, but its function 
in adults is not as clear (Liu, et al. 2007).  It has been shown that Cdk5 phosphorylates 
both tau and the amyloid precursor protein (APP), leading to the formation of 
neurofibrillary tangles (NFT’s) and increased production of the toxic Aβ peptide (Liu, et 
al. 2007).  Inhibitors of Gsk3 and Cdk5 have exciting potential as targets for the 
treatment of AD and several promising natural products leads have been identified. 
Hymenialdisine (4), marine sponge metabolite, was identified as an extremely 
potent inhibitor of both Gsk3 (IC50 = 10 nM) and Cdk5 (IC50 = 28 nM) (Meijer, et al. 
2000).  A variety of structurally related compounds were also tested against a series of 
kinases in the same study, but 4 was significantly more potent than all of the other 
compounds. 
The manzamines are a series of marine sponge alkaloids with impressive activity 
as inhibitors of Gsk3 and Cdk5 (Hamann, et al. 2007).  Manzamine A (5), 8-
hydroxymanzamine A (6), manzamine E (7), manzamine F (8), manzamine Y (9), and the 
unique manzamine dimer, neo-kauluamine (10) all inhibit Gsk3 in vitro at a 
concentration of 25 µM (Cheng, et al. 2006; El Sayed, et al. 2001).  Manzamine A also 
inhibits Cdk5 (IC50 = 1.5 µM) and decreases tau phosphorylation in human 
neuroblastoma SH-S5Y5 cells (Hamann, et al. 2007).  Compounds 5-10 all inhibited 
Gsk3 in vitro, but in a cell-based assay only 5 and 6 inhibited Gsk3 (Cheng, et al. 2006).  
None of the manzamines are active against acetylcholinesterase or β-secretase (BACE1), 
nor do they protect SH-SY5Y cells against oxidative-stress induced death (Cheng, et al. 
2006).  Manzamine A (5), B (11), C (12) and D (13) exhibit low micromolar anti-
inflammatory activity, but 7 and 8 do not (Mayer, et al. 2005).  A recent molecular 
7 
docking study also suggests that 6 binds to the ATP-noncompetitive pocket of Gsk3 
(Peng, et al. 2010).   
1.2.3 β-amyloid toxicity.  Because of its central role in AD pathogenesis, several 
models of AD based upon Aβ induced toxicity have been developed.  These include 
rodent and insect models as well as cell culture models (Bateman and Chakrabartty 2004; 
Bloom, et al. 2005; Iijima and Iijima-Ando 2008).  Some of these models transgenically 
express the amyloid precursor protein (APP), which is then cleaved by a series of 
secretases to form toxic Aβ, while other models utilize Aβ peptide infused into cultured 
4 
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8 
cells or rodent brains.  These models accurately recapitulate many of the pathological 
features of AD, such as neurotoxicity, apoptosis, formation of amyloid plaques, tau 
hyperphosphorylation, and memory loss (Bateman and Chakrabartty 2004; Bloom, et al. 
2005; Iijima and Iijima-Ando 2008). 
Akebia saponin D (14), isolated from the plant Dipsacus asperoides, protects 
PC12 cells from toxicity associated with Aβ treatment at concentrations as low as 0.1 
µg/mL (Ouyang, et al. 2009).  Treatment with 14 also decreases the influx of Ca2+ into 
the Aβ treated cells, decreases the amount of lactate dehydrogenase released by the cells 
and reduces the morphological defects caused by Aβ treatment of PC12 cells (Ouyang, et 
al. 2009).  
Two compounds, withanamide A (15) and C (16), isolated from the fruit of the 
Ayurvedic plant Withania somnifera, protect PC12 cells against toxicity induced by Aβ 
treatment (Jayaprakasam, et al. 2009).  Compound 15 significantly protects cells against 
14 
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Aβ toxicity at a concentration of 50 µg/mL, but 16 has no significant effect on cell 
viability.  The authors suggest that the difference in activity is due to the unique way in 
which the unsaturated hydrophobic side chain of 15 binds to the active motif of the Aβ 
peptide (Jayaprakasam, et al. 2009).   
Eight iridoid glycosides, isolated from Gardenia jasminoides, enhance the short-
term memory in a transgenic Aβ Drosophila model of AD (Hong, et al. 2009).  
Compounds including  6′-O-trans-p-coumaroylgeniposide (17), 10-O-
succinoylgeniposide (18), 6′-O-acetylgeniposide (19), 6′-O-trans-sinapoylgeniposide 
(20), geniposide (21), 10-O-acetylgeniposide (22), 11-(6-O-trans-
sinapoylglucopyranosyl)gardendiol (23), and 10-(6-O-trans-
sinapoylglucopyranosyl)gardendiol (24) all significantly enhance the performance index 
of flies expressing human Aβ42 in an assay testing the short-term memory of the flies 
(Hong, et al. 2009).  The compounds were administered to the flies in a 4% sucrose 
solution at a concentration of 0.00076 % (w/v) for 7 days prior to testing the short-term 
memory of the flies.   
A stilbene monomer, 2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside (25), was 
isolated from the roots of Polygonum multiflorum(Yan 1981).  When administered to a 
transgenic mouse model of AD at a dosage of 240 µmol/kg/day, 25 effectively reduces 
learning-memory deficits in the mice (Zhang, et al. 2006). 
The quinazoline alkaloid dehydroevodiamine (26), first isolated from Evodia 
rutaecarpa (Nakasato, et al. 1962), significantly reduces Aβ induced amnesia in mice 
with a minimum effective dose of 0.75 mg/kg (Wang, et al. 2001).  Compound 26 also 
10 
reduces tau hyperphosphorylation in an activated Gsk3 rat model of AD (Hamann, et al. 
2007), and in calyculin A treated rat brain slices (Fang, et al. 2007).  
1.2.4 β-secretase inhibitors.  The toxic Aβ peptide is formed from the enzymatic 
cleavage of APP.  There are three enzymes or enzyme complexes that cleave APP: α-
secretase, β-secretase (BACE1) and the γ-secretase complex (Giese).  BACE1 and the γ-
secretase complex have both been implicated as therapeutic targets for AD since their 
inhibition may be able to reduce the amount of Aβ in the brain (Panza, et al. 2009).  
There have also been some attempts to increase the activity of α-secretase since it is 
responsible for the production of non-toxic Aβ, but these have met with only limited 
success (Giese).  Most of the work in the development of secretase inhibitors for AD drug 
discovery has focused on BACE1 because it is a single enzyme and thus allows for more 
focused targeting by drugs.  BACE1 activity is elevated in the brains of AD patients and 
it has been shown that a reduction in this activity is beneficial in AD models (Vassar, et 
al. 2009).   
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A series of alkaloids isolated from the rhizome of Coptis chinensis yielded several 
compounds with inhibitory activity against BACE1 (Jung, et al. 2009).  Groenlandicine 
(27) and epiberberine (28) both inhibit BACE1 in vitro with IC50 values of 19.7 µM and 
8.6 µM, respectively.  Berberine (29) was not reported to show significant in vitro 
BACE1 inhibition in this study, but another study from 2007 reported a decrease in the 
production of Aβ in cells transgenically expressing APP upon treatment with 29 (Asai, et 
al. 2007).  This decrease indicates that although 29 does not inhibit BACE1, it may be 
active against another part of the APP processing machinery such as the γ-secretase 
complex.  Two other isoquinoline alkaloids, coptisine (30) and palmatine (31), along with 
29 significantly enhance neurite outgrowth in PC12 cells at a concentration of 5 µg/mL, 
25 µg/mL and 5 µg/mL, respectively (Shigeta, et al. 2002).  
1.3 Parkinson’s disease 
 The primary symptoms of Parkinson’s disease (PD) are a loss of motor function 
and coordination, which is largely due to the specific degeneration of dopaminergic 
neurons in the brain (Lees, et al. 2009).  The affected regions of the brain in PD 
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accumulate protein aggregates, called Lewy bodies, which consist largely of the 
misfolded protein α-synuclein (Brundin, et al. 2008).  The native function of α-synuclein 
is still not clear.  The investigation of α-synuclein function is difficult, in part because it 
changes its conformation in an environment-dependent fashion (Uversky 2007).  While 
the role of α-synuclein in the neuropathology is still not completely understood, it is 
known that the protein can act as a neurotoxin and it is believed to participate in the 
pathogenesis of the disease (Brundin, et al. 2008; Uversky 2007).  Other cellular features 
of PD include mitochondrial dysfunction, inflammation, oxidative damage and apoptosis 
(Allain, et al. 2008). 
Unfortunately, nearly all of the current therapies approved for PD exclusively 
enhance the dopaminergic activity in the brain, which is only effective for treating the 
symptoms of PD rather than its cause (Lees, et al. 2009).  The lack of a clear 
understanding of the underlying biochemical causes of PD has made the development of 
effective neuroprotective treatments for PD very difficult (Schapira, et al. 2006).  The 
following section will describe the small number of natural products that have been 
identified as having promise for development as therapies for PD. 
1.3.1 6-hydroxydopamine toxicity.  There are not as many good models of PD as 
there are for AD, but there are some models which recapitulate enough of the features of 
PD to be useful in the development of new therapies (Jenner 2008).  Perhaps the most 
commonly used model is 6-hydroxydopamine (6-OHDA) induced toxicity.  6-OHDA is a 
neurotoxin which specifically targets catecholaminergic (dopaminergic and 
noradrenalinergic) neurons and induces a handful of cellular features that are also 
observed in PD, primarily oxidative stress but also mitochondrial dysfunction as well 
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(Simola, et al. 2007).  A disadvantage to the 6-OHDA model of PD is its lack of 
usefulness in identifying compounds which reduce the non-dopaminergic defects of PD; 
however, efforts to develop non-dopaminergic therapies utilize targets which not specific 
for PD (Colosimo, et al. 2006; Simola, et al. 2007). 
Three compounds isolated from the roots of Stemona tuberosa were found to 
protect SH-SY5Y cells against toxicity from 6-OHDA treatment (Lee, et al. 2006).  
Stilbostemin B 3′-β-D-glucopyranoside (32), stilbostemin H 3′-β-D-glucopyranoside (33), 
and stilbostemin I 2″-β-D-glucopyranoside (34) all protected cells from 6-OHDA induced 
toxicity at concentrations of 1 µM (Lee, et al. 2006).   
Paeoniflorin (35), a compound with a very unique cage-like pinane moiety, has 
shown the ability to decrease the behavioral abnormalities induced by 6-OHDA in rats at 
doses as low as 5 mg/kg (Durairajan, et al.).  Interestingly, this report also showed that 35 
does not directly antagonize dopamine receptors, which may indicate the potential for 
this compound as non-dopaminergic therapy for PD. 
The quinolizidine alkaloid cytisine (36) and its derivative 5-bromocytisine (37)  
significantly reduce the decrease in striatal dopamine induced by 6-OHDA administration 
to rats, but the 3-bromocytisine (38)  derivative had no effect on striatal dopamine 
concentrations (Abin-Carriquiry, et al. 2008).  A decrease in striatal dopamine levels is a 
key pathological feature of the 6-OHDA model of PD (Simola, et al. 2007).  
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1.4 Huntington’s disease 
Huntington’s disease (HD) is a progressive neurodegenerative disorder arising 
from a CAG trinucleotide repeat expansion mutation in the huntingtin (Htt) gene 
(Imarisio, et al. 2008; Walker 2007).  Individuals carrying mutant forms of huntingtin 
(mHtt) encoding for ≥35 glutamine repeats are at risk of developing HD.  The number of 
polyglutamine-encoding CAG repeats in mHtt strongly influences the age of disease 
onset, symptom severity, and rate of HD progression (Langbehn, et al. 2010).  Although 
all of the mechanisms associated with mHtt toxicity are not clear, it is known that they 
involve both gain-of-function and loss-of-function processes (Imarisio, et al. 2008).  
Many of the same neuropathological features observed in other neurodegenerative 
diseases are present in HD, including protein aggregates, oxidative stress, mitochondrial 
dysfunction and apoptosis (Imarisio, et al. 2008).  The majority of drug discovery efforts 
for HD are focused on either reducing aggregation of the mHtt protein, enhancing 
clearance of the mHtt protein from the cell or promoting survival in mHtt expressing cells 
(Fecke, et al. 2009).  
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1.4.1 Gsk3 as a target for HD.  Although Gsk3 has been identified as a 
therapeutic target for AD (Giese 2009), there is evidence that it may be useful for HD as 
well.  It has been shown that inhibition of Gsk3 protected cells against mHtt toxicity 
(Carmichael, et al. 2002),  and it is possible that the Gsk3 inhibitors described previously 
(i.e. the manzamines and 4) as potential AD therapies may also have applications for HD. 
1.4.2 Caspase inhibitors.  Apoptosis has been implicated as playing an important 
role in HD, and the blocking of the apoptotic signals through the inhibition of caspases 
has been proposed to be another potential therapeutic target for this disease (Pattison, et 
al. 2006).  Caspases 1 and 3 are upregulated in HD patients and in HD mouse models and 
they also are able to enzymatically cleave the huntingtin protein, resulting in an increase 
in the amount of toxic mutant huntingtin fragments in diseased cells (Cornelis, et al. 
2007; Pattison, et al. 2006).  Caspase inhibitors have the potential to directly block this 
causative enzymatic step in the pathogenesis of HD, and as such they make attractive 
targets for drug discovery efforts. 
Discorhabdin P (39), isolated from a Batzella sp. of deep-water marine sponge, 
inhibits the caspase CPP32 with an IC50 value of 0.78 µM (Gunasekera, et al. 1999).  The 
related compound discorhabdin C (40) shows no inhibitory activity against CPP32, which 
is intriguing since the only structural differences between the two compounds is the 
presence of a methylamine group on the iminoquinone moiety of 39 as opposed to a 
secondary amine at the same position in 40. 
1.4.3 Autophagy enhancement.  Autophagy refers to the combined processes 
whereby a cell is able to degrade and recycle large masses, including protein bodies and 
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even organelles (Davies, et al. 2007).  It has been shown that increasing autophagy in 
cells containing toxic misfolded protein fragments can enhance survival of the cells and 
increase the clearance of the misfolded proteins from the cells (Davies, et al. 2007).  It 
has been proposed that the enhancement of autophagy may be a good therapeutic target 
for HD and possibly for other neurodegenerative diseases as well (Davies, et al. 2007; 
Ravikumar, et al. 2006; Roze, et al. 2008).   
Rapamycin (41) is a well known secondary metabolite which was first isolated 
from the bacterium Streptomyces hygroscopicus (Sehgal, et al. 1975).  Through 
interactions with its biological target, FKB12, 41 inhibits the mTOR complex, resulting 
in an upregulation of autophagy, as well as other downstream effects (Graziani 2009; 
Kang, et al. 2008).  It was recently suggested that this ability to increase autophagy may 
be a useful therapeutic approach to treating HD, especially in combination with lithium 
treatment, which enhances autophagy through an mTOR independent pathway (Sarkar, et 
al. 2008).  The potential of this combination approach was demonstrated by the 
protection of flies against mHtt induced neurodegeneration in an HD Drosophila model 
(Sarkar, et al. 2008). 
1.5 Prion diseases 
Prion diseases, also known as transmissible spongiform encephalopathies, are a 
rare but fatal group of neurodegenerative diseases observed in humans and other 
mammals (Fontaine and Brown 2009; Geissen, et al. 2007).  Although it is estimated that 
there are only 200 cases diagnosed in the U.S. each year, these diseases require a focused 
effort for therapeutic development since they are usually fatal within one year of 
diagnosis and because they are transmissible diseases (NINDS 2010).  The most common 
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prion disease in humans is Creutzfeldt-Jakob disease, but other forms of the disease 
include kuru, fatal familial insomnia (FFI), and Gerstmann-Straussler-Scheinker disease 
(NINDS 2010).  These diseases are believed to be caused by an infectious agent called a 
prion, which is a misfolded protein that forms amyloid plaques and is able to transfer its 
misfolded confirmation to other proteins (Krammer, et al. 2009). 
Several cellular models of prion diseases have been developed which have been 
useful in the development of drug discovery efforts for prion diseases (Krammer, et al. 
2009).  Almost all of the strategies under investigation as therapies for prion diseases 
target the prion protein itself and aim to either inhibit the prion misfolding process, 
reduce the total amount of prion protein in cells or to stabilize the natively folded prion 
protein (Nicoll and Collinge 2009).  Some efforts have been made to identify small 
molecules that can inhibit the amyloidogenic properties of prions, but these have been 
almost exclusively from synthetic sources (Schatzl 2009). The investigations of natural 
products with inhibitory activity against prions have been summarized in the following 
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sections. 
1.5.1 Prion amyloidogenesis inhibition.  The polyene macrocycle amphotericin 
B (42) was originally isolated from the Streptomyces nodosus in 1955 and has been 
widely used as an antifungal drug over the past 50 years (Abu-Salah 1996; Lemke, et al. 
2005; Mechlinski, et al. 1970; Oura, et al. 1955; Stiller, et al. 1955).  Compound 42 
reduces the generation of the misfolded form of the prion protein in prion-infected GT1-7 
and S12 cells when applied to the cells at a concentration of 4.5 µg/mL (Mange, et al. 
2000).  No toxicity due to 42 was observed in these cell lines. 
The plant metabolite curcumin (43) was originally isolated from Curcuma longa 
and a wide variety of biological activities have been reported for it, including several 
related to other neurodegenerative diseases (Anand, et al. 2008; Lin, et al. 2006).  The 
accumulation of the misfolded form of the prion protein in prion-infected neuroblastoma 
cells are reduced by treatment with 43 (IC50 ≈ 10 nM) (Caughey, et al. 2003). 
The screening of a library of 2000 natural products and drugs was completed in 
order to identify compounds that inhibit the accumulation of misfolded form of the prion 
protein in prion-infected cells (Kocisko, et al. 2003).  This screening effort identified 17 
active compounds with IC50 values of ≤ 1 µM.  A series of naturally occurring 
polyphenols, including epicatechin monogallate (44), epigallocatechin 3-monogallate 
(45) and 2,3,5,7,3′,4′-pentahydroxyflavin (46), were identified which were active both in 
vitro and in vivo (Kocisko, et al. 2003).   
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A series of tetracycline derivatives was recently shown to have anti-prion activity 
(Forloni, et al. 2009).  The analogues doxycycline (47) and minocycline (48) were 
particularly effective, both in vivo and in vitro.  These are attractive compounds for 
therapeutic development since they are already FDA approved antibiotics and are 
currently undergoing early stage clinical trials (Forloni, et al. 2009).   
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1.6 General neurodegeneration 
The similarity of cellular dysfunctions among the neurodegenerative diseases 
which have been described in the previous sections suggests that therapies may be 
developed which can effectively ameliorate these diseases through a mechanism which is 
not specific to any single disorder.  There are a variety of bioassays available to identify 
natural products with therapeutic potential for general neurodegeneration.  The most 
commonly used assays measure protection against glutamate induced neurotoxicity 
(Dong, et al. 2009; Planells-Cases, et al. 2006; Sheldon and Robinson 2007), 
neurotrophic activity (Gold and Villafranca 2003; Ohizumi, et al. 2004; Price, et al. 2007; 
Tohda, et al. 2005), anti-inflammatory activity (Dheen, et al. 2007; Gilgun-Sherki, et al. 
2006), and monoamine oxidase inhibition (Van der Schyf, et al. 2006).  The various 
secondary metabolites that have been tested in these assays are summarized here, 
grouped according to the assays in which they exhibited activity.  
1.6.1 Glutamate induced neurotoxicity.  Glutamate is a major neurotransmitter 
in the brain, but excessive exposure to glutamate can lead to the death of neurons due to a 
process called excitotoxicity (Dong, et al. 2009).  Cell death related to glutamate induced 
excitotoxicity has been implicated in AD, PD, and HD (Planells-Cases, et al. 2006).  
Many of the damaging effects of excitoxicity are attributed to excessive Ca2+
 
efflux in 
neurons, which can in turn trigger a signal cascade leading to apoptosis and oxidative 
stress (Dong, et al. 2009; Sheldon and Robinson 2007).  These shared features among a 
variety of neurodegenerative disorders makes glutamate induced toxicity an attractive 
target in the search for therapies for neurodegeneration.  
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Seven iridoid glycosides, 8-O-E-p-methoxycinnamoylharpagide (49), 8-O-Z-p-
methoxycinnamoylharpagide (50), 6′-O-E-p-methoxycinnamoylharpagide (51), 6′-O-Z-p-
methoxycinnamoylharpagide (52), E-harpagoside (53), Z-harpagoside (54), and 
harpagide (55), isolated from the roots of Scrophularia buergeriana have shown the 
ability to increase the viability of rat cortical cells upon treatment at concentrations 
ranging from approximately 0.1-10.0 µM (Kim, et al. 2002).  Neural toxicity was 
determined by the measurement of the release of lactate dehydrogenase into the medium 
from the cells. 
Six dihydropyranocoumarin analogues, 4″-hydroxytigloyldecursinol (56), 4″-
hydroxydecursin (57), (2″S,3″S)-epoxyangeloyldecursinol (58), (2″R,3″R)-
epoxyangeloyldecursinol (59), decursinol (60), and decursin (61), showed the ability to 
enhance the viability of rat cortical cells treated with a toxic concentration of glutamate 
(100 µM) (Kang, et al. 2005).  All six compounds (56-61) significantly increased cell 
viability of the glutamate treated cells at concentrations of 0.1-1.0 µM (Kang, et al. 
2005). 
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Six liminoid analogues isolated from the root bark of Dictamnus dasycarpus, 
dictamnusine (62), dictamdiol A (63), fraxinellone (64), calodendrolide (65), obacunone 
(66), and limonin (67), showed significant neuroprotective activity against glutamate-
induced neurotoxicity in primary cultures of rat cortical cells at a concentration of 0.1 µM 
(Kang, et al. 2008).  The neuroprotective activity of 62-67 was greater than the positive 
control used in the assay, dizocilpine maleate, a noncompetitive agonist of the NMDA 
receptor (Kang, et al. 2008).   
1.6.2 Neurotrophic activity.  Healthy neuronal activity is promoted and 
maintained by neurotrophins, small proteins which participate in the regulation of a 
variety of neuronal processes including survival, neurite outgrowth and differentiation of 
neural stem cells (Connor and Dragunow 1998; Price, et al. 2007).  Due to the 
neuroprotective and neurodegenerative effects of neurotrophins, they have potential for 
use as therapeutics for neurodegenerative diseases (Connor and Dragunow 1998; Yuen 
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and Mobley 1996), but their poor pharmacological properties make them inferior 
candidates for therapeutic development (Price, et al. 2007).  Therefore, small molecules 
with good pharmacological properties which are able to potentiate the effects of 
endogenous neurotrophins such as nerve growth factor (NGF) or modulate neurotrophic 
targets such as TrkA (the cellular receptor for NGF), hold great promise as therapies for 
neurodegeneration (Webster and Pirrung 2008).  Related to the neurotrophin-focused 
approach is the attempt to develop stem cell-based therapies for neurodegenerative 
diseases (Kim and de Vellis 2009).  Stem-cell approaches to treating neurodegeneration 
could be greatly enhanced by the availability of small molecules that can effectively 
control the differentiation of neural stem cells (NSCs).  Although there have been a small 
number of reviews concerning natural products with neurotrophic activity (Gold and 
Villafranca 2003; Ohizumi, et al. 2004; Tohda, et al. 2005), the most promising results in 
this area of research as well as highlights of more recent discoveries are presented here. 
Farnisone A (68) and C (69), isolated from the fungus Paecylomyces farinosus 
RCEF 0101, enhance neurite outgrowth in PC12 cells at a concentrations of 20 and 50 
µM, respectively (Cheng, et al. 2004).  A third compound, farnisone B, did not enhance 
neurite growth, even though it differs from 68 only by the presence of a hydroxylamine in 
the pyridone ring (Cheng, et al. 2004).  Although both 68 and 69 induced neurite growth 
independent of NGF, neither compound was as effective as NGF by itself (Cheng, et al. 
2004).   
Three diterpenes, kansuinins A (70), D (71) and E (72), isolated from the roots of 
Euphorbia kansui L., were tested for their stimulatory effects on TrkA, the cellular 
binding target of NGF (Colby, et al. 2004).  The survival of TrkA expressing fibroblasts 
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were specifically promoted by 72 (ED50 = 0.2 µg/mL), while 70 and 71 promoted the 
survival of fibroblasts expressing both TrkA and TrkB (ED50 = 7.9 and 0.6 µg/mL, 
respectively, for TrkA expressing fibroblasts).  TrkB is the receptor for brain-derived 
neurotrophic factor (BDNF), a neurotrophin that has a variety of functions and supports 
the healthy function of neurons, including cholinergic and dopaminergic neurons  
(Connor and Dragunow 1998). 
The militarinones are a series of alkaloids isolated from the fungus Paecilomyces 
militaris RCEF 0095 (Cheng, et al. 2006; Schmidt, et al. 2002; Schmidt, et al. 2003).  
Militarinone A (73) is the most active in this series, showing a significant enhancement 
of neurite outgrowth in PC12 cells at a concentration of 33 µM with no associated 
toxicity.  The dehydroxy analog of 73, (+)-N-deoxymilitarinone (74), also enhances 
neurite outgrowth in PC12 cells, but at a concentration of 100 µM.  Treatment of human 
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neurons (IMR-32) with 74 at the same concentration (100 µM) is toxic to the cells 
(Cheng, et al. 2006; Schmidt, et al. 2002).  Treatment of PC12 cells with militarinone B 
(75) and C (76) at concentrations of 100 µM results in only “marginal” enhancement of 
neurite outgrowth with very low levels toxicity (Schmidt, et al. 2003). 
Ginsenosides Rg3 (77), Rk1 (78) and Rg5 (79), isolated from the roots of Panax 
Sanchi-ginseng, enhance neuronal differentiation of neural stem cells (NSCs) 
(Durairajan, et al.).  The most active of the three compounds is 79, and its activity is 
dependent on Ca2+ influx through Ca2+ channels.  The optimal procedure for the 
induction of differentiation to neurons in NSCs required transient exposure of the NSCs 
to 8 µM 79 for 24 h followed by 72 h incubation with the same compound at 1 µM 
(Durairajan, et al.).  This treatment causes a general enhancement of cell growth in NSC 
cultures as well as an increase in the number of neurons and a decrease in the number of 
astrocytes present in the culture. 
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Four sphingolipids, (4E,6E,2S,3R)-2-N-eicosanoyl-4,6-tetradecasphingadienine 
(80), (4E,2S,3R)-2-N-eicosanoyl-4-tetradecasphingenine (81), and (4E,6E,2S,3R)-2-N-
docosanoyl-4,6-tetradecasphingadienine (82) and (4E,2S,3R)-2-N-octadecanoyl-4-
tetradecasphingenine (83), potentiate the ability of nerve growth factor (NGF) to enhance 
the outgrowth of neurites in PC12 cells at concentrations of 10 µM (Kwon, et al. 2003).  
The four compounds (80-83) were isolated from Bombycis Corpus 101A, a traditional 
Korean medicinal resource used for the treatment of movement disorders; Bombycis 
Corpus 101A is made by killing Bombyx mori (silk moth) larvae with the fungus 
Beauveria bassiana 101A (Kwon, et al. 2003).  Compounds 80 and 82 had greater 
activity than 81 and 83, with the primary difference between these compounds being the 
presence of the C-6 double bond in the more active compounds (Kwon, et al. 2003).   
1.6.3 Anti-inflammatory.  The inflammatory response in the brain can play a 
beneficial role in combating neurodegeneration, but chronic inflammation is associated 
with a variety of neurodegenerative diseases and it has been shown to be a contributing 
factor to neuronal death (Amor, et al. 2010).  Microglia are the resident macrophages in 
the brain and when activated they are able to combat pathogens, but they can also cause 
damage to neuronal cells (Dheen, et al. 2007).  Activated microglia are the prime 
participants in neuroinflammation, and they 
can contribute to neuronal death through a 
variety of mechanisms, such as the production 
of reactive nitrogen species (e.g. nitric oxide) 
and reactive oxygen species (e.g. hydrogen 
peroxide) (Brown 2007).  Consequently, anti-
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inflammatory drugs have been proposed as good candidates for neurodegenerative 
disease therapies, and some compounds have already entered clinical trials (Gilgun-
Sherki, et al. 2006).   
The diarylheptanoid (3R)-1,7-diphenyl-(4E,6E)-4,6-heptadien-3-ol (84), isolated 
from the plant Curcuma comosa, significantly reduces the expression of inducible nitric 
oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) in lipopolysaccharide (LPS) 
treated HAPI microglial cells when applied at a concentration of 1 µM (Thampithak, et 
al. 2009).  In addition, the concentration of the products of iNOS and COX-2, nitric oxide 
(NO) and prostaglandin E2 (PGE2), respectively, were observed to decrease in the treated 
microglial cells. 
Four oxindole alkaloids and one indole alkaloid glycoside exhibited the ability to 
reduce the amount of NO released by LPS treated rat microglial cells (Durairajan, et al.).  
Corynoxeine (85), rhynchophylline (86), isocorynoxeine (87), isorhynchophylline (88) 
and vincoside lactam (89), isolated from the leaves of Uncaria rhynchophylla, were 
active with IC50 values of 15.7, 18.5, 13.7, 19.0 and 16.4 µM, respectively.  These values 
compare favorably with the activity of resveratrol (IC50 = 11.5 µM) in the same assay.  
Interestingly, two other oxindole alkaloids, 18,19-dehydrocorynoxinic acid B (90) and 
18,19-dehydrocorynoxinic acid (91), were not active in the assay, even though the only 
structural differences between them and compounds 85 and 87 was the stereochemistry of 
the ethylene groups and the presence of a carboxylic acid rather than a methyl ester 
(Durairajan, et al.).   
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Plakortide P (92), isolated from the marine sponge Plakortis angulospiculatus, 
reduces the amount of thromboxane B2 (TXB2) released by LPS treated rat microglia 
(IC50 = 0.93 µM) (Kossuga, et al. 2008).  No cytotoxicity was observed upon treatment 
with 92 in a variety of mammalian cell lines and it induced the release of only low 
concentrations of lactate dehydrogenase. 
Lobetyolin (93) and tetradeca-4E,8E,12E-triene-l0-yne-l,6,7-triol (94), isolated 
from the roots of Platycodon grandiflorum, were examined for their ability to activate 
nuclear factor-κ B (NF-κB) (Dong, et al. 2009).  NF-κB is a transcription factor which 
participates in the activation of microglia and other pro-inflammatory responses (Dheen, 
et al. 2007).  These two compounds (93 and 94) increase the transcriptional activity of 
NF-κB in HEK293 human embryonic kidney cells at a concentration of 20 µM. 
1.6.4 Monoamine oxidase inhibitors.  Monoamine oxidase (MAO) is an enzyme 
which deaminates monoamine neurotransmitters, generating hydrogen peroxide as a 
byproduct (Van der Schyf, et al. 2006).  Both the MAO A and B isoforms have been 
OH
84 
N
H
N
R2
OCH3R3O
O
O
H
H
R1
85 (R1 = H, R2 = CH=CH2, R3 = H) 
86 (R1 = H, R2 = CH2CH3, R3 = CH3) 
90 (R1 = CH=CH2, R2 = H, R3 = H) 
 
N
H
N
R2
OCH3R3O
O
O
H
H
R1
87 (R1 = H, R2 = CH=CH2, R3 = CH3)  
88 (R1 = H, R2 = CH2CH3, R3 = CH3) 
91 (R1 = CH=CH2, R2 = H, R3 = H) 
N
H
N
O
O
CH2
O-β-Glc
H
H
H
89 
29 
implicated as potential targets for 
neurodegenerative disease (Van der 
Schyf, et al. 2006).  Recent evidence 
suggests that inhibition of both forms of 
this enzyme confers neuroprotection 
through antiapoptotic mechanisms, the 
reduction of ROS production and 
stabilization of the  mitochondrial 
membrane (Naoi, et al. 2009).  MAO 
inhibitors have a long history of use in 
the treatment of PD, but they have more recently shown to have potential as therapeutics 
for other neurodegenerative diseases (i.e. AD and HD) as well (Van der Schyf, et al. 
2006).   
Seven xanthone glycosides, corymbiferin 3-O-β-D-glucopyranoside (95), 
corymbiferin 1-O-β-D-glucopyranoside (96), triptexanthone C (97), veratriloside (98), 
swertianolin (99), norswertianolin (100), and swertiabisxanthone-I 8′-O-β-D-
glucopyranoside (101), and three xanthone aglycones, bellidin (102), bellidifolin (103) 
and swertiabisxanthone-I (104), were isolated from Gentianella amarella ssp. acuta and 
examined for their inhibitory activity against MAO A and B (Urbain, et al. 2008).  
Compounds 102 and 103 show the greatest inhibition of MAO A (91% and 99%, 
respectively), and these values are greater than that of the positive control pargyline 
(60%).  Paragyline is a known inhibitor of MAO A and B.  All 10 compounds inhibit 
O
O
H3C
CH3 CH3
CO2H
H3CH3C 92 
93 
OH
HO
OH
94 
OH
β-Glc-O
OH
30 
MAO B, but 96 and 99 show the greatest activity (94% and 71%, respectively), although 
this activity is less than that of the positive control pargyline (98%) (Urbain, et al. 2008).   
1.7 Summary and conclusions 
Natural products have been an excellent source of new therapies for 
neurodegenerative diseases for many decades.  Because of their naturally refined 
biological activities and novel structural features, natural products are well positioned to 
lead the way in future drug discovery efforts for these disorders.  Although there are 
currently no effective therapies for AD, HD, PD and prion diseases, the increasing 
number of natural products which can modulate potential drug targets for these diseases 
points to the development of new therapies in the near future. 
Historically, natural products have been heavily utilized in therapies for 
neurodegenerative disorders, as demonstrated by the clinical use of the 
acetylcholinesterase inhibitors 1 and 2 in the treatment of AD.  Biological targets such as 
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acetylcholinesterase inhibitors for AD and dopamine receptor agonists for PD have 
traditionally been the focus of investigations of natural products for neurodegeneration.  
There are many emerging targets for neurodegenerative diseases, however, that are 
beginning to receive more focus in natural products drug discovery efforts. 
Enzymes such as Gsk3 and Cdk5 have generated interest as targets for AD and 
HD.  Compounds such as the manzamines (5-13) have demonstrated potent activity 
against these targets.  Secondary metabolites such as 14 and 29, which can alleviate the 
toxic effects of Aβ or inhibit its production through inhibition of BACE1, are also 
receiving attention as potential therapies for AD.  Enhancement of autophagy using 
compounds such as 41 has also been proposed as a therapy for HD and other protein 
misfolding associated diseases.  There are many targets which can be used to ameliorate 
neurodegeneration in general.  A number of natural products have been identified which 
are able to reduce the harmful effects of glutamate toxicity or chronic inflammation 
associated with neurodegeneration (i.e. 63 and 84).  Other compounds have neurotrophic 
activity and hold the potential to reverse the degeneration caused by AD, HD, PD and 
prion diseases (i.e. 72 and 79). 
More than 100 secondary metabolites have been described in this comprehensive 
review of the literature pertaining to natural products drug discovery efforts for 
neurodegenerative diseases associated with protein misfolding.  Considering that millions 
of people suffer from these diseases, the work summarized here provides hope that new, 
effective therapies for curing these diseases will be available in the future. 
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The information in Chapter 1 has been adapted from a review paper that is in 
preparation for the journal Natural Products Reports. 
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Chapter 2 Hypothesis and Specific Aims 
2.1 Hypothesis 
Natural products have served a critical role in the development of modern 
Western medicine (Newman 2008).  As shown in the preceding chapter, there are many 
exciting developments emerging from natural products that may lead to effective 
therapies for neurodegenerative diseases.  The potential drug targets for 
neurodegenerative diseases which can be modulated by natural products are varied and 
numerous.  Therefore, tools are needed to simultaneously evaluate the activity of many 
targets at once.  Metabolomics, which is the concurrent examination of a pool of 
metabolites, has demonstrated the capacity to meet this demand for multifaceted drug 
discovery approaches (Kaddurah-Daouk and Krishnan 2008; Kaddurah-Daouk, et al. 
2008). 
 Given the contributions of natural products towards the development of new 
therapies for neurodegeneration and the utility of metabolomics for investigating these 
diseases, it is expected that the metabolomic investigation of a yeast model of 
neurodegeneration will lead to the identification of metabolic pathways which are 
perturbed due to the toxicity associated with protein aggregation.  Therefore, the 
following hypothesis has been proposed for this dissertation: modulation of the 
metabolic processes which are perturbed due to the toxicity associated with protein 
aggregation will alter the cellular response to protein aggregation.  In order to 
explore the validity of this hypothesis, Specific Aims 1 and 2 have been investigated.  
Specific Aim 3 diverges from the topic of neurodegeneration and instead describes the 
characterization of a series of diterpenes isolated from a soft coral specimen.  Although 
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the focus of this final project is substantially different from the other work described in 
this dissertation, its scientific merits make it an important and significant part of my 
doctoral research. 
2.2 Specific Aim 1: Identify the metabolic aberrations underlying mutant 
huntingtin toxicity in yeast and assess their degree of preservation in humans 
and mice 
Natural products-based drug discovery investigations are reliant upon assays 
which can identify compounds with biological activities that are relevant to the disease of 
interest.  Although a variety of molecular targets have begun to emerge for developing 
therapeutics to treat neurodegenerative disease, phenotypic disease models offer several 
advantages for drug discovery.  Phenotypic models have the great advantage of being 
mechanism blind, allowing for the identification of compounds which are able to 
modulate disease processes without requiring any prior knowledge of the mechanism.  
Therefore, phenotypic models can help facilitate the discovery of previously unidentified 
targets for the disease.  However, phenotypic models are often difficult to incorporate 
into target-specific drug discovery efforts that are common in modern high-throughput 
pipelines. 
Metabolomics is a powerful multi-parameter tool for evaluating phenotypic traits 
associated with disease processes and provides the means to combine the advantages of 
phenotypic disease models with the mechanistic information afforded by molecular target 
approaches.  1H NMR metabolome profiling has been employed in this project to 
characterize the metabolic aberrations in a yeast model of HD that are attributable to the 
mutant huntingtin protein’s gain-of-toxic-function effects.  Multivariate statistical 
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analysis has been used to compare the results from the yeast HD model to metabolomic 
data reported from transgenic mice expressing a mHtt gene fragment and HD patients. 
2.3 Specific Aim 2: Alter the cellular response to toxicity associated with 
protein aggregation through the modulation of trehalose metabolism 
The results of the investigation of Specific Aim 1 revealed that the intracellular 
concentration of the metabolite trehalose is dramatically altered in response to the 
presence of mHtt.  Trehalose is a disaccharide which is found in a variety of microbes, 
plants and insects (Elbein, et al. 2003).  The trehalose cycle in yeast is primarily 
maintained by seven proteins, encoded for by the genes TPS1, TPS2, TPS3, TSL1, NTH1, 
NTH2 and ATH1 (Francois and Parrou 2001; Voit 2003).  Trehalose is highly effective as 
a protectant of biomolecules from various types of stress, including desiccation and heat 
(Crowe 2007; Jain and Roy 2009; Kaushik and Bhat 2003).  It has been shown that 
trehalose can also prevent the aggregation of misfolded proteins both in vitro and in vivo 
(Singer and Lindquist 1998). 
The effects of mHtt expression have been evaluated in a series of yeast strains 
with gene knockouts for the seven enzymes which participate in trehalose cycle in order 
to elucidate the role that trehalose plays in the response of yeast to mHtt.  Each of these 
knockout strains has been engineered to express either a normal Htt protein fragment or a 
mHtt protein fragment.  Metabolic profiling has been used in combination with molecular 
techniques to investigate the altered cellular responses of these engineered strains to mHtt 
protein. 
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2.4 Specific Aim 3: Ichthyotoxicity and Metabolic Transformation of Select 
Briarane Diterpenes 
Briaranes represent a structurally diverse group of marine-derived diterpenes that 
are found among several coral species and other invertebrates.  The briaranes have 
demonstrated remarkable biosynthetic adaptability to structural variation, as shown by 
the fact that changes in structural features have been observed at all 20 positions of the 
briarane carbon skeleton.  More than 500 different briaranes have been reported and 
many of these have been tested in a wide variety of assays to investigate their biological 
activities (Sung, et al. 2005; Sung, et al. 2008; Sung, et al. 2002).  Many of these assays 
have examined the potential application of briaranes to human health, but some have also 
endeavored to ascertain the ecological role of these compounds.  Although the ecological 
function of the briaranes still remains uncertain, an ichthyotoxic role as chemical 
defensive agents against foraging reef fish is highly probable. 
The exploration of a Briarium sp. of soft coral collected from Vanuatu has led to 
the isolation of the three new briaranes designated RAMs A–C.  The structures and 
absolute configurations of these compounds have been determined using a combination 
of NMR, MS, X-ray diffraction and other techniques.  The ecological role of these 
compounds has been investigated using an ichthyotoxicity assay.   
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Chapter 3: Identification of the metabolic aberrations underlying 
mutant huntingtin toxicity in yeast and assessment of their degree of 
preservation in humans and mice 
3.1 Introduction 
Huntington’s disease (HD) is a progressive neurodegenerative disorder arising 
from a CAG trinucleotide repeat expansion mutation in the huntingtin (Htt) gene 
(Imarisio, et al. 2008; Walker 2007).  Individuals carrying mutant forms of huntingtin 
(mHtt) encoding for ≥35 glutamine repeats are at risk of developing HD.  The number of 
polyglutamine-encoding CAG repeats in mHtt strongly influences the age of disease 
onset, symptom severity, and rate of HD progression (Langbehn, et al. 2010).  
Unfortunately, the mechanisms by which mHtt and its aggregation-prone protein product 
causes HD have not yet been determined (Fang, et al. 2007).  This lack of information 
has hampered the establishment of disease-specific biochemical markers for gauging the 
toxic effects of mutant huntingtin, which has impeded efforts to develop chemical 
methods for monitoring HD progression. 
Several cellular and animal HD models have been constructed to help elucidate 
the mechanisms responsible for the toxicity of the mutant huntingtin protein including 
monkeys (Kang, et al. 2008), mice (Masuda, et al. 2008; Menalled, et al. ; Van 
Raamsdonk, et al. 2007), zebrafish (Diekmann, et al. 2009; Lumsden, et al. 2007; 
Schiffer, et al. 2007), fruit flies (Branco, et al. 2008; Jackson, et al. 1998; Ravikumar, et 
al. 2006; Wolfgang, et al. 2005), nematodes (Faber, et al. 1999; Faber, et al. 2002; Jeong, 
et al. 2009; Satyal, et al. 2000), mammalian cells (Desai, et al. 2006; Igarashi, et al. 2003; 
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Subramaniam, et al. 2009), and yeast (Giorgini and Muchowski 2009; Krobitsch and 
Lindquist 2000; Meriin, et al. 2002).  Each of these systems has provided important new 
insights regarding the cellular dysfunctions arising from mHtt expression and several of 
these models have served as screening platforms for HD drug discovery (Barsby and 
Kubanek 2005; Desai, et al. 2006; Krammer, et al. 2009; Sarkar, et al. 2007b; Wang, et 
al. 2005; Zhang, et al. 2005).  Among these models, the yeast Saccharomyces cerevisiae 
has proven to be exceptionally informative with respect to HD processes due to its ability 
to recapitulate many of the cellular and molecular features of the disease (Giorgini and 
Muchowski 2009).  Expression of the N-terminal portion of mHtt in yeast is sufficient to 
cause the rapid onset of characteristic huntingtin aggregation (Krobitsch and Lindquist 
2000) and cell death (Meriin, et al. 2002).  The ability of this organism to recapitulate 
many of the defining phenotypic features of mutant huntingtin is quite remarkable given 
the fact that yeast lack Htt orthologs (Outeiro and Giorgini 2006).  Consequently, the 
yeast model is a valuable tool for understanding the unique gain-of-toxic function 
properties attributable to mHtt and for probing the cellular mechanisms of HD. 
S. cerevisiae expressing mHtt were used for the purpose of characterizing 
metabolic biomarkers associated with mutant huntingtin’s toxicity.  This is the first report 
in which a non-mammalian transgenic model has been used to critically evaluate 
perturbations in primary metabolites that stem from mutant huntingtin’s toxicity.  In 
addition, a systematic review of published metabolomics studies performed on transgenic 
mice expressing mHtt and humans with HD was conducted in order to identify conserved 
metabolic features that are disrupted by mutant huntingtin.  The data obtained from 
human and mouse studies were qualitatively compared to results generated from the yeast 
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model, and this has provided new insight regarding the metabolic disturbances that are 
attributable to mutant huntingtin’s gain-of-toxic-function effects.  This information is 
anticipated to enhance our understanding of mutant huntingtin’s impact on biochemical 
processes in cells and improve strategies for selecting HD biomarkers. 
3.2 Experimental Procedures 
3.2.1 Yeast strains and media.  Construction and maintenance of the HD yeast 
model has been previously described (Williams, et al. 2007).  Briefly, S. cerevisiae 
strains designated “103Q” and “25Q” were prepared that expressed the N-terminal 
fragment of human Htt followed by CAG codon repeats encoding for 103 and 25 
glutamine (Q) repeats, respectively.  The Htt fragments were fused to enhanced green 
fluorescent protein (EGFP) reporters (C-terminus) and the constructs were placed under 
the control of GAL1 promoters.  The 103Q and 25Q strains were maintained on uracil-
free (plasmid selective marker) synthetic complex media (SC) supplemented with yeast 
nitrogen base (without amino acids, Sigma-Aldrich), yeast drop-out supplement (with 
histidine and methionine, Sigma-Aldrich), 0.5% (w/v) ammonium sulfate, and 2% (w/v) 
glucose.  Compared to the 25Q yeast, the 103Q yeast exhibited distinctive phenotypic 
traits attributable to expression of the human mHtt fragment.  These features included the 
characteristic aggregation of the EGFP-labeled mutant huntingtin in 103Q yeast, as well 
as their significantly reduced viability when cultured under conditions that were 
permissive for mHtt-expression (Appendix, Figure A1).   
3.2.2 Metabolomic analysis of 103Q and 25Q yeast.  Yeast were grown using a 
two-stage (I and II) culture process.  Stage I cultures were grown in 250 mL wide-mouth 
Erlenmeyer flasks containing 50 mL SC media supplemented with 2% glucose and 
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placed on a rotary shaker/incubator (140 rpm, 30 °C) for 24 h.  Stage II cultures were 
prepared by centrifuging stage I cultures (3,000×g, 5 min), decanting the supernatant, and 
suspending the cell pellet in 50 mL SC media supplemented with 2% galactose to induce 
Htt gene fragment expression.  Stage II cultures were then incubated with shaking for 
16.5 h (140 rpm, 30 °C).  Next, stage II cultures were centrifuged (3,000×g, 5 min), the 
supernatant decanted, and the cell pellet immediately suspended in 50 mL methanol (25 
°C) and vortexed vigorously.  This entire process was carefully monitored to ensure that 
precisely 20 ± 5 min reproducibly elapsed from the time cultures were removed from the 
incubator to the moment cells were placed in methanol. 
Following 3 h of extraction at 25 °C, cell suspensions were centrifuged (3,000×g, 
5 min) and the methanol was immediately decanted.  The resulting extracts were 
evaporated in vacuo and the remaining organic residues were weighed and stored in 5 
dram vials at -20 °C until NMR analysis.  Samples were prepared for NMR by adding to 
each vial a 666 µL aliquot of a solution containing deuterium oxide (D2O, 99.9% D) with 
0.2% w/v sodium azide (bacterial growth inhibitor), 10 mM imidazole (pH indicator), 
and 0.5 mM 2,2-dimethyl-2-silapentane-5-sulfonate (DSS).  The DSS standard is used by 
the data analysis software (Chenomx NMR Suite v 5.0, described below) as a chemical 
shift reference, an internal standard for quantification, and chemical shape indicator to 
assess the shim quality and predict line widths for each analyte.  No additional sample 
clean-up was performed prior to NMR analysis.  1H NMR spectra were collected on a 
500 MHz Varian VNMRS-500 spectrometer with a triple resonance probe at 20 °C.  Data 
collection parameters were as follows: number of scans = 64, relaxation delay = 1 s, pulse 
width = 2.9 µs, acquisition time = 4 s, spectral width = 6200 Hz, temperature = 20.0 °C, 
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spinning = 20 Hz, data points = 24,876; no steady-state scans were collected and no 
solvent suppression was used. 
3.2.3 Metabolomics data analysis.  All 1H NMR FIDs were imported into 
Chenomx NMR Suite v 5.0 (Chenomx, Inc.) for processing and binning.  Each spectrum 
(0–6 ppm region) was divided into 0.005 ppm bins and the regions containing the 
residual water (4.750–4.900 ppm) and methanol (3.335–3.350 ppm) signals were 
removed from further analysis.  For the purpose of this investigation, focus has been 
placed on the 0–6 ppm portions of the 1H NMR spectra because preliminary analyses 
showed that no significant changes occurred in the downfield portions of the full spectra 
(up to 12 ppm).   
Prior to statistical analyses, all Fourier-transformed 1H NMR data sets were 
normalized by expressing the peak intensities in each bin as a percentage of the total area 
under the curve for the 0–6 ppm region of the spectrum.  Data sets were analyzed by 
principal components analysis (PCA) with XLSTAT (Addinsoft, Inc.).  PCA is a data 
reduction technique that transforms data via a linear combination to uncorrelated 
orthogonal variables (principal components), allowing sources of variation in the data to 
be categorized (Jolliffe 2002).  Individual metabolites were manually identified using the 
Chenomx NMR Suite (Appendix, Table A1) and then quantified by comparison to the 
internal DSS standard.  Additional experiments using 2D NMR techniques (1H-1H 
TOCSY, 1H-13C HSQC, and 1H-13C HMBC) and spiking of samples with authentic 
standards were used to verify each metabolite identified in this study (data not shown).  
Spectral regions representing galactitol (3.660–3.695, and 3.945–3.985 ppm) and acetate 
(1.900-1.960 ppm) were removed from the principal components analysis because these 
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compounds were present in large and highly variable quantities that were unduly 
influential in terms of their effects on each sample’s profile.  Instead, these metabolites 
were manually annotated and quantified for statistical evaluation.  Two-tailed, parametric 
z-tests were performed using XLSTAT. 
3.2.4 Metabolomic analysis of potassium cyanide, amphotericin B, and 
cycloheximide treated 103Q and 25Q yeast.  Stage I and stage II were prepared as 
described in the experimental procedures, with the exception that stage II cultures were 
treated with either potassium cyanide (Way 1984), amphotericin B (Palacios, et al. 2007), 
or cycloheximide (Obrig, et al. 1971) at concentrations of 46 µM, 38 nM, and 98 nM, 
respectively. Concentrations of toxins were chosen that inhibited 25Q yeast growth to 
30% of the growth of untreated controls. Data was collected and analyzed as described 
above. 
3.2.5 Systematic review and comparison of published HD metabolic profiles.  
A systematic review of the literature was conducted to identify published data from 
model systems and humans that described metabolic changes associated with mutant 
huntingtin toxicity.  The PubMed database (United States National Library of Medicine, 
National Institutes of Health) was utilized to perform a comprehensive search for articles 
published prior to August of 2009.  A broad set of search criteria were utilized, which 
included pairing the search terms “Huntington’s disease,” “Huntington’s chorea,” 
“Huntington disease,” “Huntingtons,” and “Huntington” in combination with 
“biomarker,” “metabolite,” “metabolic,” “metabolomics,” “metabonomics,” 
“metabolism,” “MRI,” “magenetic resonance imaging,” “mass spectrometry,” 
“neurochemical,” “NMR,” “nuclear magnetic resonance,” and “spectroscopy.”   
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Only studies in which mHtt expression was determined to be responsible for 
inducing HD in humans or an HD-like condition in model organisms were retained for 
analysis.  Work employing non-mHtt-based systems (e.g., 3-nitropropionic acid induced 
neuronal toxicity) was excluded since it is uncertain the degree to which these approaches 
mimic HD pathogenesis (Tsang, et al. 2009).  The resulting reference set was 
independently reviewed by two individuals and studies were retained for analysis if 1) 
one or more primary metabolites were identified and 2) methods for assessing changes in 
the concentrations of the metabolites were described.  The complete list of metabolic 
changes observed in these studies is provided in Table A2 in the Appendixes. 
The amassed data were quantitatively assessed using correspondence analysis 
(CA) (Greenacre 1992; 2007; Greenacre and Degos 1977).  This method provides a 
means for analyzing qualitative data in a graphical format.  Weighted profile values are 
calculated for tabular (row-column) data and the relative similarities between weighted 
profile points are described in terms of their χ2 distances.  Prior to performing CA, the 
data (Appendix, Table A2) were reformatted into a contingency table that was suitable 
for testing (Appendix, Table A3).  For the purpose of this investigation, data set were 
structured to reflect the number of times each metabolite’s concentration was reported to 
have changed significantly in yeast, mice, and humans in response to mutant huntingtin 
toxicity.  CA was performed and visualized using XLSTAT. 
3.3 Results 
3.3.1 1H NMR determination of 103Q and 25Q yeast intracellular 
metabolites.  Analysis of the 1H NMR spectra generated from 103Q and 25Q yeast 
strains was undertaken using the Chenomx NMR Suite v 5.0 library of primary 
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metabolites.  This facilitated the detection of 29 compounds whose identities were 
confirmed by comparisons with 1D (Appendix, Table A1) and 2D NMR data generated 
from authentic standards.  Even with no sample cleanup prior to 1H NMR analysis, the 
observed signal detection was excellent, which enabled the confident assignment of 
proton resonances that were subject to considerable signal overlap (Figure 3.1).  
Biomolecules were identified which represent a wide range of metabolically and 
chemically distinct classes including amino acids (4-aminobutyrate, alanine, arginine, 
asparagine, aspartate, glutamate, glutamine, histidine, isoleucine, leucine, methionine, 
phenylalanine, proline, threonine, tryptophan, tyrosine, and valine), a nucleoside 
(adenosine), a cofactor (NAD+), and osmolytes (glycerol, trehalose), as well as 
Figure 3.1.  Representative 1H NMR spectra (δH 0–6 ppm) of A) 25Q and B) 103Q HD yeast 
extracts acquired at 500 MHz in D2O with 0.2% w/v sodium azide, 10 mM imidazole, and 0.5 
mM DSS.  
 
A
B
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metabolites associated with energy metabolism (ATP, acetate, formate, galactose, 
propylene glycol, succinate) and stress response (glutathione).  Galactitol was also 
identified, but its definitive biochemical role(s) in yeast is not well defined. 
3.3.2 Expression of mHtt alters the metabolome of 103Q yeast.  The 
application of principal components analysis (PCA) was tested as a multivariate 
statistical method for reducing the dimensionality of the metabolomics data.  It was 
anticipated that this would enable the identification of changes in the metabolic profiles 
of HD yeast attributable to mutant huntingtin’s toxicity.  Examination of the 1H NMR 
data by PCA revealed well-defined clusters for the metabolite profiles of 103Q and 25Q 
yeast (Figure 3.2).  Remarkably, these data represent an accumulation of 61 replicates per 
strain, which were collected by three individuals from 17 independent experiments 
carried out over a non-consecutive 17 week period.  The notable clustering of these data, 
despite the relatively challenging conditions used for this experiment, demonstrates the 
robustness and reproducibility of this 
metabolomics approach.   
Inspection of the loadings plot 
from the F1 axis (Figure 3.3) revealed 
several regions in the 1H NMR spectra 
that substantially contributed to the 
metabolic differences between yeast 
expressing normal versus mutant Htt 
fragments.  In view of the fact that the 
Figure 3.2.  PCA scores plot of 1H NMR data for 
25Q () and 103Q () yeast.  Data points 
represents single experimental replicates (n = 61 
for each strain).  The data were obtained from 17 
different experiments performed on different 
days and show notable consistency.  Substantial 
differentiation between the 25Q and 103Q yeast 
metabolomes is reflected in the distinct 
clustering among replicates of the two HD yeast 
strains.  
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sole difference between 25Q and 103Q yeast was the number of CAG repeats present in 
Figure 3.3.  Loadings plot of the F1 axis from the PCA of 25Q and 103Q yeast metabolomes.  
The loadings plot was used to identify sources of variability that contributed to the 
differentiation between 25Q and 103Q yeast.  Regions of high variability that corresponded to 
decreased (phased upward) or increased (phased downward) concentrations of primary 
metabolites in 103Q yeast are labeled.  Modeled spectral data for each metabolite (and DSS 
standard) are stacked above the loadings plot for reference.  
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their respective Htt gene fragments, this enabled the use of the loadings plot data to 
search for metabolic changes that were attributable to mutant huntingtin’s toxicity.  These 
data assisted in the identification of 11 metabolites that exhibited substantial variations in 
their respective concentrations between the two yeast strains (Figure 3.3).  The 
significantly altered metabolites included alanine, galactose, glutamine, glycerol, 
threonine, and valine, which were more abundant in 103Q yeast, while acetate, histidine, 
proline, succinate, and trehalose were markedly decreased (note: although acetate levels 
significantly decreased in 103Q yeast (Figure 3.4), they were removed from PCA 
analysis (Figure 3.3) due to their disproportionate and overwhelming influence during the 
initial statistical analysis).  Using a 
quantitative method based on an 
internal DSS standard (Weljie, et 
al. 2006), the concentrations for 
each of the 11 metabolites in the 
25Q and 103Q samples (Figure 
3.4) were determined.  No attempt 
was made to ascertain the 
recoveries for the 11 substances; 
therefore, this data does not 
represent their absolute cellular 
concentrations in yeast.  However, 
the recovery efficiencies can be 
assumed to be equivalent because 
Figure 3.4.  Changes in the relative concentrations of 
metabolites identified by PCA of 25Q and 103Q 
yeast.  The sample concentrations of the metabolites 
were determined by quantifying the integrals 
attributed to each of the non-exchangeable proton 
resonances in all 25Q and 103Q samples and 
expressing them relative to an internal DSS standard.  
Data are expressed as the percent change in 
metabolite concentration in 103Q yeast relative to 
control 25Q yeast.  A two-tailed, parametric z-test (α 
= 0.05) was used to determine the significance of the 
change in relative concentrations for each metabolite 
(n = 61).  Bars represent the mean relative 
metabolite concentration and standard deviations.  
All values were significantly different from zero with P 
≤ 0.0001 except for galactose (P = 0.0018) and 
threonine (P = 0.0096).  
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all of the sample extractions were carried out under identical conditions, thus enabling the 
determination of the relative percent change in the quantity of each primary metabolite.  
Using this approach, the relative concentrations of the 11 metabolites identified from the 
F1 loadings plot were shown to be significantly (two-tailed parametric z-test, α = 0.05) 
altered in yeast expressing a human mHtt fragment (Figure 3.4). 
Although the changes in the relative concentrations of primary metabolites had 
been ascribed to the toxic effect of mutant huntingtin, the possibility that some or all of 
the variation observed might be reflective of a generalized ‘toxic’ response in yeast could 
not be ruled out.  Therefore, the impact of several small molecule toxins on the yeast 
metabolome was explored.  The compounds potassium cyanide (inhibits complex IV of 
the mitochondrial electron transport chain), amphotericin B (forms pores in cellular 
membranes leading to the release of electrolytes), and cycloheximide (inhibits ribosomal 
protein biosynthesis) were screened against 25Q yeast at concentrations that caused 
decreases in cell proliferation equivalent to the ~30% reduction in 103Q versus 25Q cell 
growth following galactose-induced expression of the mHtt fragment.  Examination of 
the 1H NMR data by PCA revealed that each of the toxins caused restructuring of the 
yeast metabolome in a manner that was distinct from the 103Q yeast profile (Appendix, 
Figure A2).  Moreover, the individual metabolites (along with their respective changes in 
concentrations) that contributed to the toxin-induced metabolic profiles were different 
from those distinguishing 103Q versus 25Q yeast (data not shown).  This supported the 
conclusion that changes in the yeast metabolome induced by mHtt fragment expression 
are reflective of a specific gain-of-toxic function response stemming from mutant 
huntingtin’s toxicity. 
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3.3.3 Comparison of conserved HD metabolic features in humans, mice, and 
yeast.  It became clear through the course of this work that a multispecies comparison of 
metabolomics datasets would facilitate the identification of primary metabolites that are 
candidate conserved biomarkers for mutant huntingtin’s gain-of-toxic function properties.  
Identifying these biomarkers is important since huntingtin’s effects in humans are 
speculated to result from a combination of both loss-of-function and gain-of-toxic-
function properties (Cattaneo, et al. 2005; Imarisio, et al. 2008).  A systematic review of 
published studies documenting the metabolic changes exhibited in HD patients (Nicoli, et 
al. 1993; Reynolds, et al. 2005; Taylor-Robinson, et al. 1996; Underwood, et al. 2006) 
and transgenic mice expressing mHtt (Jenkins, et al. 2005; Jenkins, et al. 2000; Tkac, et 
al. 2007; Tsang, et al. 2006; Underwood, et al. 2006) was conducted in order to 1) 
identify which cellular metabolites were present in the mouse model and humans with 
HD and 2) determine which of these metabolites changed in response to disease.  
Correspondence analysis (CA), a descriptive multivariate statistical technique that is used 
for creating maps depicting the underlying relationships among categories of tabularized 
data, was selected as a statistical tool for this study.  This technique enabled the direct 
comparison of results from the HD yeast model with data obtained from metabolomics 
experiments performed in mice and humans.  In this case, CA was used to probe for 
primary metabolites whose concentration changes in yeast, mice, and humans were 
indicative of a generalized metabolic response to mHtt toxicity.  
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The metabolic changes 
reported in mice and humans 
were combined with results 
derived from HD yeast and the 
data were arranged in a 
contingency table identifying 1) 
the frequency with which each 
metabolite’s concentration was 
reported to have changed 
significantly and 2) the specific 
biological system in which 
metabolic changes occurred (Appendix, Table A3).  Examination of the multispecies 
dataset by CA resulted in the separation of the variables into two categories (organism 
and metabolite) along the principal axes, which accounted for all of the variation (inertia) 
in the data set (Figure 3.5).  The CA plot revealed that the overall metabolic patterns of 
yeast, mice, and humans were distinguishable from one another.  Interestingly, the 
metabolomes of mice and humans were clearly separated from yeast along the first 
principal (F1) axis; however, the profiles of yeast and mice were distinct from humans in 
the second principal (F2) dimension.  Further inspection of the CA plot revealed that 
several metabolites responded similarly in two or more HD systems, which suggested 
that these metabolites could be potential biomarkers for toxicity associated with mHtt 
expression.  Therefore, focused attention was placed on examining the relationships 
among these metabolites in reference to their source organisms.   
Figure 3.5  Asymmetric plot from CA of metabolic 
changes reported for cells in which mHtt expression 
occurs.  For CA, column profiles represent the different 
biological systems (humans, mice, yeast), while row 
profiles represent the metabolites identified as having 
undergone significant changes.  Metabolites that were 
reported from a single HD model occupy coordinates 
that superimpose upon the source organism.  For 
clarity, these metabolites have been removed from this 
diagram, but they can be found in Supporting 
Information, Table 3.  
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Examination of the CA plot revealed that the four metabolites, alanine, glutamine, 
glycerol and valine exhibited similar changes in model organisms and humans expressing 
mHtt (Figure 3.5).  The occurrence of these four metabolites in the CA plot in a region 
that was central to both the F1 (separating mice and humans) and F2 (separating mice and 
yeast) dimensions indicates that alanine, glutamine, glycerol and valine might be 
important multispecies biomarkers for gauging mutant huntingtin’s gain-of-toxic effects.  
Other notable trends that were observed in the CA plot included the co-localization of 
creatine, glutamate, lactate, malonate, N-acetylaspartate, and urea with mice and humans 
in the F1 dimension.  This indicates that these six metabolites behaved similarly in both 
mammalian systems.  We also noted that succinate and acetate clustered in the F2 
dimension of the CA plot with mice and yeast, which indicated that these metabolites 
responded similarly in the two model organisms.  Besides alanine, glutamine, glycerol 
and valine, no additional metabolites were observed that were unique solely to yeast and 
humans. 
3.4 Discussion 
Metabolomics is concerned with determining the identities, concentrations, and 
distributions of small molecules in living systems with the presumption that the resulting 
metabolic profiles are reflective of an organism’s physiological status.  Therefore, 
perturbation to an organism’s biological processes should result in distinct changes to its 
steady-state metabolome, making metabolomics a powerful multi-parameter profiling 
technique that is well suited for identifying disease-dependent metabolic aberrations 
(Dunckley, et al. 2005; Gowda, et al. 2008; Kaddurah-Daouk and Krishnan 2008; Powers 
2009).  A metabolomics approach has been applied as a tool for discerning the unique 
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gain-of-toxic function effects attributable to mutant huntingtin’s toxicity in a HD yeast 
model and these results have been compared to the metabolic restructuring that occurs in 
human HD patients and transgenic mice.   
Using a yeast model to map metabolites that exhibited significant shifts in their 
relative intracellular concentrations showed that disruptions are detected in the steady-
state concentrations of small molecules whose metabolic pathways are seemingly 
independent (Figure 3.6).  For example, the biochemically distinct compounds trehalose, 
Figure 3.6.  Map illustrating the biochemical linkages among the primary metabolites identified 
in HD yeast.  Only the most predominant metabolic pathways are shown for simplicity.  
Metabolites shown in bold underwent significant concentration changes in 25Q versus 103Q 
yeast.  Arrows represent individual metabolic (enzymatic) steps required for biotransformation 
(note – italicized metabolites were not observed in yeast extracts, but represent known and 
important metabolic links).  
 
succinate
NAD+ glutamate
acetate
aspartate
pyruvate
alanine
TCA CYCLE
phenylalanine
tryptophan
tyrosine
glucose galactose galactitol
lactate
glycerol 1,2-propanediol
methionine
threonine
G
L
Y
C
O
L
Y
S
I
S
4-aminobutyrate
glutathione
glutamine
PURINE 
METABOLISM
adenosine ATP
arginine proline
histidinetrehalose
asparagine
isoleucine
leucine
valine
formate
53 
proline, glutamine, galactose, and acetate exhibited large changes in their respective 
concentrations following mHtt expression.  However, if these metabolites are considered 
in terms of their major cellular roles – energy storage/generation (acetate, galactose and 
trehalose) and maintenance of intracellular nitrogen pools (glutamine and proline) – then 
potential links among these small molecules begin to emerge.  Consequently, 
metabolomics can be used to provide evidence for errant or disrupted regulatory 
processes that are involved in HD-related cell death.  However, caution should be used in 
applying this form of interpretation to these findings since inferences based simply on 
assigning gross biochemical roles to individual metabolites can be deceptive of their true 
functions within complex metabolic networks (Steuer 2006). 
Several conserved metabolic changes have been observed that are shared among 
HD yeast, mice, and humans (Figure 3.7), and this has revealed what appears to be a core 
set of phenotypic (metabolic) markers related to mHtt expression.  The metabolites 
alanine, glutamine, glycerol, and valine show substantial promise as biomarkers for 
gauging mutant huntingtin’s gain-of-toxic function effects.  It is anticipated that 
metabolomics and other ‘-omics’-based strategies will have important applications that 
may be applied to discerning the cellular mechanisms of HD.  However, at the present 
time, it is not immediately apparent how altered levels of alanine, glutamine, glycerol, 
and valine are linked to mutant huntingtin’s toxicity.  Further experiments will be needed 
to probe the relationships among cellular pathways that are impacted by mutant 
huntingtin.   
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Despite the passing of 
nearly two decades since the 
genetic basis of HD was defined 
(MacDonald, et al. 1993), no 
clinically-approved therapeutic 
agents have been developed that 
allay the toxicity component of 
this disorder (Fecke, et al. 2009).  
One exciting potential application 
of the multispecies approach 
described above to investigating 
mutant huntingtin’s toxicity is this 
method’s capacity for sifting 
through large biomarker sets so 
that metabolic perturbations arising from the disruption of conserved biological features 
can be identified.  These pathways are anticipated to provide focused insight into the 
biochemical networks that may be involved in HD and respond positively to therapeutic 
modulation.  Currently, several of these pathways are being explored further as part of a 
comprehensive effort to develop novel therapeutic approaches for treating the underlying 
toxicity component of mutant huntingtin.  It is anticipated that these efforts toward this 
endeavor will be reported in due course. 
The material in Chapter 3 is adapted from Joyner et al. Journal of Proteome Research 
2010, 9 (1), 404-412.  
Figure 3.7.  Venn diagram illustrating similarities 
among the metabolomes of humans, mice, and yeast 
expressing mHtt.  Pairs of integers represent the 
number of metabolites identified within a given 
organism or set of organisms (first integer) versus the 
number of biomolecules that are reported to undergo 
significant concentration changes (second integer).  
Among the eight metabolites that are reported from all 
three HD systems, four (alanine, glutamine, glycerol, 
and valine) undergo significant shifts in concentrations 
following mutant huntingtin expression.  The 
metabolites listed in the diagram are those found 
significantly altered in the three pair-wise comparisons 
(clockwise from left side: yeast and mice, mice and 
humans, and yeast and humans).  A complete list of 
all metabolites is provided in Supporting Information, 
Table 2.  
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Chapter 4 Alteration of the cellular response to toxicity associated with 
protein aggregation through the modulation of trehalose metabolism 
4.1 Introduction 
The recent metabolomic examination of the baker’s yeast (Saccharomyces 
cerevisiae) model of Huntington’s disease (HD) demonstrated the practicality of using 
metabolic profiling to investigate the metabolic aberrations associated with HD (Joyner, 
et al. 2010).  Huntington’s disease (HD) is a progressive neurodegenerative disorder 
arising from a CAG trinucleotide repeat expansion mutation in the huntingtin (Htt) gene 
(Imarisio, et al. 2008; Walker 2007).  Individuals carrying mutant forms of huntingtin 
(mHtt) encoding for ≥35 glutamine repeats are at risk of developing HD, and the number 
of polyglutamine-encoding CAG repeats in mHtt strongly influences the age of disease 
onset, symptom severity, and rate of HD progression (Langbehn, et al. 2010).  The recent 
metabolomic examination of the yeast HD model revealed that the metabolite which 
showed the greatest change in concentration in response to mHtt expression was trehalose 
(Joyner, et al. 2010). 
Trehalose is a disaccharide which is found in a variety of microbes, plants and 
insects (Elbein, et al. 2003).  The trehalose cycle in yeast is primarily maintained by 
seven proteins, encoded for by the genes TPS1, TPS2, TPS3, TSL1, NTH1, NTH2 and 
ATH1 (Figure 4.1) (Francois and Parrou 2001; Voit 2003).  The protein products of 
TPS1, TPS2, TPS3 and TSL1 combine to form the trehalose synthase complex, which 
catalyzes in two steps the formation of trehalose from glucose-6-phosphate and UDP-
glucose.  Trehalose is hydrolyzed by the products of NTH1 and ATH1.  In contrast to the 
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other proteins in the trehalose cycle, the function of the protein product of NTH2 is not 
well understood. 
Biomolecules can be protected from many types of stress, including desiccation 
and heat, by the presence of trehalose (Crowe 2007; Jain and Roy 2009; Kaushik and 
Bhat 2003).  It has been shown that trehalose can also prevent the aggregation of 
misfolded proteins both in vitro and in vivo, which lends support to its putative role as a 
chemical chaperone (Singer and Lindquist 1998).  These results have inspired the 
exploration of the use of trehalose to inhibit the aggregation of disease-related proteins in 
a handful of neurodegenerative disorders, including Alzheimer’s disease, prion diseases 
and HD (Beranger, et al. 2008; Fung, et al. 2005; Liu, et al. 2005; Qi, et al. 2009; Tanaka, 
et al. 2005).  
Figure 4.1  The trehalose metabolic cycle in yeast.  Trehalose is biosynthesized from UDP-
glucose and glucose-6-phosphate in a two-step process by the trehalose synthase complex 
(Tps1p, Tps2p, Tps3p, and Tsl1p).  Trehalose can be hydrolyzed to form glucose by the 
neutral trehalases (Nth1p and Nth2p) and by acid trehalase (Ath1p). 
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  In this study, a series of yeast strains with gene knockouts for each of the genes 
which participate in the trehalose cycle were engineered to express either normal Htt or 
mHtt.  The deletion of ATH1 leads to the elevation of intracellular concentrations of 
trehalose and the alleviation of the reduced cell growth caused by mHtt expression.  The 
metabolic profiles of each strain were also analyzed, showing that the metabolic 
aberrations associated with the expression of mHtt can be decoupled from the toxicity of 
the mutant huntingtin protein.  Finally, the mechanism of protection against mutant 
huntingtin toxicity by trehalose was explored using a series of protein degradation 
inhibitors. 
4.2 Experimental Procedures 
4.2.1 Yeast strains, plasmids and transformations. Seven Saccharomyces 
cerevisiae knockout strains prepared in the background BY4742 (MATα his3∆1 leu2∆0 
lys2∆0 ura3∆0) were used in this study (Table 1).  The plasmids containing the 
huntingtin construct were prepared and used as described previously (Williams, et al. 
2007).  Briefly, constructs containing the N-terminal fragment of human Htt followed by 
CAG codon repeats encoding for either 103 or 25 glutamine (Q) repeats fused at the C-
terminus to enhanced green fluorescent protein (EGFP) reporters were placed under the 
control of GAL1 promoters (Zhang, et al. 2005).  Transformations were performed using 
the lithium acetate-heat shock method (Gietz and Schiestl 2007).  Transformation success 
was confirmed by observation of fluorescing huntingtin-EGFP and by reverse 
transcriptase (RT) PCR amplification of huntingtin-EGFP mRNA.  Strains expressing the 
construct with 103 glutamine repeats or 25 glutamine repeats were designated “103Q” 
and “25Q”, respectively.  The 103Q and 25Q lines of each strains were maintained on 
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uracil-free (plasmid selective 
marker) synthetic complex media 
(SC) supplemented with 2% 
(w/v) glucose. 
4.2.2 Yeast growth 
assays (spot tests).  Yeast cultures were grown for 24 hours in SC media supplemented 
with 2% (w/v) glucose.  Prior to performing the assays, the optical density of each culture 
was determined and the cultures were diluted to ensure that each assay began with a 
uniform number of cells.  Cells were spotted onto SC agar media supplemented with 2% 
(w/v) galactose in four five-fold dilutions and incubated at 30˚ C.  
4.2.3 Fluorescent microscopy and image processing.  All microscopic images 
were collected using an Olympus BH-2 microscope (Olympus America Inc.) with an 
Olympus DApo100x oil-immersion objective, a BH2-RFL-T3 high pressure mercury 
burner and SPOT Insight 2 MP digital camera (Diagnostic Instruments, Inc.).  Images 
were uniformly cropped to remove empty space in the image and adjusted for contrast 
and brightness. 
4.2.4 Confirmation of gene transcription using RT-PCR.  Expression of the 
Htt-EGFP constructs was confirmed using reverse transcriptase (RT) PCR. Total RNA 
was isolated from yeast cultures using an RNEasy Mini Kit (Qiagen, Inc.) and reverse 
transcriptase and PCR reactions were carried out in a single tube for each sample.  
Amplified products were analyzed using agarose gel electrophoresis. 
Table 4.1 S. cerevisiae strains used in this study 
Strain Genotype 
BY4742 MATα his3∆1 leu2∆0 lys2∆0 ura3∆0 
∆tps1 isogenic to BY4742, ∆tps1::KanMX
 
∆tps3 isogenic to BY4742, ∆tps3:: KanMX 
∆tsl1 isogenic to BY4742, ∆tsl1:: KanMX 
∆ath1 isogenic to BY4742, ∆ath1:: KanMX 
∆nth1 isogenic to BY4742, ∆nth1:: KanMX 
∆nth2 isogenic to BY4742, ∆nth2:: KanMX 
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4.2.5 Metabolomic characterization of yeast strains.  Collection and analysis of 
metabolomics data from the yeast model of HD has been described previously by our 
group (Joyner, et al. 2010).  Briefly, yeast were grown using a two-stage (I and II) culture 
process at 30 °C.  Stage I cultures were grown in 50 mL SC media supplemented with 
2% (w/v) glucose for 24 h.  Stage II cultures were prepared by centrifuging stage I 
cultures, decanting the supernatant, and suspending the cell pellet in SC media 
supplemented with 2% (w/v) galactose to induce Htt gene fragment expression.  After 
16.5 h, stage II cultures were centrifuged, the supernatant was decanted, and the cell 
pellet was immediately suspended in methanol.  After 3 h of extraction, cell suspensions 
were centrifuged and the methanol was decanted.  The solvent in the resulting extracts 
was evaporated in vacuo and the samples were prepared for NMR by adding 666 µL of a 
solution containing deuterium oxide with a pH indicator (10 mM imidazole) and an 
internal standard (0.5 mM 2,2-dimethyl-2-silapentane-5-sulfonate (DSS)) to each sample.  
No additional sample clean-up was performed prior to NMR analysis.  1H NMR spectra 
were collected on a 500 MHz Varian VNMRS-500 spectrometer with a triple resonance 
probe at 20 °C. 
4.2.6 Metabolomics data analysis.  Data were analyzed as described previously 
with minor modifications (Joyner, et al. 2010).  Briefly, all 1H NMR FIDs were imported 
into Chenomx NMR Suite v 5.0 (Chenomx, Inc.) for processing and binning.  The 0–6 
ppm region of each spectrum was divided into 0.005 ppm bins and the regions containing 
the signals for residual water (4.750–4.900 ppm) and methanol (3.335–3.350 ppm) were 
removed from further analysis.     
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All processed 1H NMR data sets were normalized to the total area under the curve 
for the 0–6 ppm region of the spectrum prior to statistical analyses.  Chenomx NMR 
Suite was used to manually identify metabolites and quantify their respective 
concentrations based upon comparisons to an internal DSS standard.  Principal 
components analysis (PCA) was used to analyze the data sets with the software package 
XLSTAT (Addinsoft, Inc.).  Two-tailed, parametric t-tests were performed using 
XLSTAT. 
4.2.7 Protein degradation inhibition assay.  Yeast strains were grown in SC 
media supplemented with 2% (w/v) glucose for 24 h and standardized aliquots were 
taken from each culture, centrifuged, and re-suspended in 50 mL 0.85% (w/v) sodium 
chloride solution.  Ten-fold dilutions were made from the sodium chloride-yeast 
suspension into SC media supplemented with 2% (w/v) galactose and 200 µL aliquots 
were transferred into the wells of a 96-well microplate.  The protein degradation 
inhibitors phenylmethylsulfonyl fluoride (PMSF), tunicamycin and salinosporamide were 
then added to individual wells of the microplate at final concentrations of 1 mM, 0.25 
µg/mL and 1 µM, respectively. 
4.3 Results 
4.3.1 Transformation of yeast knockout strains and comparison of their 
growth profiles.  A series of yeast knockout strains deficient for genes involved in 
trehalose metabolism were engineered to express either a normal Htt fragment (25Q) or 
mHtt fragment (103Q).  Successful transformations were completed for the wild type 
strain (BY4742) and five of the seven knockouts, which were designated WT-25Q, WT-
61 
103Q, ∆tps1-25Q, ∆tps1-103Q, ∆tps3-25Q, ∆tps3-103Q, ∆nth1-25Q, ∆nth1-103Q, 
∆nth2-25Q, ∆nth2-103Q, ∆ath1-25Q and ∆ath1-103Q. 
The growth profiles of all 10 transformants were compared using spot cultures on 
agar plates (Figure 4.2).  Remarkably, the ∆ath1-103Q line grew almost as well as the 
∆ath1-25Q line.  This enhanced growth strongly suggested that the lack of functional 
Ath1p resulted in a reduction in the toxic effects of the mutant huntingtin protein.  The 
growth profiles of the WT, ∆nth1, ∆nth2 and ∆tps3 strains were almost identical, with 
the 103Q lines for each of these strains growing significantly less than the 25Q lines due 
to the toxic effects of mutant huntingtin (Figure 4.2).  The ∆tps1 lines grew much less 
than the others, which was not unexpected since these lines should not be able to produce 
any trehalose, thus leading to a reduction in growth.  However, the ∆tps1-25Q line still 
grew more than the ∆tps1-103Q line, indicating that even in this background mutant 
huntingtin exhibits toxicity. 
Figure 4.2  Yeast cell growth assay of 25Q and 103Q lines of 
yeast knockout strains. The ∆ath1-103Q line was the only line with 
enhanced growth while expressing mHtt. 
25Q (normal Htt) 103Q (mutant Htt)
WT
∆ath1
∆nth1
∆nth2
∆tps3
∆tps1
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4.3.2 Comparison of mutant huntingtin aggregation in yeast knockout 
strains.  Fusion of the huntingtin fragments at the C-terminus to enhanced green 
fluorescent protein (EGFP) enabled us to visualize the huntingtin fragment in all 10 
transformants (Figure 4.3).  All of the 25Q lines exhibited similar appearances, showing 
that the normal huntingtin was diffused throughout the cells.  In contrast to the 25Q lines, 
the WT-103Q line exhibited a series of pronounced aggregates distributed throughout the 
cells.  Both the ∆nth1-103Q and ∆tps3-103Q lines had similar phenotypes to the WT-
103Q line.  Interestingly, the ∆nth2-103Q line displayed a different phenotype from the 
other 103Q lines, with only very small aggregates visible in the cells and in much fewer 
numbers.    The ∆tps1-103Q line was similar to both the WT-103Q and ∆nth2-103Q lines 
Figure 4.3  Fluorescence microscope images of yeast knockout strains expressing human Htt 
fragments.  Images of the 25Q and 103Q line of each knockout are shown.  Aggregates are 
visible in all of the 103Q lines except ∆ath1-103Q.  No aggregates are visible in any of the 
25Q lines.  All images are shown at equivalent magnifications. 
103Q (mutant Htt)25Q (normal Htt)
WT
∆ath1
∆tps3
∆nth1
∆nth2
∆tps1
103Q (mutant Htt)25Q (normal Htt)
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in that it contained aggregates, but differed from the other strains in that it contained a 
large number of very small aggregates that were distributed evenly throughout the cell.  
The ∆ath1-103Q line exhibited a very different phenotype in which the 
huntingtin-EGFP was localized to what appeared to be a single compartment.  Although 
the low fluorescent intensity observed in the ∆ath1-103Q line suggested that the amount 
of transgenic protein in the cell was very low, RT-PCR confirmed that the mHtt-EGFP 
construct was being expressed at similar levels as in the WT-103Q line. 
4.3.3 Metabolic profiling of yeast knockout strains and measurement of 
intracellular trehalose concentration.  The metabolic profiles of the transformants were 
determined by 1H NMR metabolomics.  PCA was used to analyze these data and to 
investigate changes in the metabolite profile of each strain.  As previously observed 
(Joyner, et al. 2010), the metabolic profiles of the WT-25Q and WT-103Q lines were 
distinct and did not overlap, indicating severe perturbations in primary metabolic 
functions in response to the expression of the mHtt fragment (Figure 4.4). 
The metabolic profile of the ∆ath1-103Q line was indistinguishable from those of 
the ∆ath1-25Q and WT-25Q lines (Figure 4.4a).  These similarities suggested that the 
∆ath1 deletion conferred protection from mutant huntingtin toxicity, which is in 
agreement with the enhanced growth observed in the spot test assay (Figure 4.2).  
Surprisingly, the profile of the ∆nth1-103Q line was also indistinguishable from those of 
the ∆nth1-25Q and WT-25Q lines (Figure 4.4b), even though no growth enhancement 
was observed in the spot test assay.  The metabolic profiles of the ∆nth2 lines mimicked 
those of the WT lines, with both of the 103Q lines clustering together and both of the 
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25Q lines clustering together (Figure 4.4c).  Similar to the ∆nth1 lines, the profile of the 
∆tps3-103Q line was indistinguishable from those of the ∆tps3-25Q and WT-25Q lines 
Figure 4.4  Scatter plot from PCA of metabolic data for 25Q and 103Q lines of WT (n = 18) vs 
a) ∆ath1 (n = 18), b) ∆nth1 (n = 18), c) ∆nth2 (n = 9), d) ∆tps3 (n = 9), and e) ∆tps1 (n = 9).  
The percentage value in each axis lable represents the total amount of independent variation 
in the data set which is captured by that axis.   f) The intracellular concentration of trehalose in 
yeast knockouts as determined from yeast extracts generated for metabolomic analysis.  
Asterisks over bars indicate significance of difference from WT-103Q based on a Dunnet's 2-
sided test.  Asterisks over brackets indicate significance of difference between values in 25Q 
and 103Q lines of each strain based on a Student’s t-test (** P < 0.0001, * P ≤ 0.01, ns = not 
significant, ND = not detected). 
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(Figure 4.4d).  These similarities in metabolic profile between the 103Q and 25Q lines of 
∆nth1 and ∆tps3 stand in stark contrast to the growth profile of these transformants 
(Figure 4.2).  The metabolic profile of the ∆tps1-25Q and ∆tps1-103Q lines were quite 
unique, with a dramatic separation from the WT lines in the F1 axis (Figure 4.4e).  
Examination of the F1 loadings plot from the PCA showed that this large separation was 
primarily due to the extreme difference in trehalose concentrations between the ∆tps1 and 
WT lines (4.4f).  
The relative intracellular concentration of trehalose was also determined for each 
transformant (Figure 4.4f).  Trehalose concentrations in the 103Q lines were generally 
much lower than in the 25Q lines, particularly for the WT, ∆nth1 and ∆nth2 lines.  
However, the concentration of trehalose was indistinguishable between the ∆ath1-25Q 
and ∆ath1-103Q lines.  Trehalose was detected in higher concentrations in the ∆tps3-
103Q line than in most of the other 103Q lines, but it was still significantly lower than in 
the ∆tps3-25Q line and much lower than the observed trehalose concentration in the 
∆ath1 lines.  No trehalose was detected in any of the ∆tps1 lines, which is in agreement 
with previous observations (Bell, et al. 1998).  
4.3.4 Inhibition of protein degradation in yeast HD model.  In view of the 
emerging link between the protective role of trehalose in cells and its impact on protein 
processing and degradation, we examined a series of protein degradation inhibitors in the 
WT and ∆ath1 strains.  Three inhibitors were selected which target different protein 
degradation pathways in yeast: PMSF, salinosporamide and tunicamycin.  PMSF disrupts 
autophagy by inhibiting serine proteases involved in the degradation of autophagic 
bodies, leading to a severe reduction in autophagy (Jones 1991; Takeshige, et al. 1992).  
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Salinosporamide is a potent inhibitor of the 20S proteasome, reducing the functionality of 
the ubiquitin-proteasome system (Feling, et al. 2003).  Tunicamycin inhibits protein 
glycosylation, leading to the accumulation of unfolded proteins in the endoplasmic 
reticulum (ER) which induces ER stress.    The concentration of each inhibitor was 
determined based upon published examinations of the activity of these compounds in 
yeast systems. 
The effects of the three protein degradation inhibitors were determined by 
measuring the relative amount of huntingtin per cell as well as the total growth of the 
Figure 4.5  Treatment of yeast expressing mHtt  with protein degradation inhibitors.  PMSF 
inhibits autophagy, tunicamycin disrupts ERAD, and salinosporamide inhibits the proteasome.   
a)The ratio of huntingtin/cell as determined by fluorescent measurements and OD600 
measurements of cell cultures treated with inhibitors of protein degradation.   The significance 
of the difference between the huntingtin/cell values in the 25Q and 103Q lines of each strain 
were determined using a Students t test: WT PMSF (P < 0.0001), WT tunicamycin (P = 
0.0540), WT salinosporamide (P < 0.0001), ∆ath1 PMSF (P = 0.3240), ∆ath1 tunicamycin (P 
= 0.3605), ∆ath1 salinosporamide (P = 0.2168).  b) The OD600 of cultures treated with protein 
degradation inhibitors. The significance of the difference between the OD600 values in the 25Q 
and 103Q lines of each strain were determined using a Students t test: WT PMSF (P = 
0.4128), WT tunicamycin (P = 0.0049), WT salinosporamide (P < 0.0001), ∆ath1 PMSF (P = 
0.1095), ∆ath1 tunicamycin (P = 0.8802), ∆ath1 salinosporamide (P < 0.0001).  All data was 
normalized to vehicle treated controls. Dashed lines shows the relative value of vehicle treated 
cultures. 
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WT-25Q, WT-103Q, ∆ath1-25Q and ∆ath1-103Q lines after treatment with these 
compounds (Figure 4.5).  The relative amount of huntingtin per cell was determined by 
measuring the total fluorescence from EGFP in a culture and normalizing this value to the 
OD600 of the culture.  Treatment of the WT-103Q line resulted in an increase in 
huntingtin levels for each inhibitor tested.  However, only treatment with tunicamycin 
and salinosporamide caused an increase in huntingtin levels in the WT-25Q line.  
Tunicamycin was the only inhibitor which caused an increase in huntingtin in the ∆ath1-
25Q and ∆ath1-103Q lines. 
The effects of the protein degradation inhibitors on the growth of the WT-25Q, 
WT-103Q, ∆ath1-25Q and ∆ath1-103Q lines were also determined.  Tunicamycin caused 
the most severe reduction in growth in the WT-25Q line, but in the WT-103Q line all 
three inhibitors had approximately the same effect.  PMSF and salinosporamide caused 
very little reduction in growth of the ∆ath1-25Q and ∆ath1-103Q lines, but tunicamycin 
treatment severely impeded the growth of both lines.  
4.5 Discussion 
A metabolomics-based approach has been employed in this study in combination 
with yeast knockout strains deficient in trehalose metabolic pathways in order to 
investigate the role of trehalose in protecting cells against the toxicity of mHtt.  There is 
substantial evidence that trehalose functions as a chemical chaperone and that its activity 
is due to the disruption of hydrogen bonding between the water molecules surrounding a 
protein (Jain and Roy 2009).  It is hypothesized that interactions between water and 
trehalose molecules alters the thermodynamic folding landscape for misfolded proteins, 
causing them to remain in isolated misfolded conformations rather than form aggregates 
68 
(Liu, et al. 2008).  This hypothesis may explain the ability of trehalose to increase the 
accessibility of misfolded proteins to molecular chaperones (Singer and Lindquist 1998). 
Interestingly, only the deletion of the acid trehalase (∆ath1) resulted in increased 
trehalose concentrations and protection against mutant huntingtin toxicity.  There is 
currently considerable debate regarding the role of acid trehalase in cells (Fecke, et al. 
2009; Garre, et al. 2009; Huang, et al. 2007), which makes interpretation of these results 
difficult.  Even more surprising was the observation that neutral trehalase does not afford 
protection against mutant huntingtin toxicity.  While the deletion of the neutral trehalase 
was expected to have a significant effect on intracellular trehalose levels, only a very 
modest effect was observed. 
Intracellular concentrations of trehalose were not predictive of the metabolic 
response of the knockouts to mHtt expression.  The metabolic aberrations associated with 
mHtt expression were completely alleviated in the ∆ath1-103Q line; this line also 
exhibited a significant increase in intracellular trehalose levels.  However, the metabolic 
aberrations associated with mHtt expression were also assuaged in the ∆nth1-103Q line, 
which did not show an increase in intracellular trehalose, and in the ∆tps3-103Q line, 
which exhibited only a small increase in trehalose (Figure 4.4).  Neither the ∆nth1-103Q 
line nor the ∆tps3-103Q line showed any increase in growth compared to the WT-103Q 
line, suggesting that the metabolic dysfunction caused by mHtt can be decoupled from 
the reduction in growth associated with its expression. 
The variation in aggregation patterns observed in this series of yeast 
transformants confirms previous observations that aggregation of mutant huntingtin is not 
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necessarily linked to its toxicity (Duennwald, et al. 2006).  Intriguingly, it has recently 
been shown that misfolded proteins can be sequestered into distinct cellular 
compartments in yeast (Kaganovich, et al. 2008).  The destination of the misfolded 
protein depends on whether the protein is destined for degradation via the proteasome or 
if it is simply being sequestered to protect the cell from potential toxicity associated with 
misfolded proteins.  The localization of the mutant huntingtin in the ∆ath1-103Q line 
appears similar to the compartmentalization described by Kaganovich et al., but the data 
collected in this study are insufficient to determine which compartment is being utilized 
by the cell. 
Considering the lack of toxicity observed in the ∆ath1-103Q transformant, the 
increase in intracellular trehalose in this line, the lack of aggregation of mutant huntingtin 
and the alleviation of the metabolic defects associated with mHtt expression, it appears 
that trehalose protects yeast from mutant huntingtin toxicity via a chemical chaperone 
mechanism.  This conclusion is supported by the fact that inhibition of autophagy has no 
effect on the clearance of mutant huntingtin from the cells with elevated trehalose 
concentrations (Figure 4.5).  These results are in contrast to a previous observation that 
trehalose can enhance the clearance of protein aggregates from cells by inducing 
autophagy (Sarkar, et al. 2007a). 
Although trehalose has been repeatedly shown to be one of the most effective 
osmolytes for preventing the aggregation of amyloidogenic proteins, other osmolytes 
have demonstrated similar properties (Singer and Lindquist 1998; Tanaka, et al. 2004).  It 
is possible that molecular systems which function as chemical chaperones in a similar 
fashion to trehalose may be present in humans.  If such a process is identified, it may 
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hold potential as a therapy for many protein misfolding diseases, including HD and other 
neurodegenerative diseases. 
The information in Chapter 4 has been adapted from a manuscript which is in 
preparation for publication in the FEBS Journal. 
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Chapter 5 Ichthyotoxicity and Metabolic Transformation of Select 
Briarane Diterpenes 
5.1 Introduction 
Briarane diterpenes constitute a unique class of marine-derived secondary 
metabolites that are composed of a conserved bicyclo[8.4.0] system and fused γ-lactone.  
Since the first briarane diterpene, briareine A, was reported in 1977 from a gorgonian 
coral by Burks and colleagues at the University of Oklahoma (Burks, et al. 1977), >500 
related metabolites have been described from various corals, and other marine 
invertebrates (Sung, et al. 2005; Sung and Chen 2002; Sung, et al. 2008; Sung, et al. 
2002).  A notable feature of the structural diversity within this compound family is that 
functionalization, ring opening/closure, and epimerization is observed throughout all 20 
positions of the briarane carbon skeleton.  The extraordinary biosynthetic adaptability of 
the briaranes to structural variation has made these metabolites an attractive subject for 
assessing how their naturally-occurring chemical variation influences the biological 
activities of this compound class. 
While the majority of bioassays performed on these compounds have focused on 
the potential applications of briaranes to human health and diseases (e.g., cancer cell 
cytotoxicity, anti-inflammatory, and antiviral activities), a subset of the investigations 
were designed to query the ecological roles of briaranes (Changyun, et al. 2008).  These 
studies have evaluated the antifouling properties of briaranes, as well as their toxicity and 
antifeedant activities against marine invertebrates and fish.  For example, a fraction 
enriched in erythrolides A, B, and D from the encrusting gorgonian octacoral 
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Erythropodium caribaeorum deterred reef fish from feeding on agar baits infused with 
the briarane mixture; however, the antifeedant effects of the purified erythrolides were 
substantially diminished (Fenical and Pawlik 1991).  Whereas erythrolide A was 
completely inactive as a feeding deterrent, the antifeedant effects of purified erythrolides 
B and D were rather marginal.  In another example, renillins A–D were shown to inhibit 
feeding on baits presented to lesser blue crabs (Callinectes similis); however, only 
renillins C and D showed antifeedant activity against mummichog fish (Fundulus 
heteroclitus) (Barsby and Kubanek 2005). 
In addition to the observed antifeedant properties of briaranes, it is worth 
considering other ecologically-relevant functions that these compounds may serve for 
their biogenic hosts.  One possibility is that the briaranes may function as acute biotoxins, 
which would help prevent predation.  Although toxins are generally believed to convey a 
competitive advantage to the host organism, there is little evidence that these types of 
compounds are capable of directly modulating the palatability of potential food items 
(Molyneux and Ralphs 1992).  Moreover, it has been proposed that compounds capable 
of eliciting a toxic response have a greater impact on substantially limiting the dietary 
adaptation of predators to potential food sources than compounds which act only as 
feeding deterrents (Glendinning, et al. 2001).  Therefore, it is reasonable to deduce that 
defensive toxins should play an important role in community-scale interactions between 
chemically-protected prey and their prospective predators (Swihart, et al. 2009).  While a 
substantial number of putative marine-derived defensive diterpenes have been shown to 
be lethal to fish (Albericci, et al. 1978; Cimino, et al. 1990; Cimino, et al. 1988; De 
Petrocellis, et al. 1991; Gavagnin, et al. 1992; Iwagawa, et al. 1995; Iwagawa, et al. 1996; 
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McPhail and Davies-Coleman 1997; Miyamoto, et al. 1995; Schlenk and Gerwick 1987; 
Uchio, et al. 1985), we are aware of only a single ichthyotoxicity study involving a 
metabolite bearing a briarane-skeleton (Uchio, et al. 1989).  In this particular example, it 
was reported that compound 1 was toxic to Gambusia affinis at concentrations ranging 
from 2–5 ppm. 
The hypothesis of this investigation is that in comparison to the modest feeding 
deterrent activity exhibited by some briaranes, the toxicity of these compounds might 
play an important role in mounting an effective defensive strategy against predation.  
This conjecture is supported by the observation that although briaranes often accumulate 
at relatively substantial levels in certain corals, only a limited subset of these compounds 
exhibit efficacy toward deterring foraging behavior.  In order to test this hypothesis, the 
chemical diversity of a Briarium sp. collected in Vanuatu has been explored.  This 
examination led to the purification and subsequent structure determination of three new 
briaranes RAMs A–C (2-4).  The ichthyotoxicity and brine shrimp toxicity of the RAMs 
were assessed against a reporter fish strain (Pimephales promelas) and Artemia salina.  
This research has also afforded the unique opportunity to analyze a heretofore unexplored 
aspect of the interaction of briaranes with biological systems – the metabolic 
transformation of briaranes by fish.  The major RAM metabolites were also subjected to 
bioassay testing against Artemia salina.  Based on this study, the theory is proposed that 
briarane toxicity plays a defensive role by providing protection to certain corals against 
predatory fish.  Furthermore, these data demonstrate that the metabolism of briarane 
toxins by fish leads to further expansion of the already remarkable structural diversity 
exhibited by the briaranes. 
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5.2 Experimental Procedures 
5.2.1 General Experimental Procedures.  NMR data were obtained on Varian 
VNMR spectrometers (400 and 500 MHz for 1H, 100 and 125 MHz for 13C) with broad 
band and triple resonance probes at 20 ± 0.5 °C.  Electrospray-ionization mass 
spectrometry data was performed on a LCT Premier (Waters Corp.) time-of-flight 
instrument.  Optical rotations were measured on a Rudolph Research Autopol III 
automatic polarimeter.  HPLC separations were performed on a Shimadzu system using a 
SCL-10A VP system controller and Gemini 5µm C18 column, (110Å, 250 x 21.2 mm) 
with a flow rate of 10 mL/min.  X-ray diffraction data were collected on a Bruker-AXS 
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with an APEX CCD area detector with a Cu X-ray source.  All solvents were of ACS 
grade or better. 
5.2.2 Animal Material and Sample Preparation.  The Briarium sp. used for this 
project was obtained from the National Cancer Institute’s Natural Products Repository of 
marine invertebrates (identification number C020997-A/20).  The sample was collected 
in the Republic of Vanuatu at a depth of 10 meters.  The sample had been extracted using 
1:1 dichloromethane–methanol and then water.  The material extracted using the 1:1 
mixture of dichloromethane–methanol was selected for this study. 
5.2.3 Purification of the RAMs A–C (2–4).  The extract was suspended in water 
and partitioned against ethyl acetate.  The ethyl acetate soluble material (4 g) was 
prepared for HPLC by passing it through a C18 SPE cartridge and eluting it with 
methanol.  The extract was subjected to preparative-scale HPLC by passing the material 
over a C18 column with a mobile phase of 40–100% acetonitrile–water over 50 minutes.  
The first substantial peak to elute from the column (965 mg) was determined to be pure 2.  
The second major peak to elute from the preparative HPLC was determined by ESIMS 
and 1H NMR to be a mixture of structurally related metabolites.  The mixture was further 
purified by subjecting the material to a second round of C18 HPLC, but this time an 
isocratic elution scheme utilizing 68% acetonitrile in water was used.  This provided 520 
mg of 3.  The third fraction to elute from preparative HPLC (96 mg) was determined to 
be a mixture and it was subsequently purified by C18 HPLC with a 45–65% acetonitrile–
water gradient, which yielded 54 mg of 4. 
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5.2.4 RAM A (2) : colorless crystalline solid from methanol; [α]21D –109.0 (c 
0.001, acetone); HRESIMS m/z 545.2004, C26H34NaO11 ([M + Na]+, clad. 545.1999); 1H 
NMR, see Table 2; 13C NMR see Table 1. 
5.2.5 RAM B (3) : white powder; [α]21D –100.8 (c 0.0024, chloroform); 
HRESIMS m/z 601.2616, C30H42NaO11 ([M + Na]+, calcd. 601.2625); 1H NMR, see 
Table 2; 13C NMR see Table 1. 
5.2.6 RAM C (4) : white powder; [α]21D –102.0 (c 0.0024, chloroform); 
HRESIMS m/z 629.2938, C32H46NaO11 ([M + Na]+, calcd 629.2938); 1H NMR, see Table 
2; 13C NMR see Table 1. 
5.2.7 Ichthyotoxicity Assay.  The ichthyotoxicity of RAMs A and B were 
determined as specified in EPA-821-R-02-012 (US EPA, 2002) (with the modifications 
noted below) and were approved by the University of Oklahoma Institutional Animal 
Care and Use Committee.  For each assay, 90 mL clear glass jars were filled with 50 mL 
of filtered and aged tap water and 10-14 day old Pimephales promelas fry (three per jar) 
were added and allowed to acclimatize for 1 h.  The jars were randomized and samples 
dissolved in 0.5 mL methanol were added to the jars.  The RAM A (2) sample used in 
this experiment appeared to contain < 1% (by mass) contaminants as determined by 1H 
NMR and HPLC.  The RAM B (3) sample used in the assay was determined to contain 
~5% (by mass) RAM C (4) as determined by 1H NMR and HPLC.  Controls consisting of 
vehicle-only were included in each experiment.  Fish were maintained under 12 h light/12 
h dark photoperiods at 24 ºC.  Samples were tested in triplicate and the results were 
expressed as the LC50 (the concentration lethal to 50% of fish) ± standard deviation at 48 
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h.  The LC50 values were determined in SigmaPlot v10 (Systat Software Inc) using 
sigmoidal dose-response regression analyses with variable slope parameters.  All fish 
were euthanized at the conclusion of each experiment. 
5.2.8 Purification of the RAMs A-M1, B-M1, and C-M1 (5–7).  The water from 
all treatment groups for compounds 2 and 3 were pooled separately and the samples were 
partitioned against ethyl acetate.  The ethyl acetate soluble materials from the two 
samples were subjected to preparative-scale HPLC by passing the material over a C18 
column with a mobile phase of 50–100% methanol–water over 60 minutes.  The samples 
pooled from the ichthyotoxicity test of 2 yielded one major new metabolite that was 
designated RAM A-M1 (5) (12 mg), while the samples from the ichthyotoxicity test of 3 
yielded one new major metabolite designated RAM B-M1 (6) (5 mg) and one minor new 
metabolite designated RAM C-M1 (7) (3 mg).  The chromatograms generated during the 
purification of the metabolites are illustrated in Figure 4. 
5.2.9 RAM A-M1 (5) : colorless crystalline solid from methanol; [α]21D –45.0 (c 
0.0024, methanol); HRESIMS m/z 503.1895, C24H32NaO10 ([M + Na]+, calcd 503.1893); 
1H NMR, see Table 2; 13C NMR see Table 1. 
5.2.10 RAM B-M1 (6) : white powder; [α]21D –13.0 (c 0.0024, methanol); 
HRESIMS m/z 559.2529, C28H40NaO10 ([M + Na]+, calcd 559.2519); 1H NMR, see Table 
2; 13C NMR see Table 1. 
5.2.11 RAM C-M1 (7) : white powder; [α]21D –2.9 (c 0.0024, methanol); 
HRESIMS m/z 587.2818, C30H44NaO10 ([M + Na]+, calcd 587.2832); 1H NMR, see Table 
2; 13C NMR see Table 1. 
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HRESIMS and NMR (1H and 13C NMR, HSQC, HMBC, COSY, and NOESY) 
data for compounds 2–7 and crystallographic data for 2 and 5 are included in the 
Appendix. 
5.3 Results and Discussion 
The methanol extract of the Briareum sp. was partitioned between water and ethyl 
acetate.  The ethyl acetate layer was retained and the solvent removed under vacuum.  
The resulting organic residue was analyzed by gradient C18 HPLC, which revealed three 
major metabolites that were targeted for isolation.  Compound 2 eluted first from the C18 
column and it exhibited a pseudomolecular ion [M+Na]+ with a m/z of 545.2004 under 
HRESIMS conditions.  This corresponded to a molecular formula of C26H34NaO11 (calcd 
545.1999) for the metabolite.  Inspection of the 13C NMR data for 2 (Table 5.1) revealed 
a total of 26 unique carbon atoms, which included four carbonyls (δC 168.3, 169.8, 170.3 
and 170.4), four olefinic carbons (δC 121.9, 122.5, 142.0, and 144.2), and eight sp3 
hybridized carbons attached to oxygens (δC 64.8, 65.1, 71.3, 72.4, 72.8, 73.5, 73.6, and 
77.4).  The remaining carbon resonances appeared between δC 9.7 to 48.2 and 1JH-C 
HSQC data enabled the determination that seven of the carbons were methyls (δC 9.7, 
14.0, 20.9, 21.0, 21.2, 21.6, and 26.5).  Given the biogenic source of compound 2, both 
the HRESIMS and HSQC data were consistent with what was expected for briarane-
diterpene-type metabolites that are commonly encountered in these organisms.  Structure 
determination efforts focused on dereplicating compound 2 ultimately proved fruitless, 
however, we did observe notable similarities between the data for 2 and those reported by 
Wu et al. for briaexcavatolide S (C26H34O11) (Wu, et al. 2003).  Consequently, attention 
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was focused on using the basic briarane diterpene scaffold of briaexcavatolide S as a 
convenient tool for accelerating the structural characterization of 2. 
While all of the proton and carbon resonances in the cyclodecane and fused γ-
lactone ring portions of 2 closely matched the data for briaexcavatolide S, some 
substantial differences among the carbon resonances in the vicinity of the hexene ring 
Table 5.1 13C NMR Data (CDCl3) for RAMs A, B, C, A-M1, B-M1 and C-M1 (2–7) 
position 
δC, number of attached protonsa 
2b 3c 4c 5c 6c 7c 
1 48.2, C 48.2, C 48.2, C 48.0, C 48.0, C 48.0, C 
2 77.4, CH 77.5, CH 77.5, CH 77.7, CH 77.6, CH 77.7, CH 
3 40.1, CH2 40.2, CH2 40.2, CH2 40.1, CH2 40.1, CH2 40.1, CH2 
4 72.8, CH 72.5, CH 72.5, CH 72.9, CH 72.8, CH 72.7, CH 
5 144.2, C 144.3, C 144.4, C 144.2, C 144.3, C 144.3, C 
6 122.5, CH 122.4, CH 122.4, CH 122.4, CH 122.3, CH 122.3, CH 
7 73.6, CH 73.6, CH 73.6, CH 73.9, CH 73.8, CH 73.7, CH 
8 71.3, C 71.4, C 71.4, C 71.4, C 71.4, C 71.4, C 
9 65.1, CH 65.2, CH 65.2, CH 65.6, CH 65.6, CH 65.6, CH 
10 44.6, CH 44.7, CH 44.7, CH 44.0, CH 44.0, CH 44.0, CH 
11 72.4, C 72.6, C 72.6, C 77.2, C 73.9, C 73.9, C 
12 73.5, CH 73.5, CH 73.5, CH 70.6, CH 70.6, CH 70.6, CH 
13 121.9, CH 122.1, CH 122.0, CH 124.4, CH 124.2, CH 124.3, CH 
14 142.0, CH 141.9, CH 142.0, CH 140.0, CH 140.1, CH 140.1, CH 
15 14.0, CH3 14.1, CH3 14.1, CH3 14.1, CH3 14.1, CH3 14.1, CH3 
16 26.5, CH3 26.5, CH3 26.5, CH3 26.6, CH3 26.6, CH3 26.6, CH3 
17 64.8, C 64.9, C 64.9, C 64.9, C 64.9, C 64.9, C 
18 9.7, CH3 9.7, CH3 9.7, CH3 9.8, CH3 9.8, CH3 9.8, CH3 
19 170.4, C 170.4, C 170.4, C 170.5, C 170.5, C 170.5, C 
20 21.2, CH3 21.2, CH3 21.2, CH3 21.4, CH3 21.4, CH3 21.4, CH3 
1’
 
 173.2, C 173.1, C  173.1, C 173.1, C 
2’ 
 34.2, CH2 34.2, CH2  34.2, CH2 34.3, CH2 
3’ 
 24.5, CH2 24.8, CH2  24.6, CH2 24.9, CH2 
4’ 
 31.2, CH2 29.0, CH2  31.2, CH2 29.0, CH2 
5’ 
 22.3, CH2 28.9, CH2  22.3, CH2 28.9, CH2 
6’ 
 13.9, CH3 31.6, CH2  13.9, CH3 31.6, CH2 
7’ 
 
 22.6, CH2   22.6, CH2 
8’ 
 
 14.1, CH3   14.07, CH3 
4-OCOCH3 170.3, C   170.2, C   
4-OCOCH3 21.0, CH3   21.1, CH3   
9-OCOCH3 168.3, C 168.3, C 168.3, C 168.3, C 168.3, C 168.3, C 
9-OCOCH3 21.6, CH3 21.6, CH3 21.6, CH3 21.6, CH3 21.6, CH3 21.6, CH3 
12-OCOCH3 169.8, C 169.8, C 169.8, C    
12-OCOCH3 20.9, CH3 20.9, CH3 20.9, CH3    
aDetermined by HSQC experiment 
bData for 13C NMR determined at 125 MHz 
cData for 13C NMR determined at 100 MHz 
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system were noted.  For example, the observation was made that C-20 in 2 resonated at 
δC 21.2, whereas in briaexcavatolide S this carbon was reported to appear at δC 28.8 (∆ -
7.6 ppm).  Other carbon chemical shifts in the hexene system that varied between 2 
versus briaexcavatolide S included C-1 (∆ 0.2 ppm), C-10 (∆ -1.1 ppm), C-11 (∆ -1.5 
ppm), C-12 (∆ -1.8 ppm), C-13 (∆ 3.1 ppm), and C-14 (∆ -3.2 ppm). 
Using a 2-3JH-C HMBC experiment (Appendix, Table A4), the entire planar 
structure of 2 was independently confirmed.  Focusing on the hexene portion of the 
compound, correlations were observed from H-10 → C-1, C-11, C-12, and C-20; from H-
12 → C-11, C-13, C-14, C-20, and C-25; from H-13 → C-1 and C-11; from H-14 → C-1, 
C-10, C-12, and C-15; from H-20 → C-10; and from H-26 → C-25.  This established that 
the hexene ring systems in 2 and briaexcavatolide S shared the same planar configuration 
and that the compounds must be stereoisomers that differed in the configuration of one or 
more asymmetric centers.  Using NOESY to probe this portion of 2 (Appendix, Table 
A4), a series of informative correlations were observed that enabled the investigation of 
the relative configuration of the four asymmetric carbons.  Whereas the H-15 methyl 
protons exhibited NOE correlations with H-14 and H-20, the H-10 proton was only 
correlated with H-2.  The H-20 protons also exhibited additional correlations that 
included H-9, H-12, and OH-2.  An additional set of correlations were detected between 
OH-11 and H-9 and H-12.  In view of these data, compound 2 was determined to be the 
C-11, C-12 diastereomer of briaexcavatolide S. 
While in the process of establishing the relative configuration of 2, crystals of the 
new metabolite were successfully prepared for X-ray diffraction studies.  A thermal 
ellipsoid plot generated from these data is shown in Figure 5.1.  The data from this 
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experiment not only supported the proposed relative configuration of 2, but it also 
enabled the unequivocal determination of the absolute configuration of the metabolite as 
1S,2S,4R,7S,8S,9S,10S,11S,12R,17R. 
The HRESIMS analysis of compound 3 provided a pseudomolecular ion [M + 
Na]+ at m/z 601.2616 that was consistent with a molecular formula of C30H42NaO11 
(calcd 601.2625).  Upon examination of the 1H NMR data, it became apparent that 
compound 3 was structurally similar to 2 (Tables 5.1 and 5.2).  Two notable changes in 
the 1H NMR spectrum of 3 were that an acetate methyl singlet that had appeared in 2 was 
replaced by a methyl triplet (δH 0.9, t, J = 7.0 Hz) in 3 and that eight new protons were 
detected at δH 2.32 (t, J = 7.5 Hz, 2H), 1.64 (m, 2H), and 1.32 (m, 4H).  In addition, the 
13C NMR (Table 5.1) and 1JH-C HSQC spectra of 3 exhibited four new methylene carbon 
resonances at δC 22.3, 24.5, 31.2, and 34.2 that accounted for all eight of the new protons.  
Given the substantial quantity of 3 that was available (>500 mg), the opportunity to 
perform a 13C–13C INADEQUATE experiment was capitalized on (Figure 5.2).  Based on 
the results from this study, it was 
concluded that the aforementioned 
methylenes were part of a pendant 
hexanoate that began with an ester 
carbonyl (δC 173.2) and terminated in 
a methyl group (δC 13.9). 
Figure 5.1  Thermal ellipsoid plot drawing for the 
X-ray crystal structure of 2. 
  
Table 5.2 1H NMR Data (CDCl3) for RAMs A, B, C, A-M1, B-M1 and C-M1 (2–7) 
position 
δH, multiplicity (J in Hz) 
2a 3b 4a 5a 6a 7a 
2 3.25, dd (5.5, 7.0) 3.27, dd (5.0, 7.0) 3.26, t (7.5) 3.32, d (7.7) 3.32, d (7.3) 3.33, d (7.0) 
3a 2.00, m 2.00, m 2.00, m 2.00, m 2.00, m 2.00, m 
3b 2.84, t (13.0) 2.84, dd (13.0, 14.3) 2.85, dd (12.7, 14.3) 2.83, dd (12.5, 14.0) 2.83, dd (12.4, 14.5) 2.83, dd (12.5, 14.0) 
4 5.16, ddd (1.0, 5.5, 13.0) 5.17, dd (5.0, 7.0, 13.0) 5.17, ddd (1.0, 5.5, 12.7) 5.17, ddd (12.5, 5.5, 1.0) 5.17, dd (5.4, 12.4) 5.17, dd (5.4, 12.5) 
6 5.41, dt (1.3, 9.5) 5.41, dt (1.3, 9.5) 5.40, dt (1.5, 9.5) 5.39, dt (9.5, 1.5) 5.38, dt (9.5, 1.2) 5.38, d (9.4) 
7 5.78, d (9.5) 5.78, d (9.5) 5.78, d (9.5) 5.78, d (9.5) 5.76, d (9.5) 5.76, d (9.4) 
9 5.92, d (4.0) 5.92, d (3.8) 5.92, d (4.0) 5.92, d (3.4) 5.92, d (3.5) 5.92, d (3.0) 
10 2.46, d (4.0) 2.47, d (3.8) 2.47, d (4.0) 2.40, d (3.4) 2.40, d (3.5) 2.40, d (3.0) 
12 4.73, d (6.0) 4.75, d  (6.0) 4.74, d (6.0) 3.75, d (6.0) 3.75, d (6.0) 3.75, d (6.0) 
13 5.96, dd (6.0, 10.3) 5.97, dd (6.0, 10.3) 5.96, dd (6.0, 10.3) 5.90, dd (10.3, 6.0) 5.90, dd (6.0, 10.2) 5.90, dd (6.0, 10.4) 
14 5.89, d (10.3) 5.89, d (10.3) 5.89, d (10.3) 5.83, d (10.3) 5.84, d (10.2) 5.84, d (10.4) 
15 1.13, s 1.13, s 1.13, s 1.13, s 1.13, s 1.13, s 
16 2.04, d (1.3) 2.05, d (1.3) 2.05, d (1.5) 2.04, d (1.5) 2.04, d (1.2) 2.04, s 
18 1.67, s 1.69, s 1.68, s 1.71, s 1.70, s 1.71, s 
20 1.21, s 1.22, s 1.22, s 1.17, s 1.16, s 1.17, s 
2’ 
 
2.32, t (7.5) 2.32, t (7.5)  2.32, t, 7.4 2.32, t (7.5) 
3’ 
 
1.64, m 1.62, m  1.63, m, 7.4 1.63, m 
4’ 
 
1.32, m 1.31  1.32, m 1.31, m 
5’ 
 
1.32, m 1.31  1.32, m 1.31, m 
6’ 
 
0.90, t (7.0) 1.29 
 
0.90, t (7.0) 1.27, m 
7’ 
  
1.28 
  
1.29, m 
8’ 
  
0.88, t (7.0) 
  
0.88, t (7.5) 
4-OCOCH3 2.08, s   2.09, s   
9-OCOCH3 2.24, s 2.24, s 2.24, s 2.25, s 2.24, s 2.24, s 
12-OCOCH3 2.06, s 2.07, s 2.06, s    
2-OH 2.14, d (5.5) 4.87, br s 2.63, br s  
  
11-OH 2.38, s 2.39, br s 2.39, br s 2.65, br s 2.67, br. s 2.67, br. s 
aData for 1H NMR determined at 500 MHz 
bData for 1H NMR determined at 400 MHz 
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Rather than further optimizing the 13C–13C INADEQUATE experiment to capture 
all possible 1JC-C correlations, these data were supplemented with information from a 2-
3JH-C HMBC experiment and this enabled the confirmation that the only variation in the 
planar structures of 2 and 3 was the type of ester substituent attached at the C-4 position 
(Figure 5.2).  NOESY data collected for 3 (Appendix, Table A5) exhibited a strikingly 
similar pattern of proton correlations with 2 (Appendix, Table A4) and this enabled the 
conclusion to be made that 3 shared the same relative configuration.  While the 
preparation of a crystal suitable for X-ray analysis of 3 was not successful, it is proposed 
that the absolute configuration of 3 is also 1S,2S,4R,7S,8S,9S,10S,11S,12R,17R based on 
its shared biogenic origins and similar optical rotation data ([α]21D –109.0 and –100.8 for 
2 and 3, respectively) 
Compound 4 yielded a pseudomolecular ion (HRESIMS [M + Na]+) at m/z 
629.2938 consistent with a molecular formula 
of C32H46NaO11 (calcd 629.2938).  Compared 
to 3, the molecular formula of 4 represented an 
increase in C2H4, from which the speculation 
was made that this was due to the addition of 
two methylenes.  Examination of the 1H NMR 
integration data for 4 revealed four new protons 
in the region spanning from δH 1.28 to 1.31 
(Table 5.2).  HSQC confirmed that these 
protons were associated to two new methylenes 
(δC 28.9 and 29.0), while HMBC established 
CH3
O
O
OH3C
O
O
HO
H3C
H3C
OH
O
H3C
H3C
O
O
CH3O
13C-13C INADEQUATE
1H-13C HMBC
Figure 5.2  13C-13C INADEQUATE and 
selected 1H-13C HMBC data that were 
used to establish the structure of 3. 
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that these carbons were situated among a group of four other methylenes (δC 22.6, 24.8, 
31.6, and 34.2), a carbonyl (δC 173.1), and a methyl group (δC 14.1) (Appendix, Table 
A6).  Together, these carbons formed an octanoate ester.  Consideration of the remaining 
HMBC correlations and NOESY data for 4 (Appendix, Table A6) confirmed that the 
compound shared the same briarane skeleton that had previously been established for 2 
and 3.  The only difference in the new metabolite was that 4 bore a C-4 octanoate ester 
whereas 2 and 3 possessed C-4 acetate and hexanoate groups, respectively.  In light of the 
fact that all three compounds have the same biogenic source and exhibit similar optical 
rotations values ([α]21D –102.0 for 4), it is proposed that the absolute configuration of 4 is 
1S,2S,4R,7S,8S,9S,10S,11S,12R,17R. 
Given the substantial quantity of 2 (> 99% purity based on HPLC) and 3 (mixture 
of approximately 95% of 3 with 5% of 4) that was obtained, the investigation of the 
ichthyotoxicity of these compounds was initiated.  The flathead minnow (Pimephales 
promelas) was employed for this study since it is a widely used and well accepted model 
for determining the acute toxicity of a broad range of chemicals against aquatic 
vertebrates (EPA-821-R-02-012 2002).  After a preliminary assessment of the toxicity of 
2 and 3, both compounds were tested across a series seven concentrations (each 
concentration was tested in triplicate sets of three fish) that spanned the estimated LC50 
range of the toxin.  Based on these experiments, 3 was found to be quite toxic to fish with 
an LC50 of 0.3 mM, while 2 was 4.7 times less potent with an LC50 of 1.4 mM (Figure 
5.3). 
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At the conclusion of the ichthyotoxicity studies, the water from each vessel that 
had supported the fish throughout the assay was collected and pooled separately for all 
doses of 2 and 3.  Although the RAMs demonstrate remarkable stability with no 
detectable signs of degradations for periods of up to one month in aqueous and organic-
based solvents, the surprising finding was made that < 30% of the RAMs used in the 
ichthyotoxicity test were left in the assay water.  Instead, it was noted that the samples 
from the two treatment groups each contained new metabolites (Figure 5.4).  The 
separation of the metabolites was carried out by gradient C18 HPLC resulting in the 
isolation of 5-7. 
The assumption that 5 (RAM A-M1) had been derived from 2 was confirmed by 
comparative inspection of the 1H NMR data for both compounds (Table 5.2).  The spectra 
of 2 and 5 looked remarkably similar with two notable exceptions: the C-12 acetate 
methyl singlet was missing for 5 and H-12 had shifted upfield from δH 4.73 (d, J = 6.0 
Hz, 1H) in 2 to δH 3.75 (d, J = 6.0 Hz, 1H) in 5.  The HRESIMS analysis of compound 5 
provided a pseudomolecular ion [M + Na]+ at m/z 503.1895 that was consistent with a 
molecular formula of C24H32NaO10 (calcd 503.1893).  This represented a loss of C2H3O, 
which could be readily 
accounted for if an acetate 
had been lost through 
hydrolytic cleavage.  In 
addition to the 1H NMR 
and HRESIMS data that 
supported the loss of an Figure 5.3  Dose-dilution ichthyotoxicity results for RAM A (2) 
and RAM B (3) against P. promelas fry. 
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acetate from 2, the 13C NMR 
data further substantiated 
this proposal showing the 
loss of methyl and carbonyl 
resonances in 5, as well as 
the upfield shift of C-12 
from δC 73.5 in 2 to δC 70.6 
in 5 (Table 5.1).  In 
addition, compound 5 was 
successfully crystallized 
from chloroform and the 
crystal was analyzed by X-
ray diffraction spectroscopy.  
The thermal ellipsoid plot 
diagram of 5 illustrated in Figure 5.5 supported the loss of the C-12 acetate and 
confirmed that the rest of the briarane structure remained intact with a relative 
configuration of 1S,2S,4R,7S,8S,9S,10S,11S,12R,17R.  Given the relative stability 
previously noted for 2, the proposal was made that 5 was the product of metabolic 
transformation of 2 by the fish and therefore retained the absolute configuration of 2.  
The fish were not directly ingesting the compounds under the assay conditions; therefore 
the uptake of 2 may have occurred through the gill membrane.  Following its 
deacetylation, it is postulated that 5 was excreted back into the water either through the 
gills or urine. 
Figure 5.4  New metabolites that were generated from 
treating fish (P. promelas fry) with RAMs A-C (2-4).  A) Fish 
treated with RAM A (2) resulted in the formation of the RAM 
A-M1 (5).  B) Fish treated with a mixture of RAM B (3) and 
RAM C (4) (~95:5 mixture) led to the formation of RAM B-M1 
(6) and RAM C-M1 (7).  Only the sections of the HPLC 
chromatogram where the RAMs and their metabolite eluted 
(20-50 minutes) when passed over C18 (50–100% MEOH 
over 60 minutes) are shown for clarity.  The structures of 
compounds corresponding to the other minor abundance 
peaks were not determined. 
20.0 25.0 30.0 35.0 40.0 45.0 min
0.00
0.25
0.50
0.75
1.00
mV(x1,000)RAM A-M1 (5)
503.1895 [M+Na]+
C24H32O10Na
RAM A (2)
545.2004 [M+Na]+
C26H34O11Na 
20.0 25.0 30.0 35.0 40.0 45.0 min
0.00
0.25
0.50
0.75
1.00
mV(x1,000)
A
B
RAM B-M1 (6)
559.2529 [M+Na]+
C28H40O10Na
RAM B (3)
601.2626 [M+Na]+
C30H42O11Na
RAM C-M1 (7)
587.2818 [M+Na]+
C30H44O10Na
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Compound 6 (RAM B-M1) yielded a pseudomolecular ion (HRESIMS [M + 
Na]+) at m/z 559.2529 that was consistent with a molecular formula of C24H32NaO10 
(calcd 559.2519).  The loss of C2H3O in 6 compared to 3 suggested that this compound 
was also the product of a deacetylation process.  This was quickly confirmed by 
comparisons 1H (loss of methyl singlet and upfield shift of the H-12 doublet from δH 4.75 
in 3 to δH 3.75 in 6) (Table 5.2) and 13C (loss of methyl and carbonyl resonances in 6 and 
upfield shift of C-12 from δC 73.5 in 3 to δC 70.6 in 6) (Table 5.1) NMR data for both 
compounds.  HMBC and NOESY experiments (Appendix, Table A8) confirmed that the 
remainder of 6 shared the same planar structure and relative configuration as 3 and it is 
proposed that this metabolite also shares the same absolute configuration. 
HRESIMS analysis of compound 7 (RAM C-M1) provided a pseudomolecular 
ion [M + Na]+ at m/z 587.2818 that was consistent with a molecular formula of 
C24H32NaO10 (calcd 587.2832).  Although the relationship of this metabolite to 3 was at 
first perplexing, the recollection was made that approximately 5% by mass of 3 used in 
the fish assay had been contaminated with 4.  Reconsideration of the possibility that the 
residual quantity of 4 could have been 
metabolically transformed into 7 led 
to the reexamination of the HRESIMS 
data where it was noted that this 
metabolite had likely arisen as the 
result of 4 being deacetylated.  
Inspection of the 1H NMR (loss of 
methyl singlet and upfield shift of the Figure 5.5  Thermal ellipsoid plot drawing for the 
X-ray crystal structure of 5. 
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H-12 doublet from δH 4.74 in 4 to δH 3.75 in 7) (Table 5.2) and 13C NMR (loss of methyl 
and carbonyl resonances in 7 and upfield shift of C-12 from δC 73.5 in 4 to δC 70.6 in 7) 
(Table 5.1) data for 7 quickly confirmed that this metabolite was derived from 4.  
Examination of the HMBC and NOESY data (Appendix, Table A9) showed that other 
than the loss of the C-12 acetate, the remaining portion of the structure for 7 was identical 
to the parent compound.  Consequently, it is proposed that 7 also shared the same 
absolute configuration with the rest of the briarane diterpenes and metabolic 
transformation products obtained in this study. 
Although insufficient material was available to test the relative ichthyotoxic 
properties of the RAM metabolites (5–7), the toxicity of these compounds and 2–4 were 
evaluated against Artemia salina.  However, even at doses ranging up to 2 mM, no brine 
shrimp toxicity was observed for any of the compounds.  These data suggest that the 
ichthyotoxic effects of briaranes likely contribute to a toxic defensive strategy used by 
certain corals and marine invertebrates to protect against foraging fish predators, but may 
be inactive against other invertebrate species.  It has also been shown for the first time 
that these compounds are subjected to structural modification via metabolic 
transformation in fish.  These data serve as a cautionary reminder of the role that 
metabolic transformations can play when testing natural products in vivo. 
The information in Chapter 5 has been adapted from a manuscript which is in 
preparation for publication in the Journal of Natural Products. 
 
  
89 
References 
 Abin-Carriquiry, J. A.; Costa, G.; Urbanavicius, J.; Cassels, B. K.; Rebolledo-
Fuentes, M.; Wonnacott, S.; Dajas, F. In vivo modulation of dopaminergic nigrostriatal 
pathways by cytisine derivatives: Implications for Parkinson's Disease. Eur. J. 
Pharmacol. 2008, 589 (1-3), 80-84. 
 Abu-Salah, K. M. Amphotericin B: an update. Br. J. Biomed. Sci. 1996, 53 (2), 
122-33. 
 Albericci, M.; Braekman, J. C.; Daloze, D.; Tursch, B.; Declercq, J. P.; Gemain, 
G.; Van Meerssche, M. Chemical studies of marine invertebrates. XXXV. Sarcoglaucol, 
a novel cembrane diterpene from the soft coral Sarcophyton glaucum (Coelenterata, 
Octocorallia). Bull. Soc. Chim. Belg. 1978, 87 (6), 487-92. 
 Allain, H.; Bentué-Ferrer, D.; Akwa, Y. Disease-modifying drugs and Parkinson's 
disease. Prog. Neurobiol. 2008, 84 (1), 25-39. 
 Amor, S.; Puentes, F.; Baker, D.; van der Valk, P. Inflammation in 
neurodegenerative diseases. Immunology 2010, 129, 154-169. 
 Anand, P.; Thomas, S. G.; Kunnumakkara, A. B.; Sundaram, C.; Harikumar, K. 
B.; Sung, B.; Tharakan, S. T.; Misra, K.; Priyadarsini, I. K.; Rajasekharan, K. N.; 
Aggarwal, B. B. Biological activities of curcumin and its analogues (Congeners) made by 
man and Mother Nature. Biochem. Pharmacol. 2008, 76 (11), 1590-1611. 
 Asai, M.; Iwata, N.; Yoshikawa, A.; Aizaki, Y.; Ishiura, S.; Saido, T. C.; 
Maruyama, K. Berberine alters the processing of Alzheimer's amyloid precursor protein 
to decrease Aβ secretion. Biochem. Biophys. Res. Commun. 2007, 352 (2), 498-502. 
 Barbosa Filho, J. M.; Medeiros, K. C. P.; Diniz, M. d. F. F. M.; Batista, L. M.; 
Athayde-Filho, P. F.; Silva, M. S.; Cunha, E. V. L. d.; Almeida, J. R. G. S.; Quintans-
Júnior, L. J. Natural products inhibitors of the enzyme acetylcholinesterase. Rev. Bras. 
Farmacogn. 2006, 16, 258-285. 
 Barsby, T.; Kubanek, J. Isolation and Structure Elucidation of Feeding Deterrent 
Diterpenoids from the Sea Pansy, Renilla reniformis. J. Nat. Prod. 2005, 68 (4), 511-516. 
 Bastianetto, S.; Brouillette, J.; Quirion, R. Neuroprotective Effects of Natural 
Products: Interaction with Intracellular Kinases, Amyloid Peptides and a Possible Role 
for Transthyretin. Neurochem. Res. 2007, 32 (10), 1720-1725. 
 Bateman, D. A.; Chakrabartty, A. Interactions of Alzheimer amyloid peptides 
with cultured cells and brain tissue, and their biological consequences. Biopolymers 2004, 
76 (1), 4-14. 
 Bell, W.; Sun, W.; Hohmann, S.; Wera, S.; Reinders, A.; De Virgilio, C.; 
Wiemken, A.; Thevelein, J. M. Composition and Functional Analysis of the 
Saccharomyces cerevisiae Trehalose Synthase Complex. J. Biol. Chem. 1998, 273 (50), 
33311-33319. 
 Beranger, F.; Crozet, C.; Goldsborough, A.; Lehmann, S. Trehalose impairs 
aggregation of PrPSc molecules and protects prion-infected cells against oxidative 
damage. Biochem. Biophys. Res. Commun. 2008, 374 (1), 44-48. 
 Bloom, G. S.; Ren, K.; Glabe, C. G. Cultured cell and transgenic mouse models 
for tau pathology linked to β-amyloid. BBA-Mol. Basis Dis. 2005, 1739 (2-3), 116-124. 
 Branco, J.; Al-Ramahi, I.; Ukani, L.; Perez, A. M.; Fernandez-Funez, P.; Rincon-
Limas, D.; Botas, J. Comparative analysis of genetic modifiers in Drosophila points to 
90 
common and distinct mechanisms of pathogenesis among polyglutamine diseases. Hum. 
Mol. Genet. 2008, 17 (3), 376-90. 
 Brown, G. C. Mechanisms of inflammatory neurodegeneration: iNOS and 
NADPH oxidase. Biochem. Soc. Trans. 2007, 35 (Pt 5), 1119-21. 
 Brundin, P.; Jia-Yi, L.; Holton, J. L.; Lindvall, O.; Revesz, T. Research in motion: 
the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9 (10), 
741-745. 
 Burks, J. E.; Van der Helm, D.; Chang, C. Y.; Ciereszko, L. S. The crystal and 
molecular structure of briarein A, a diterpenoid from the gorgonian Briareum asbestinum. 
Acta Crystallogr. B 1977, B33 (3), 704-709. 
 Butler, M. S. The Role of Natural Product Chemistry in Drug Discovery J. Nat. 
Prod. 2004, 67 (12), 2141-2153. 
 Carmichael, J.; Sugars, K. L.; Bao, Y. P.; Rubinsztein, D. C. Glycogen Synthase 
Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the 
Huntington's Disease Mutation. J. Biol. Chem. 2002, 277 (37), 33791-33798. 
 Cattaneo, E.; Zuccato, C.; Tartari, M. Normal huntingtin function: an alternative 
approach to Huntington's disease. Nat. Rev. Neurosci. 2005, 6 (12), 919-30. 
 Caughey, B.; Raymond, L. D.; Raymond, G. J.; Maxson, L.; Silveira, J.; Baron, 
G. S. Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin. 
J. Virol. 2003, 77 (9), 5499-5502. 
 Changyun, W.; Haiyan, L.; Changlun, S.; Yanan, W.; Liang, L.; Huashi, G. 
Chemical defensive substances of soft corals and gorgonians. Acta Ecolog. Sin. 2008, 28 
(5), 2320-2328. 
 Cheng, Y.; Schneider, B.; Riese, U.; Schubert, B.; Li, Z.; Hamburger, M. 
Farinosones A-C, neurotrophic alkaloidal metabolites from the entomogenous 
deuteromycete Paecilomyces farinosus. J. Nat. Prod. 2004, 67 (11), 1854-8. 
 Cheng, Y.; Schneider, B.; Riese, U.; Schubert, B.; Li, Z.; Hamburger, M. (+)-N-
Deoxymilitarinone A, a neuritogenic pyridone alkaloid from the insect pathogenic fungus 
Paecilomyces farinosus. J. Nat. Prod. 2006, 69 (3), 436-8. 
 Cimino, G.; Crispino, A.; Gavagnin, M.; Sodano, G. Diterpenes from the 
nudibranch Chromodoris luteorosea. J. Nat. Prod. 1990, 53 (1), 102-6. 
 Cimino, G.; Gavagnin, M.; Sodano, G.; Puliti, R.; Mattia, C. A.; Mazzarella, L. 
Verrucosin-A and -B. Ichthyotoxic diterpenoic acid glycerides with a new carbon 
skeleton from the dorid nudibranch Doris verrucosa. Tetrahedron 1988, 44 (8), 2301-10. 
 Clement, J. A.; Yoder, B. J.; Kingston, D. G. I. Natural Products as a Source of 
CNS-Active Agents. Mini Rev. Org. Chem. 2004, 1 (2), 183-208. 
 Colby, D. W.; Chu, Y.; Cassady, J. P.; Duennwald, M.; Zazulak, H.; Webster, J. 
M.; Messer, A.; Lindquist, S.; Ingram, V. M.; Wittrup, K. D. Potent inhibition of 
huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain 
intracellular antibody. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (51), 17616?17621-
17616?17621. 
 Colosimo, C.; Fabbrini, G.; Berardelli, A. Drug Insight: new drugs in 
development for Parkinson's disease. Nat. Clin. Pract. Neurol. 2006, 2 (11), 600-610. 
 Connor, B.; Dragunow, M. The role of neuronal growth factors in 
neurodegenerative disorders of the human brain. Brain. Res. Rev. 1998, 27 (1), 1-39. 
91 
 Cornelis, S.; Kersse, K.; Festjens, N.; Lamkanfi, M.; Vandenabeele, P. 
Inflammatory Caspases: Targets for Novel Therapies. Curr. Pharm. Des. 2007, 13 (4), 
367-385. 
 Crowe, J. H., Trehalose as a "chemical chaperone": Fact and fantasy. In 
Molecular Aspects of the Stress Response: Chaperones, Membranes and Networks, 
Springer-Verlag Berlin: Berlin, 2007; Vol. 594, pp 143-158. 
 Davies, J.; Sarkar, S.; Rubinsztein, D. The ubiquitin proteasome system in 
Huntington's disease and the spinocerebellar ataxias. BMC Biochem. 2007, 8 (Suppl 1), 
S2-S2. 
 Davies, J. E.; Sarkar, S.; Rubinsztein, D. C. Trehalose reduces aggregate 
formation and delays pathology in a transgenic mouse model of oculopharyngeal 
muscular dystrophy. Hum. Mol. Genet. 2006, 15 (1), 23-31. 
 De Petrocellis, L.; Di Marzo, V.; Arca, B.; Gavagnin, M.; Minei, R.; Cimino, G. 
The effect of diterpenoidic diacylglycerols on tentacle regeneration in Hydra vulgaris. 
Comp. Biochem. Physiol., C: Comp. Pharmacol. Toxicol. 1991, 100C (3), 603-7. 
 Desai, U. A.; Pallos, J.; Ma, A. A.; Stockwell, B. R.; Thompson, L. M.; Marsh, J. 
L.; Diamond, M. I. Biologically active molecules that reduce polyglutamine aggregation 
and toxicity. Hum. Mol. Genet. 2006, 15 (13), 2114-24. 
 Dheen, S. T.; Kaur, C.; Ling, E. A. Microglial activation and its implications in 
the brain diseases. Curr. Med. Chem. 2007, 14 (11), 1189-97. 
 Diekmann, H.; Anichtchik, O.; Fleming, A.; Futter, M.; Goldsmith, P.; Roach, A.; 
Rubinsztein, D. C. Decreased BDNF levels are a major contributor to the embryonic 
phenotype of huntingtin knockdown zebrafish. J. Neurosci. 2009, 29 (5), 1343-9. 
 Dong, X.-x.; Wang, Y.; Qin, Z.-h. Molecular mechanisms of excitotoxicity and 
their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin. 
2009, 30 (4), 379-387. 
 Duennwald, M. L.; Jagadish, S.; Muchowski, P. J.; Lindquist, S. Flanking 
sequences profoundly alter polyglutamine toxicity in yeast. Proc. Natl. Acad. Sci. U.S.A. 
2006, 103 (29), 11045-50. 
 Dunckley, T.; Coon, K. D.; Stephan, D. A. Discovery and development of 
biomarkers of neurological disease. Drug Discov. Today 2005, 10 (5), 326-34. 
 Durairajan, S. S. K.; Yuan, Q.; Xie, L.; Chan, W.-S.; Kum, W.-F.; Koo, I.; Liu, 
C.; Song, Y.; Huang, J.-D.; Klein, W. L.; Li, M. Salvianolic acid B inhibits Aβ fibril 
formation and disaggregates preformed fibrils and protects against Aβ-induced 
cytotoxicty. Neurochem. Int. 52 (4-5), 741-750. 
 El Sayed, K. A.; Kelly, M.; Kara, U. A. K.; Ang, K. K. H.; Katsuyama, I.; 
Dunbar, D. C.; Khan, A. A.; Hamann, M. T. New Manzamine Alkaloids with Potent 
Activity against Infectious Diseases. J. Am. Chem. Soc. 2001, 123 (9), 1804-1808. 
 Elbein, A. D.; Pan, Y. T.; Pastuszak, I.; Carroll, D. New insights on trehalose: a 
multifunctional molecule. Glycobiology 2003, 13 (4), 17R-27. 
 EPA-821-R-02-012, Methods for Measuring the Acute Toxicity of Effluents and 
Receiving Waters to Freshwater and Marine Organisms. 5th ed.; U.S. Environmental 
Protection Agency: Washington, DC., 2002. 
 Faber, P. W.; Alter, J. R.; MacDonald, M. E.; Hart, A. C. Polyglutamine-mediated 
dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. 
Acad. Sci. U.S.A. 1999, 96 (1), 179-184. 
92 
 Faber, P. W.; Voisine, C.; King, D. C.; Bates, E. A.; Hart, A. C. 
Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from 
huntingtin polyglutamine neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (26), 
17131-6. 
 Fang, J.; Liu, R.; Tian, Q.; Hong, X. P.; Wang, S. H.; Cao, F. Y.; Pan, X. P.; 
Wang, J. Z. Dehydroevodiamine attenuates calyculin A-induced tau 
hyperphosphorylation in rat brain slices. Acta Pharmacol. Sin. 2007, 28 (11), 1717-23. 
 Farooqui, T.; Farooqui, A. A. Aging: an important factor for the pathogenesis of 
neurodegenerative diseases. Mech. Ageing Dev. 2009, 130 (4), 203-15. 
 Fecke, W.; Gianfriddo, M.; Gaviraghi, G.; Terstappen, G. C.; Heitz, F. Small 
molecule drug discovery for Huntington's Disease. Drug Discov. Today 2009, 14 (9-10), 
453-464. 
 Feling, R. H.; Buchanan, G. O.; Mincer, T. J.; Kauffman, C. A.; Jensen, P. R.; 
Fenical, W. Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel 
microbial source, a marine bacterium of the new genus salinospora. Angew. Chem. Int. 
Ed. Engl. 2003, 42 (3), 355-7. 
 Fenical, W.; Pawlik, J. R. Defensive properties of secondary metabolites from the 
Caribbean gorgonian coral Erythropodium caribaeorum. Mar. Ecol. Prog. Ser. 1991, 75 
(1), 1-8. 
 Fontaine, S. N.; Brown, D. R. Mechanisms of Prion Protein Aggregation. Protein 
Pept. Lett. 2009, 16 (1), 14-26. 
 Forloni, G.; Salmona, M.; Marcon, G.; Tagliavini, F. Tetracyclines and Prion 
Infectivity. Infect. Disord. Drug Targets 2009, 9 (1), 23-30. 
 Francois, J.; Parrou, J. L. Reserve carbohydrates metabolism in the yeast 
Saccharomyces cerevisiae. FEMS Microbiol. Rev. 2001, 25 (1), 125-45. 
 Fung, J.; Darabie, A. A.; McLaurin, J. Contribution of simple saccharides to the 
stabilization of amyloid structure. Biochem. Biophys. Res. Commun. 2005, 328 (4), 1067-
1072. 
 Garre, E.; Perez-Torrado, R.; Gimeno-Alcaniz, J. V.; Matallana, E. Acid trehalase 
is involved in intracellular trehalose mobilization during postdiauxic growth and severe 
saline stress in Saccharomyces cerevisiae. FEMS Yeast Res. 2009, 9 (1), 52-62. 
 Gavagnin, M.; Vardaro, R. R.; Avila, C.; Cimino, G.; Ortea, J. Ichthyotoxic 
diterpenoids from the Cantabrian nudibranch Chromodoris luteorosea. J. Nat. Prod. 
1992, 55 (3), 368-71. 
 Geissen, M.; Krasemann, S.; Matschke, J.; Glatzel, M. Understanding the natural 
variability of prion diseases. Vaccine 2007, 25 (30), 5631-5636. 
 Giese, K. P. GSK-3: a key player in neurodegeneration and memory. IUBMB Life 
2009, 61 (5), 516-21. 
 Gietz, R. D.; Schiestl, R. H. High-efficiency yeast transformation using the 
LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2007, 2 (1), 31-4. 
 Gilgun-Sherki, Y.; Melamed, E.; Offen, D. Anti-Inflammatory Drugs in the 
Treatment of Neurodegenerative Diseases: Current State. Curr. Pharm. Des. 2006, 12 
(27), 3509-3519. 
 Giorgini, F.; Muchowski, P. J., Exploiting Yeast Genetics to Inform Therapeutic 
Strategies for Huntington's Disease. In Yeast Functional Genomics and Proteomics, 
Stagljar, I., Ed. Humana Press: New York, 2009; Vol. 548, pp 161-174. 
93 
 Glendinning, J. I.; Domdom, S.; Long, E. Selective adaptation to noxious foods 
by a herbivorous insect. J. Exp. Biol. 2001, 204 (19), 3355-3367. 
 Gold, B. G.; Villafranca, J. E. Neuroimmunophilin ligands: the development of 
novel neuroregenerative/ neuroprotective compounds. Curr. Top. Med. Chem. 2003, 3 
(12), 1368-75. 
 Gomes, N. G.; Campos, M. G.; Orfao, J. M.; Ribeiro, C. A. Plants with 
neurobiological activity as potential targets for drug discovery. Prog. 
Neuropsychopharmacol. Biol. Psychiatry 2009, 33 (8), 1372-89. 
 Gowda, G. A.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery, D. 
Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 
2008, 8 (5), 617-33. 
 Graziani, E. I. Recent advances in the chemistry, biosynthesis and pharmacology 
of rapamycin analogs. Nat. Prod. Rep. 2009, 26 (5), 602-9. 
 Greenacre, M. Correspondence analysis in medical research. Stat. Methods Med. 
Res. 1992, 1 (1), 97-117. 
 Greenacre, M., Correspondence analysis in practice. 2nd ed.; Chapman & 
Hall/CRC Taylor & Francis Group: Boca Raton, 2007. 
 Greenacre, M. J.; Degos, L. Correspondence analysis of HLA gene frequency data 
from 124 population samples. Am. J. Hum. Genet. 1977, 1 (1), 60-75. 
 Gunasekera, S. P.; McCarthy, P. J.; Longley, R. E.; Pomponi, S. A.; Wright, A. 
E.; Lobkovsky, E.; Clardy, J. Discorhabdin P, a new enzyme inhibitor from a deep-water 
Caribbean sponge of the genus Batzella. J. Nat. Prod. 1999, 62 (1), 173-5. 
 Hamann, M.; Alonso, D.; Martin-Aparicio, E.; Fuertes, A.; Perez-Puerto, M. J.; 
Castro, A.; Morales, S.; Navarro, M. L.; Del Monte-Millan, M.; Medina, M.; Pennaka, 
H.; Balaiah, A.; Peng, J.; Cook, J.; Wahyuono, S.; Martinez, A. Glycogen synthase 
kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of 
the manzamine alkaloids. Potential for Alzheimer's disease. J. Nat. Prod. 2007, 70 (9), 
1397-405. 
 Heinrich, M.; Lee Teoh, H. Galanthamine from snowdrop--the development of a 
modern drug against Alzheimer's disease from local Caucasian knowledge. J. 
Ethnopharmacol. 2004, 92 (2-3), 147-62. 
 Hernandez, F.; Avila, J. The role of glycogen synthase kinase 3 in the early stages 
of Alzheimers' disease. FEBS Lett. 2008, 582 (28), 3848-54. 
 Hong, S.; Yong, Y.; Kang, K.; Shin, S. Y.; Lee, Y. H.; Lim, Y. NF-κB Activation 
by compounds found in Platycodon grandiflorum extract. J. Microbiol. Biotechnol. 2009, 
19 (6), 556-9. 
 Houghton, P. J.; Howes, M. J. Natural products and derivatives affecting 
neurotransmission relevant to Alzheimer's and Parkinson's disease. Neurosignals 2005, 
14 (1-2), 6-22. 
 Huang, J.; Reggiori, F.; Klionsky, D. J. The transmembrane domain of acid 
trehalase mediates ubiquitin-independent multivesicular body pathway sorting. Mol. Biol. 
Cell 2007, 18 (7), 2511-24. 
 Igarashi, S.; Morita, H.; Bennett, K. M.; Tanaka, Y.; Engelender, S.; Peters, M. 
F.; Cooper, J. K.; Wood, J. D.; Sawa, A.; Ross, C. A. Inducible PC12 cell model of 
Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 2003, 
14 (4), 565-8. 
94 
 Iijima, K.; Iijima-Ando, K. Drosophila Models of Alzheimer's Amyloidosis: The 
Challenge of Dissecting the Complex Mechanisms of Toxicity of Amyloid-β 42. J. 
Alzheimers Dis. 2008, 15 (4), 523-540. 
 Imarisio, S.; Carmichael, J.; Korolchuk, V.; Chen, C.-W.; Saiki, S.; Rose, C.; 
Krishna, G.; Davies, J. E.; Ttofi, E.; Underwood, B. R.; Rubinsztein, D. C. Huntington's 
disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412 (2), 
191-209. 
 Iwagawa, T.; Nakamura, S.; Masuda, T.; Okamura, H.; Nakatani, M.; Siro, M. 
Irregular cembranoids containing a 13-membered carbocyclic skeleton isolated from a 
soft coral, Sarcophyton species. Tetrahedron 1995, 51 (18), 5291-8. 
 Iwagawa, T.; Nakamura, S.; Okamura, H.; Nakatani, M. New cembranoids from 
Sarcophyton sp. collected at Bonotsu, Kagoshima prefecture. 3. Ichthyotoxic 
cembranoids from the soft coral, Sarcophyton sp. Bull. Chem. Soc. Jpn. 1996, 69 (12), 
3543-3549. 
 Jackson, G. R.; Salecker, I.; Dong, X.; Yao, X.; Arnheim, N.; Faber, P. W.; 
MacDonald, M. E.; Zipursky, S. L. Polyglutamine-Expanded Human Huntingtin 
Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons. Neuron 1998, 21 
(3), 633-642. 
 Jain, N. K.; Roy, I. Effect of trehalose on protein structure. Protein Sci. 2009, 18 
(1), 24-36. 
 Jayaprakasam, B.; Padmanabhan, K.; Nair, M. G. Withanamides in Withania 
somnifera fruit protect PC-12 cells from β-amyloid responsible for Alzheimer's disease. 
Phytother. Res. 2009. 
 Jenkins, B. G.; Andreassen, O. A.; Dedeoglu, A.; Leavitt, B.; Hayden, M.; 
Borchelt, D.; Ross, C. A.; Ferrante, R. J.; Beal, M. F. Effects of CAG repeat length, HTT 
protein length and protein context on cerebral metabolism measured using magnetic 
resonance spectroscopy in transgenic mouse models of Huntington's disease. J. 
Neurochem. 2005, 95 (2), 553-62. 
 Jenkins, B. G.; Klivenyi, P.; Kustermann, E.; Andreassen, O. A.; Ferrante, R. J.; 
Rosen, B. R.; Beal, M. F. Nonlinear decrease over time in N-acetyl aspartate levels in the 
absence of neuronal loss and increases in glutamine and glucose in transgenic 
Huntington's disease mice. J. Neurochem. 2000, 74 (5), 2108-19. 
 Jenner, P. Functional models of Parkinson's disease: A valuable tool in the 
development of novel therapies. Ann. Neurol. 2008, 64 (S2), S16-S29. 
 Jeong, H.; Then, F.; Melia, T. J., Jr.; Mazzulli, J. R.; Cui, L.; Savas, J. N.; 
Voisine, C.; Paganetti, P.; Tanese, N.; Hart, A. C.; Yamamoto, A.; Krainc, D. Acetylation 
targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137 (1), 60-72. 
 Jolliffe, I. T., Principal Component Analysis. Springer-Verlag: 2002. 
 Jones, E. W. Tackling the protease problem in Saccharomyces cerevisiae. Meth. 
Enzymol. 1991, 194, 428-53. 
 Joyner, P. M.; Matheke, R. M.; Smith, L. M.; Cichewicz, R. H. Probing the 
metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their 
degree of preservation in humans and mice. J. Proteome Res. 2010, 9 (1), 404-12. 
 Jung, H. A.; Min, B.-S.; Yokozawa, T.; Lee, J.-H.; Kim, Y. S.; Choi, J. S. Anti-
Alzheimer and Antioxidant Activities of Coptidis Rhizoma Alkaloids. Biol. Pharm. Bull. 
2009, 32 (8), 1433-1438. 
95 
 Jung, M.; Park, M. Acetylcholinesterase inhibition by flavonoids from Agrimonia 
pilosa. Molecules 2007, 12 (9), 2130-9. 
 Kaddurah-Daouk, R.; Krishnan, K. R. R. Metabolomics: A Global Biochemical 
Approach to the Study of Central Nervous System Diseases. Neuropsychopharmacology 
2008, 34 (1), 173-186. 
 Kaddurah-Daouk, R.; Kristal, B. S.; Weinshilboum, R. M. Metabolomics: A 
Global Biochemical Approach to Drug Response and Disease. Annu. Rev. Pharmacol. 
Toxicol. 2008, 48 (1), 653-683. 
 Kaganovich, D.; Kopito, R.; Frydman, J. Misfolded proteins partition between 
two distinct quality control compartments. Nature 2008, 454 (7208), 1088-1095. 
 Kang, C. B.; Hong, Y.; Dhe-Paganon, S.; Yoon, H. S. FKBP family proteins: 
immunophilins with versatile biological functions. Neurosignals 2008, 16 (4), 318-25. 
 Kang, S. Y.; Lee, K. Y.; Sung, S. H.; Kim, Y. C. Four new neuroprotective 
dihydropyranocoumarins from Angelica gigas. J. Nat. Prod. 2005, 68 (1), 56-9. 
 Kaushik, J. K.; Bhat, R. Why is trehalose an exceptional protein stabilizer? An 
analysis of the thermal stability of proteins in the presence of the compatible osmolyte 
trehalose. J. Biol. Chem. 2003, 278 (29), 26458-26465. 
 Kim, S. R.; Lee, K. Y.; Koo, K. A.; Sung, S. H.; Lee, N. G.; Kim, J.; Kim, Y. C. 
Four new neuroprotective iridoid glycosides from Scrophularia buergeriana roots. J. Nat. 
Prod. 2002, 65 (11), 1696-9. 
 Kim, S. U.; de Vellis, J. Stem cell-based cell therapy in neurological diseases: a 
review. J. Neurosci. Res. 2009, 87 (10), 2183-200. 
 Kocisko, D. A.; Baron, G. S.; Rubenstein, R.; Chen, J.; Kuizon, S.; Caughey, B. 
New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 
Drugs and Natural Products. J. Virol. 2003, 77 (19), 10288-10294. 
 Kossuga, M. H.; Nascimento, A. M.; Reimao, J. Q.; Tempone, A. G.; Taniwaki, 
N. N.; Veloso, K.; Ferreira, A. G.; Cavalcanti, B. C.; Pessoa, C.; Moraes, M. O.; Mayer, 
A. M.; Hajdu, E.; Berlinck, R. G. Antiparasitic, antineuroinflammatory, and cytotoxic 
polyketides from the marine sponge Plakortis angulospiculatus collected in Brazil. J. Nat. 
Prod. 2008, 71 (3), 334-9. 
 Krammer, C.; Vorberg, I.; Schatzl, H. M.; Gilch, S. Therapy in Prion Diseases: 
From Molecular and Cellular Biology to Therapeutic Targets. Infect. Disord. Drug 
Targets 2009, 9 (1), 3-14. 
 Krobitsch, S.; Lindquist, S. Aggregation of huntingtin in yeast varies with the 
length of the polyglutamine expansion and the expression of chaperone proteins. Proc. 
Natl. Acad. Sci. U.S.A. 2000, 97 (4), 1589-94. 
 Kwon, H. C.; Lee, K. C.; Cho, O. R.; Jung, I. Y.; Cho, S. Y.; Kim, S. Y.; Lee, K. 
R. Sphingolipids from Bombycis Corpus 101A and their neurotrophic effects. J. Nat. 
Prod. 2003, 66 (4), 466-9. 
 Langbehn, D. R.; Hayden, M. R.; Paulsen, J. S. and The Predict-H.D. 
Investigators of the Huntington Study Group CAG-repeat length and the age of onset in 
Huntington disease (HD): A review and validation study of statistical approaches. Am. J. 
Med. Genet. B Neuropsychiatr. Genet. 2010, 153B (2), 397-408. 
 Lee, K. Y.; Sung, S. H.; Kim, Y. C. Neuroprotective bibenzyl glycosides of 
Stemona tuberosa roots. J. Nat. Prod. 2006, 69 (4), 679-81. 
96 
 Lees, A. J.; Hardy, J.; Revesz, T. Parkinson's disease. Lancet 2009, 373 (9680), 
2055-66. 
 Lemke, A.; Kiderlen, A. F.; Kayser, O. Amphotericin B. Appl. Microbiol. 
Biotechnol. 2005, 68 (2), 151-62. 
 Lin, L.; Lee, K.-H.; Atta-ur, R., Structure-activity relationships of curcumin and 
its analogs with different biological activities. In Studies in Natural Products Chemistry, 
Elsevier: 2006; Vol. Volume 33, Part 13, pp 785-812. 
 Liu, F. F.; Dong, X. Y.; Sun, Y. Molecular mechanism for the effects of trehalose 
on β-hairpin folding revealed by molecular dynamics simulation. J. Mol. Graph. Model. 
2008, 27 (4), 421-429. 
 Liu, J. W.; Tian, S. J.; de Barry, J.; Luu, B. Panaxadiol glycosides that induce 
neuronal differentiation in neurosphere stem cells. J. Nat. Prod. 2007, 70 (8), 1329-34. 
 Liu, R.; Barkhordarian, H.; Emadi, S.; Park, C. B.; Sierks, M. R. Trehalose 
differentially inhibits aggregation and neurotoxicity of β-amyloid 40 and 42. Neurobiol. 
Dis. 2005, 20 (1), 74-81. 
 Lleo, A. Current Therapeutic Options for Alzheimer's Disease. Curr. Genomics 
2007, 8 (8), 550-558. 
 Loizzo, M. R.; Tundis, R.; Menichini, F. Natural products and their derivatives as 
cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. Curr. 
Med. Chem. 2008, 15 (12), 1209-28. 
 Lumsden, A. L.; Henshall, T. L.; Dayan, S.; Lardelli, M. T.; Richards, R. I. 
Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum. 
Mol. Genet. 2007, 16 (16), 1905-20. 
 MacDonald, M. E.; Ambrose, C. M.; Duyao, M. P.; Myers, R. H.; Lin, C.; 
Srinidhi, L.; Barnes, G.; Taylor, S. A.; James, M.; Groot, N.; MacFarlane, H.; Jenkins, 
B.; Anderson, M. A.; Wexler, N. S.; Gusella, J. F.; Bates, G. P.; Baxendale, S.; 
Hummerich, H.; Kirby, S.; North, M.; Youngman, S.; Mott, R.; Zehetner, G.; Sedlacek, 
Z.; Poustka, A.; Frischauf, A.-M.; Lehrach, H.; Buckler, A. J.; Church, D.; Doucette-
Stamm, L.; O'Donovan, M. C.; Riba-Ramirez, L.; Shah, M.; Stanton, V. P.; Strobel, S. 
A.; Draths, K. M.; Wales, J. L.; Dervan, P.; Housman, D. E.; Altherr, M.; Shiang, R.; 
Thompson, L.; Fielder, T.; Wasmuth, J. J.; Tagle, D.; Valdes, J.; Elmer, L.; Allard, M.; 
Castilla, L.; Swaroop, M.; Blanchard, K.; Collins, F. S.; Snell, R.; Holloway, T.; 
Gillespie, K.; Datson, N.; Shaw, D.; Harper, P. S. A novel gene containing a trinucleotide 
repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72 
(6), 971-983. 
 Mange, A.; Nishida, N.; Milhavet, O.; McMahon, H. E. M.; Casanova, D.; 
Lehmann, S. Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion 
Protein in Infected Cultures. J. Virol. 2000, 74 (7), 3135-3140. 
 Masuda, N.; Peng, Q.; Li, Q.; Jiang, M.; Liang, Y.; Wang, X.; Zhao, M.; Wang, 
W.; Ross, C. A.; Duan, W. Tiagabine is neuroprotective in the N171-82Q and R6/2 
mouse models of Huntington's disease. Neurobiol. Dis. 2008, 30 (3), 293-302. 
 Mayer, A. M.; Hall, M. L.; Lynch, S. M.; Gunasekera, S. P.; Sennett, S. H.; 
Pomponi, S. A. Differential modulation of microglia superoxide anion and thromboxane 
B2 generation by the marine manzamines. BMC Pharmacol. 2005, 5, 6. 
 McPhail, K.; Davies-Coleman, M. T. New spongian diterpenes from the east 
African nudibranch Chromodoris hamiltoni. Tetrahedron 1997, 53 (13), 4655-4660. 
97 
 Mechlinski, W.; Schaffner, C. P.; Ganis, P.; Avitabile, G. Structure and absolute 
configuration of the polyene macrolide antibiotic amphotericin B. Tetrahedron Lett. 
1970, 11 (44), 3873-3876. 
 Meijer, L.; Thunnissen, A. M.; White, A. W.; Garnier, M.; Nikolic, M.; Tsai, L. 
H.; Walter, J.; Cleverley, K. E.; Salinas, P. C.; Wu, Y. Z.; Biernat, J.; Mandelkow, E. M.; 
Kim, S. H.; Pettit, G. R. Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by 
hymenialdisine, a marine sponge constituent. Chem. Biol. 2000, 7 (1), 51-63. 
 Menalled, L.; El-Khodor, B. F.; Patry, M.; Suarez-Farinas, M.; Orenstein, S. J.; 
Zahasky, B.; Leahy, C.; Wheeler, V.; Yang, X. W.; MacDonald, M.; Morton, A. J.; 
Bates, G.; Leeds, J.; Park, L.; Howland, D.; Signer, E.; Tobin, A.; Brunner, D. Systematic 
behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. 
Neurobiol. Dis. 2009, 35 (3), 319-36. 
 Meriin, A. B.; Zhang, X.; He, X.; Newnam, G. P.; Chernoff, Y. O.; Sherman, M. 
Y. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated 
by a prion-like protein Rnq1. J. Cell Biol. 2002, 157 (6), 997-1004. 
 Miyamoto, T.; Takenaka, Y.; Yamada, K.; Higuchi, R. Bioactive diterpenoids 
from octocorallia, 2. Deoxyxeniolide B, a novel ichthyotoxic diterpenoid from the soft 
coral Xenia elongata. J. Nat. Prod. 1995, 58 (6), 924-8. 
 Molyneux, R. J.; Ralphs, M. H. Plant Toxins and Palatability to Herbivores. J. 
Range Manage. 1992, 45 (1), 13-18. 
 Nakasato, T.; Asada, S.; Marui, K. Dehydroevodiamine, main alkaloid from the 
leaves of Evodia rutaecarpa. Yakugaku Zasshi 1962, 82, 619-626. 
 Naoi, M.; Maruyama, W.; Yi, H.; Inaba, K.; Akao, Y.; Shamoto-Nagai, M. 
Mitochondria in neurodegenerative disorders: regulation of the redox state and death 
signaling leading to neuronal death and survival. J. Neural Transm. 2009, 116 (11), 1371-
1381. 
 Newman, D. J. Natural Products as Leads to Potential Drugs: An Old Process or 
the New Hope for Drug Discovery? J. Med. Chem. 2008, 51 (9), 2589-2599. 
 Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 
last 25 years. J. Nat. Prod. 2007, 70 (3), 461-77. 
 Nicoli, F.; Vion-Dury, J.; Maloteaux, J. M.; Delwaide, C.; Confort-Gouny, S.; 
Sciaky, M.; Cozzone, P. J. CSF and serum metabolic profile of patients with Huntington's 
chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci. Lett. 
1993, 154 (1-2), 47-51. 
 Nicoll, A. J.; Collinge, J. Preventing Prion Pathogenicity by Targeting the 
Cellular Prion Protein. Infect. Disord. Drug Targets 2009, 9 (1), 48-57. 
 NINDS National Institute of Neurological Disorders and Stroke, National 
Institutes of Health. http://www.ninds.nih.gov/index.htm (February 2010),  
 Obrig, T. G.; Culp, W. J.; McKeehan, W. L.; Hardesty, B. The mechanism by 
which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on 
reticulocyte ribosomes. J. Biol. Chem. 1971, 246 (1), 174-81. 
 Ohizumi, Y.; Yamakuni, T.; Li, Y. Search for Constituents with Neurotrophic 
Factor Activity from Medicinal Plants and their Application to Drug Development. J. 
Appl. Pharmacol. 2004, 12, 195-197. 
98 
 Orhan, G.; Orhan, I.; Subutay-Oztekin, N.; Ak, F.; Sener, B. Contemporary 
anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the 
treatment of Alzheimer's disease. Recent Pat. CNS Drug Discov. 2009, 4 (1), 43-51. 
 Oura, M.; Sternberg, T. H.; Wright, E. T. A new antifungal antibiotic, 
amphotericin B. Antibiot. Annu. 1955, 3, 566-73. 
 Outeiro, T. F.; Giorgini, F. Yeast as a drug discovery platform in Huntington's 
and Parkinson's diseases. Biotechnol. J. 2006, 1 (3), 258-69. 
 Ouyang, Y. H.; Xu, Q. H.; Mitsui, K.; Motizuki, M.; Xu, Z. J. Human trehalase is 
a stress responsive protein in Saccharomyces cerevisiae. Biochem. Biophys. Res. 
Commun. 2009, 379 (2), 621-625. 
 Palacios, D. S.; Anderson, T. M.; Burke, M. D. A post-PKS oxidation of the 
amphotericin B skeleton predicted to be critical for channel formation is not required for 
potent antifungal activity. J. Am. Chem. Soc. 2007, 129 (45), 13804-5. 
 Pallas, M.; Camins, A. Molecular and Biochemical Features in Alzheimer's 
Disease. Curr. Pharm. Des. 2006, 12 (33), 4389-4408. 
 Panza, F.; Solfrizzi, V.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A. 
M.; Vendemiale, G.; Capurso, A.; Imbimbo, B. P. Disease-Modifying Approach to the 
Treatment of Alzheimer's Disease: From α-Secretase Activators to γ-Secretase Inhibitors 
and Modulators. Drugs Aging 2009, 26 (7), 537-555. 
 Patel, A. K.; Rogers, J. T.; Huang, X. Flavanols, mild cognitive impairment, and 
Alzheimer's dementia. Int. J. Clin. Exp. Med. 2008, 1 (2), 181-91. 
 Pattison, L. R.; Kotter, M. R.; Fraga, D.; Bonelli, R. M. Apoptotic cascades as 
possible targets for inhibiting cell death in Huntington's disease. J. Neurol. 2006, 253 (9), 
1137-42. 
 Peng, J.; Kudrimoti, S.; Prasanna, S.; Odde, S.; Doerksen, R. J.; Pennaka, H. K.; 
Choo, Y.-M.; Rao, K. V.; Tekwani, B. L.; Madgula, V.; Khan, S. I.; Wang, B.; Mayer, A. 
M. S.; Jacob, M. R.; Tu, L. C.; Gertsch, J. r.; Hamann, M. T. Structure-Activity 
Relationship and Mechanism of Action Studies of Manzamine Analogues for the Control 
of Neuroinflammation and Cerebral Infections. J. Med. Chem. 2010, 53 (1), 61-76. 
 Planells-Cases, R.; Lerma, J.; Ferrer-Montiel, A. Pharmacological Intervention at 
Ionotropic Glutamate Receptor Complexes. Curr. Pharm. Des. 2006, 12 (28), 3583-3596. 
 Powers, R. NMR metabolomics and drug discovery. Magn. Reson. Chem. 2009, 
47 Suppl 1, S2-11. 
 Price, R. D.; Milne, S. A.; Sharkey, J.; Matsuoka, N. Advances in small molecules 
promoting neurotrophic function. Pharmacol. Ther. 2007, 115 (2), 292-306. 
 Qi, W.; Zhang, A.; Good, T. A.; Fernandez, E. J. Two Disaccharides and 
Trimethylamine N-Oxide Affect Aβ Aggregation Differently, but All Attenuate 
Oligomer-Induced Membrane Permeability. Biochemistry 2009, 48 (37), 8908-8919. 
 Querfurth, H. W.; LaFerla, F. M. Alzheimer's disease. N. Engl. J. Med. 362 (4), 
329-44. 
 Ravikumar, B.; Berger, Z.; Vacher, C.; O'Kane, C. J.; Rubinsztein, D. C. 
Rapamycin pre-treatment protects against apoptosis. Hum. Mol. Genet. 2006, 15 (7), 
1209-16. 
 Reynolds, N. C.; Prost, R. W.; Mark, L. P. Heterogeneity in 1H-MRS profiles of 
presymptomatic and early manifest Huntington's disease. Brain Res. 2005, 1031 (1), 82-
9. 
99 
 Roze, E.; Saudou, F.; Caboche, J. Pathophysiology of Huntington's disease: from 
huntingtin functions to potential treatments. Curr. Opin. Neurol. 2008, 21 (4), 497-503. 
 Sarkar, S.; Davies, J. E.; Huang, Z.; Tunnacliffe, A.; Rubinsztein, D. C. 
Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance 
of Mutant Huntingtin and α-Synuclein. J. Biol. Chem. 2007a, 282 (8), 5641-5652. 
 Sarkar, S.; Krishna, G.; Imarisio, S.; Saiki, S.; O'Kane, C. J.; Rubinsztein, D. C. A 
rational mechanism for combination treatment of Huntington's disease using lithium and 
rapamycin. Hum. Mol. Genet. 2008, 17 (2), 170-178. 
 Sarkar, S.; Perlstein, E. O.; Imarisio, S.; Pineau, S.; Cordenier, A.; Maglathlin, R. 
L.; Webster, J. A.; Lewis, T. A.; O'Kane, C. J.; Schreiber, S. L.; Rubinsztein, D. C. Small 
molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat. 
Chem. Biol. 2007b, 3 (6), 331-338. 
 Satyal, S. H.; Schmidt, E.; Kitagawa, K.; Sondheimer, N.; Lindquist, S.; Kramer, 
J. M.; Morimoto, R. I. Polyglutamine aggregates alter protein folding homeostasis in 
Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (11), 5750-5. 
 Scatena, R.; Martorana, G. E.; Bottoni, P.; Botta, G.; Pastore, P.; Giardina, B. An 
update on pharmacological approaches to neurodegenerative diseases. Expert. Opin. 
Investig. Drugs 2007, 16 (1), 59-72. 
 Schapira, A. H. V.; Bezard, E.; Brotchie, J.; Calon, F. d. r.; Collingridge, G. L.; 
Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Novare, N. L.; Obeso, J. A.; 
Schwarzschild, M. A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for 
the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 2006, 5 (10), 845-854. 
 Schatzl, H. M. Drug Targets in Prion Diseases. Infect. Disord. Drug Targets 
2009, 9 (1), 1-2. 
 Schiffer, N. W.; Broadley, S. A.; Hirschberger, T.; Tavan, P.; Kretzschmar, H. A.; 
Giese, A.; Haass, C.; Hartl, F. U.; Schmid, B. Identification of anti-prion compounds as 
efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J. Biol. 
Chem. 2007, 282 (12), 9195-203. 
 Schlenk, D.; Gerwick, W. H. Dilophic acid, a diterpenoid from the tropical brown 
seaweed Dilophus guineensis. Phytochemistry 1987, 26 (4), 1081-4. 
 Schmidt, K.; Gunther, W.; Stoyanova, S.; Schubert, B.; Li, Z.; Hamburger, M. 
Militarinone A, a neurotrophic pyridone alkaloid from Paecilomyces militaris. Org. Lett. 
2002, 4 (2), 197-9. 
 Schmidt, K.; Riese, U.; Li, Z.; Hamburger, M. Novel tetramic acids and pyridone 
alkaloids, militarinones B, C, and D, from the insect pathogenic fungus Paecilomyces 
militaris. J. Nat. Prod. 2003, 66 (3), 378-83. 
 Sehgal, S. N.; Baker, H.; Vezina, C. Rapamycin (AY-22,989), a new antifungal 
antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 1975, 28 
(10), 727-32. 
 Sheldon, A. L.; Robinson, M. B. The role of glutamate transporters in 
neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 
2007, 51 (6-7), 333-355. 
 Shigeta, K.; Ootaki, K.; Tatemoto, H.; Nakanishi, T.; Inada, A.; Muto, N. 
Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by a 
Coptidis Rhizoma extract and protoberberine alkaloids. Biosci. Biotechnol. Biochem. 
2002, 66 (11), 2491-4. 
100 
 Simola, N.; Morelli, M.; Carta, A. The 6-Hydroxydopamine model of parkinson’s 
disease. Neurotox. Res. 2007, 11 (3), 151-167. 
 Singer, M. A.; Lindquist, S. Multiple effects of trehalose on protein folding in 
vitro and in vivo. Mol. Cell 1998, 1 (5), 639-48. 
 Skovronsky, D. M.; Lee, V. M.; Trojanowski, J. Q. Neurodegenerative diseases: 
new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 
2006, 1, 151-70. 
 Stefani, M. Generic Cell Dysfunction in Neurodegenerative Disorders: Role of 
Surfaces in Early Protein Misfolding, Aggregation, and Aggregate Cytotoxicity. 
Neuroscientist 2007, 13 (5), 519-531. 
 Steuer, R. Review: On the analysis and interpretation of correlations in 
metabolomic data. Brief. Bioinformatics 2006, 7 (2), 151-158. 
 Stiller, E. T.; Vandeputte, J.; Wachtel, J. L. Amphotericins A and B, antifungal 
antibiotics produced by a streptomycete. II. The isolation and properties of the crystalline 
amphotericins. Antibiot. Annu. 1955, 3, 587-91. 
 Subramaniam, S.; Sixt, K. M.; Barrow, R.; Snyder, S. H. Rhes, a striatal specific 
protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324 (5932), 1327-30. 
 Sung, P.-J.; Chang, P.-C.; Fang, L.-S.; Sheu, J.-H.; Chen, W.-C.; Chen, Y.-P.; 
Lin, M.-R. Survey of briarane-related diterpenoids-Part II. Heterocycles 2005, 65 (1), 
195-204. 
 Sung, P.-J.; Chen, M.-C. The heterocyclic natural products of gorgonian corals of 
genus Briareum exclusive of briarane-type diterpenoids. Heterocycles 2002, 57 (9), 1705-
1715. 
 Sung, P.-J.; Sheu, J.-H.; Wang, W.-H.; Fang, L.-S.; Chung, H.-M.; Pai, C.-H.; Su, 
Y.-D.; Tsai, W.-T.; Chen, B.-Y.; Lin, M.-R.; Li, G.-Y. Survey of briarane-type 
diterpenoids - part III. Heterocycles 2008, 75 (11), 2627-2648. 
 Sung, P.-J.; Sheu, J.-H.; Xu, J.-P. Survey of briarane-type diterpenoids of marine 
origin. Heterocycles 2002, 57 (3), 535-579. 
 Swihart, R.; DeAngelis, D.; Feng, Z.; Bryant, J. Troublesome toxins: time to re-
think plant-herbivore interactions in vertebrate ecology. BMC Ecol. 2009, 9 (1), 5. 
 Takeshige, K.; Baba, M.; Tsuboi, S.; Noda, T.; Ohsumi, Y. Autophagy in Yeast 
Demonstrated with Proteinase-Deficient Mutants and Conditions for Its Induction. J. Cell 
Biol. 1992, 119 (2), 301-311. 
 Tanaka, M.; Machida, Y.; Niu, S.; Ikeda, T.; Jana, N. R.; Doi, H.; Kurosawa, M.; 
Nekooki, M.; Nukina, N. Trehalose alleviates polyglutamine-mediated pathology in a 
mouse model of Huntington disease. Nat. Med. 2004, 10 (2), 148-54. 
 Tanaka, M.; Machida, Y.; Nukina, N. A novel therapeutic strategy for 
polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules. J. 
Mol. Med. 2005, 83 (5), 343-352. 
 Taylor-Robinson, S. D.; Weeks, R. A.; Bryant, D. J.; Sargentoni, J.; Marcus, C. 
D.; Harding, A. E.; Brooks, D. J. Proton magnetic resonance spectroscopy in 
Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov. 
Disord. 1996, 11 (2), 167-73. 
 Thampithak, A.; Jaisin, Y.; Meesarapee, B.; Chongthammakun, S.; 
Piyachaturawat, P.; Govitrapong, P.; Supavilai, P.; Sanvarinda, Y. Transcriptional 
101 
regulation of iNOS and COX-2 by a novel compound from Curcuma comosa in 
lipopolysaccharide-induced microglial activation. Neurosci. Lett. 2009, 462 (2), 171-5. 
 Tkac, I.; Dubinsky, J. M.; Keene, C. D.; Gruetter, R.; Low, W. C. Neurochemical 
changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. 
J. Neurochem. 2007, 100 (5), 1397-406. 
 Tohda, C.; Kuboyama, T.; Komatsu, K. Search for natural products related to 
regeneration of the neuronal network. Neurosignals 2005, 14 (1-2), 34-45. 
 Triggle, D., J.; Mitchell, J., M.; Filler, R. The Pharmacology of Physostigmine. 
CNS Drug Rev. 1998, 4 (2), 87-136. 
 Tsang, T. M.; Haselden, J. N.; Holmes, E. Metabonomic Characterization of the 
3-Nitropropionic Acid Rat Model of Huntington's Disease. Neurochem. Res. 2009, 34 
(7), 1261-1271. 
 Tsang, T. M.; Woodman, B.; McLoughlin, G. A.; Griffin, J. L.; Tabrizi, S. J.; 
Bates, G. P.; Holmes, E. Metabolic characterization of the R6/2 transgenic mouse model 
of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J. Proteome Res. 
2006, 5 (3), 483-92. 
 Uchio, Y.; Eguchi, S.; Kuramoto, J.; Nakayama, M.; Hase, T. Denticulatolide, an 
ichthyotoxic peroxide-containing cembranolide from the soft coral Lobophytum 
denticulatum. Tetrahedron Lett. 1985, 26 (37), 4487-90. 
 Uchio, Y.; Fukazawa, Y.; Bowden, B. F.; Coll, J. C. New diterpenes from an 
Australian Pachyclavularia species (Coelenterata, Anthozoa, Octocorallia). Tennen Yuki 
Kagobutsu Toronkai Koen Yoshishu 1989, 31, 548-553  
 Underwood, B. R.; Broadhurst, D.; Dunn, W. B.; Ellis, D. I.; Michell, A. W.; 
Vacher, C.; Mosedale, D. E.; Kell, D. B.; Barker, R. A.; Grainger, D. J.; Rubinsztein, D. 
C. Huntington disease patients and transgenic mice have similar pro-catabolic serum 
metabolite profiles. Brain 2006, 129 (Pt 4), 877-86. 
 Urbain, A.; Marston, A.; Grilo, L. S.; Bravo, J.; Purev, O.; Purevsuren, B.; 
Batsuren, D.; Reist, M.; Carrupt, P. A.; Hostettmann, K. Xanthones from Gentianella 
amarella ssp. acuta with acetylcholinesterase and monoamine oxidase inhibitory 
activities. J. Nat. Prod. 2008, 71 (5), 895-7. 
 Uversky, V. N. Neuropathology, biochemistry, and biophysics of α-synuclein 
aggregation. J. Neurochem. 2007, 103 (1), 17-37. 
 Vafeiadou, K.; Vauzour, D.; Spencer, J. P. E. Neuroinflammation and its 
Modulation by Flavonoids. Endocr. Metab. Immune Disord. Drug Targets 2007, 7 (3), 
211-224. 
 Van der Schyf, C. J.; Gal, S.; Geldenhuys, W. J.; Youdim, M. B. Multifunctional 
neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine 
receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. 
Expert. Opin. Investig. Drugs 2006, 15 (8), 873-86. 
 Van der Schyf, C. J.; Mandel, S.; Geldenhuys, W. J.; Amit, T.; Avramovich, Y.; 
Zheng, H.; Fridkin, M.; Gal, S.; Weinreb, O.; Bar Am, O.; Sagi, Y.; Youdim, M. B. 
Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets 
and neuroprotective moieties. Curr. Alzheimer Res. 2007, 4 (5), 522-36. 
 Van Raamsdonk, J. M.; Warby, S. C.; Hayden, M. R. Selective degeneration in 
YAC mouse models of Huntington disease. Brain Res. Bull. 2007, 72 (2-3), 124-31. 
102 
 Vassar, R.; Kovacs, D. M.; Yan, R.; Wong, P. C. The β-Secretase Enzyme BACE 
in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic 
Potential. J. Neurosci. 2009, 29 (41), 12787-12794. 
 Viegas Jr, C.; Bolzani, V. d. S.; Barreiro, E. J.; Fraga, C. A. M. New Anti-
Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase 
Inhibitors. Mini Rev. Med. Chem. 2005, 5 (10), 915-926. 
 Voit, E. O. Biochemical and genomic regulation of the trehalose cycle in yeast: 
review of observations and canonical model analysis. J. Theor. Biol. 2003, 223 (1), 55-
78. 
 Walker, F. O. Huntington's disease. Lancet 2007, 369 (9557), 218-28. 
 Wang, H.-H.; Chou, C.-J.; Liao, J.-F.; Chen, C.-F. Dehydroevodiamine attenuates 
β-amyloid peptide-induced amnesia in mice. Eur. J. Pharmacol. 2001, 413 (2-3), 221-
225. 
 Wang, W.; Duan, W.; Igarashi, S.; Morita, H.; Nakamura, M.; Ross, C. A. 
Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease 
neuronal cell model. Neurobiol. Dis. 2005, 20 (2), 500-8. 
 Way, J. L. Cyanide intoxication and its mechanism of antagonism. Annu. Rev. 
Pharmacol. Toxicol. 1984, 24, 451-81. 
 Webster, N.; Pirrung, M. Small molecule activators of the Trk receptors for 
neuroprotection. BMC Neurosci. 2008, 9 (Suppl 2), S1. 
 Weljie, A. M.; Newton, J.; Mercier, P.; Carlson, E.; Slupsky, C. M. Targeted 
profiling: quantitative analysis of 1H NMR metabolomics data. Anal. Chem. 2006, 78 
(13), 4430-42. 
 Williams, R. B.; Gutekunst, W. R.; Joyner, P. M.; Duan, W.; Li, Q.; Ross, C. A.; 
Williams, T. D.; Cichewicz, R. H. Bioactivity profiling with parallel mass spectrometry 
reveals an assemblage of green tea metabolites affording protection against human 
huntingtin and alpha-synuclein toxicity. J. Agric. Food Chem. 2007, 55 (23), 9450-6. 
 Wolfgang, W. J.; Miller, T. W.; Webster, J. M.; Huston, J. S.; Thompson, L. M.; 
Marsh, J. L.; Messer, A. Suppression of Huntington's disease pathology in Drosophila by 
human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (32), 11563-8. 
 Wu, S.-L.; Sung, P.-J.; Su, J.-H.; Sheu, J.-H. Briaexcavatolides S-V, Four New 
Briaranes from a Formosan Gorgonian Briareum excavatum. J. Nat. Prod. 2003, 66 (9), 
1252-1256. 
 Yan, X.-Z. Isolation and identification of stilbene glycoside from Polygonum 
multiflorum Thunb. Shanghai Diyi Yixueyuan Xuebao 1981, 8 (2), 123-126. 
 Yuan, D.; Ma, B.; Wu, C.; Yang, J.; Zhang, L.; Liu, S.; Wu, L.; Kano, Y. 
Alkaloids from the leaves of Uncaria rhynchophylla and their inhibitory activity on NO 
production in lipopolysaccharide-activated microglia. J. Nat. Prod. 2008, 71 (7), 1271-4. 
 Yuen, E. C.; Mobley, W. C. Therapeutic potential of neurotrophic factors for 
neurological disorders. Ann. Neurol. 1996, 40 (3), 346-354. 
 Zangara, A. The psychopharmacology of huperzine A: an alkaloid with cognitive 
enhancing and neuroprotective properties of interest in the treatment of Alzheimer's 
disease. Pharmacol. Biochem. Behav. 2003, 75 (3), 675-686. 
 Zhang, L.; Xing, Y.; Ye, C.-F.; Ai, H.-X.; Wei, H.-F.; Li, L. Learning-memory 
deficit with aging in APP transgenic mice of Alzheimer's disease and intervention by 
using tetrahydroxystilbene glucoside. Behav. Brain Res. 2006, 173 (2), 246-254. 
103 
 Zhang, X.; Smith, D. L.; Meriin, A. B.; Engemann, S.; Russel, D. E.; Roark, M.; 
Washington, S. L.; Maxwell, M. M.; Marsh, J. L.; Thompson, L. M.; Wanker, E. E.; 
Young, A. B.; Housman, D. E.; Bates, G. P.; Sherman, M. Y.; Kazantsev, A. G. A potent 
small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and 
suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (3), 892-7. 
 
 
  
104 
Appendix 
 
 
  
A
B
25Q
103Q
Figure A1 False-color fluorescent 
microscopy images of yeast cells 
expressing human Htt fragments.   A) 
Yeast expressing Htt fragment with 25 
glutamine repeats.  B) Yeast 
expressing mHtt fragment with 103 
glutamine repeats.  Spot cultures (A, 
lower panel; B, lower panel) show a 
significant decrease in cell viability due 
to mutant huntingtin toxicity.  
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Figure A2 Comparison of metabolic changes in 
response to various toxins.  Potassium cyanide 
(KCN) and cycloheximide treatment cause 
distinct metabolic changes in 25Q yeast that are 
different from the changes caused by mHtt 
toxicity. 
Table A1  Structures of Metabolites with 
Metabolite 
4-aminobutyrate 
acetate 
adenosine 
adenosine triphosphate 
alanine 
arginine 
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Metabolite 
asparagine 
aspartate 
formate 
galactitol 
galactose 
glutamate 
glutamine 
glutathione 
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Metabolite 
glycerol 
histidine 
isoleucine 
leucine 
methionine 
Nicotinamide adenine 
dinucleotide 
(oxidized) 
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) 
Structure with 1H NMR Chemical Shifts and Multiplicities
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Metabolite 
phenylalanine 
proline 
propylene glycol 
succinate 
threonine 
trehalose 
tryptophan 
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) 
Structure with 1H NMR Chemical Shifts and Multiplicities
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Metabolite 
tyrosine 
valine 
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Structure with 1H NMR Chemical Shifts and Multiplicities
 
 
 
 
 
 Table A2 Metabolic Profiling Data for Selected Key Metabolites Identified in Studies of Huntington’s Disease Model Systems and Humans 
  
This study Nicoli et al. (1993)4 
Taylor-Robinson et 
al. (1996)5 
Reynolds et al. 
(2005)6 
Underwood et al. 
(2006)7 
Jenkins et al. 
(2000)8 
Jenkins et al. 
(2005)9 
Tsang et al. 
(2006)10 Tkac et al. (2007)
11 
Organism yeast human a, b human c, d human d human b, mouse b mouse c, d, e mouse c, d mouse b, c, e, f mouse c, d 
Data collection 
technique 
1H NMR 
1H NMR, 
HPLC 
1H MRS 1H MRS GC-TOF-MS 1H-NMR 1H MRS 
1H NMR, HR-MAS 
1H NMR in vivo 
1H NMR 
2-amino-n-butyrate ND ND ND ND significant g, h ND ND ND ND 
2-oxoglutarate ND ND ND ND ND ND ND increase ND 
4-aminobutyrate ns ns ND ND ND ns ND decrease ns 
acetate decrease ns ND ND ND ND ND decrease ND 
adenosine ns ND ND ND ND ND ND ND ND 
alanine decrease ns ND ND significant g, h ns ND decrease ND 
arginine ns ND ND ND ND ND ND ND ND 
ascorbate ND ND ND ND ND ND ND ND increase 
asparagine ns ND ND ND ND ND ND ND ND 
aspartate ns ns ND ND ND ns ND decrease ND 
ATP ns ND ND ND ND ND ND ND ND 
choline ND ND ns ND ND increase increase decrease ND 
citrate ND ns ND ND ND ND ND ND ND 
creatine ND ns ns decrease ND ns ns increase increase 
dimethylglycine ND ND ND ND ND ND ND decrease ND 
ethylene glycol ND ND ND ND significant g, h ND ND ND ND 
formate ns ND ND ND ND ND ND ND ND 
galactitol ns ND ND ND ND ND ND ND ND 
galactose increase ND ND ND ND ND ND ND ND 
glucose ND ND ND ND significant g, i increase ND ND ns 
glutamate ns ns increase increase ND decrease ns decrease increase 
glutamine increase ns increase increase ND increase ns increase increase 
glutathione ns ND ND ND ND ND ND ND increase 
glycerol increase ND ND ND significant g ND ND ND ND 
glycerophosphocholine ND ND ND ND ND ND ND increase increase 
glycine ND increase ND ND ND ns ND ns ND 
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 Table A2 Metabolic Profiling Data for Selected Key Metabolites Identified in Studies of Huntington’s Disease Model Systems and Humans (continued from 
page 110) 
  
This study Nicoli et al. (1993)4 
Taylor-Robinson et 
al. (1996)5 
Reynolds et al. 
(2005)6 
Underwood et al. 
(2006)7 
Jenkins et al. 
(2000)8 
Jenkins et al. 
(2005)9 
Tsang et al. 
(2006)10 Tkac et al. (2007)
11 
Organism yeast human a, b human c, d human d human b, mouse b mouse c, d, e mouse c, d mouse b, c, e, f mouse c, d 
Data collection 
technique 
1H NMR 
1H NMR, 
HPLC 
1H MRS 1H MRS GC-TOF-MS 1H-NMR 1H MRS 
1H NMR, HR-MAS 
1H NMR in vivo 
1H NMR 
histidine decrease ND ND ND ND ND ND ND ND 
isoleucine ns ns ND ND ND ND ND ND ND 
lactate ND ns ns increase significant g decrease ND increase ns 
leucine ns ns ND ND ND ND ND ND ND 
lysine ND ns ND ND ND ND ND ND ND 
malonate ND ND ND ND significant g ND ND ND ND 
methionine ns ND ND ND ND ND ND ND ND 
myo-inositol ND ND ND ns ND ns ND increase increase 
N-acetylaspartate ND ND ns decrease ND decrease decrease decrease decrease 
N-acetylaspartate 
glutamate ND ND ND ND ND ND ND increase/ decrease ns 
NAD+ ns ND ND ND ND ND ND ND ND 
phenylalanine ns ND ND ND ND ND ND ND ND 
phosphocholine ND ND ND ND ND ND ND decrease ns 
phosphocreatine ND ND ND ND ND ND ND ND increase 
phosphorylethanolamine ND ND ND ND ND ND ND ND decrease 
proline decrease ns ND ND ND ND ND ND ND 
propylene glycol ns ND ND ND ND ND ND ND ND 
pyroglutamate ND ND ND ND significant g, i ND ND ND ND 
pyruvate ND increase ND ND ND ND ND ND ND 
scyllo-inositol ND ND ND ND ND increase ND increase ND 
spermine ND ND ND ND ND ND ND decrease ND 
succinate decrease ND ND ND ND decrease ND decrease ND 
taurine ND ND ND ND ND increase increase increase increase 
threonine increase ND ND ND ND ND ND ND ND 
trehalose decrease ND ND ND ND ND ND ND ND 
  
111
 
 Table A2 Metabolic Profiling Data for Selected Key Metabolites Identified in Studies of Huntington’s Disease Model Systems and Humans (continued from 
page 111) 
  
This study Nicoli et al. (1993)4 
Taylor-Robinson et 
al. (1996)5 
Reynolds et al. 
(2005)6 
Underwood et al. 
(2006)7 
Jenkins et al. 
(2000)8 
Jenkins et al. 
(2005)9 
Tsang et al. 
(2006)10 Tkac et al. (2007)
11 
Organism yeast human a, b human c, d human d human b, mouse b mouse c, d, e mouse c, d mouse b, c, e, f mouse c, d 
Data collection 
technique 
1H NMR 
1H NMR, 
HPLC 
1H MRS 1H MRS GC-TOF-MS 1H-NMR 1H MRS 
1H NMR, HR-MAS 
1H NMR in vivo 
1H NMR 
trimethylamine ND ND ND ND ND ND ND decrease ND 
trimethylamine N-oxide ND ND ND ND ND ND ND increase ND 
tryptophan ns ND ND ND ND ND ND ND ND 
tyrosine ns ND ND ND ND ND ND ND ND 
urea ND ND ND ND significant g ND ND ND ND 
valine increase ND ND ND significant g ND ND ND ND 
α-hydroxybutyric acid ND ND ND ND significant g, h ND ND ND ND 
α-ketoisocaproate ND ND ND ND ND ND ND decrease ND 
Abbreviations: ND = Not detected or not reported, ns = not significant, MRS = magnetic resonance spectroscopy, HR-MAS = high-resolution magic angle spinning, HPLC = high performance liquid 
chromatography.  a Cerebrospinal fluid.  b Serum.  c Results from multiple tissue types summarized in this table.  d In vivo brain.  e In vitro brain.  f Urine. g Direction of change (increase/decrease) not 
reported.  h Detected only in human serum. 
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Table A3 Contingency Table of Metabolic Studies of Mutant Huntingtin Toxicity 
Metabolite Yeast Human Mouse TOTALS 
2-amino-n-butyrate 0 1 0 1 
2-oxoglutarate 0 0 1 1 
4-aminobutyrate 0 0 1 1 
acetate 1 0 1 2 
alanine 1 1 1 3 
ascorbate 0 0 1 1 
aspartate 0 0 1 1 
choline 0 0 3 3 
creatine 0 1 2 3 
dimethylglycine 0 0 1 1 
ethylene glycol 0 1 0 1 
galactitol 1 0 0 1 
glucose 0 0 2 2 
glutamate 0 2 3 5 
glutamine 1 2 3 6 
glutathione 0 0 1 1 
glycerol 1 1 1 3 
glycerophosphocholine 0 0 2 2 
glycine 0 1 0 1 
histidine 1 0 0 1 
lactate 0 2 3 5 
malonate 0 1 1 2 
myo-inositol 0 0 2 2 
N-acetylaspartate 0 1 4 5 
phosphocholine 0 0 1 1 
phosphocreatine 0 0 1 1 
phosphorylethanolamine 0 0 1 1 
proline 1 0 0 1 
pyroglutamate 0 0 1 1 
pyruvate 0 1 0 1 
scyllo-inositol 0 0 2 2 
spermine 0 0 1 1 
succinate 1 0 2 3 
taurine 0 0 4 4 
threonine 1 0 0 1 
trehalose 1 0 0 1 
trimethylamine 0 0 1 1 
trimethylamine N-oxide 0 0 1 1 
urea 0 1 1 2 
valine 1 1 1 3 
alpha-hydroxybutyric acid 0 1 0 1 
alpha-ketoisocaproate 0 0 1 1 
TOTALS 11 18 52 81 
 Table A4 NMR Spectroscopic Data (CDCl3) for RAM A (2) 
 
 
 
 
 
 
 
 
 
 
 
aData determined at 100 MHz 
bDetermined by HSQC experiment at 500 MHz 
cData determined at 500 MHz 
  
position δC,a mult.b δH (J in Hz)c COSYc HMBCc NOESYc 
1 48.2, C     
2 77.4, CH 3.25, dd (5.5, 7.0) 3a, 2-OH 4, 10, 15 16, 10 
3a 40.1, CH2 2.00, m 2, 3b, 4 2, 4, 5 3b 
3b  2.84, t (13.0) 3a, 4 1, 2, 4, 5 3a, 7 
4 72.8, CH 5.16, ddd (1.0, 5.5, 13.0) 3a 3, 6, 5, 16, 4-OCOCH3 16 
5 144.2, C     
6 122.5, CH 5.41, dt (1.3, 9.5) 7, 16 4, 16 16 
7 73.6, CH 5.78, d (9.5) 6, 12-OCOCH3 5, 6, 19 3b 
8 71.3, C     
9 65.1, CH 5.92, d (4.0) 10 1, 8, 12, 17, 9-OCOCH3 18, 20 
10 44.6, CH 2.46, d (4.0) 9 1, 2, 8, 9, 11, 12, 15, 20 2 
11 72.4, C     
12 73.5, CH 4.73, d (6.0) 13 9, 10, 11, 13, 14, 20, 12-OCOCH3 13, 20 
13 121.9, CH 5.96, dd (6.0, 10.3) 12, 14 1, 11 12 
14 142.0, CH 5.89, d (10.3) 13 1, 2, 10, 12, 15 15, 2-OH 
15 14.0, CH3 1.13, s  1, 2, 10, 13, 14 14, 20, 9-OCOCH3 
16 26.5, CH3 2.04, d (1.3) 6 4, 5, 6 2, 4, 6 
17 64.8, C     
18 9.7, CH3 1.67, s  8, 10, 17, 19 9 
19 170.4, C     
20 21.2, CH3 1.21, s 11-OH 4, 10 9, 12, 15, 2-OH 
4-OCOCH3 170.3, C     
4-OCOCH3 21.0, CH3 2.08, s  4-OCOCH3  
9-OCOCH3 168.3, C     
9-OCOCH3 21.6, CH3 2.24, s  9, 9-OCOCH3 15 
12-OCOCH3 169.8, C     
12-OCOCH3 20.9, CH3 2.06, s 7 12-OCOCH3  
2-OH  2.14, d (5.5) 2 2, 3 14, 20 
11-OH  2.38, s 20 11, 20 9 (vw), 12 (w) 
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 Table A5 NMR Spectroscopic Data (CDCl3) for RAM B (3) 
position δC, a mult.b δH (J in Hz)c COSYc HMBCc INADEQUATEa NOESYd 
1 48.2, C    2, 10, 14  
2 77.5, CH 3.27, dd (5.0, 7.0) 3a 15 1, 3 10, 16 
3a 40.2, CH2 2.00, m 2, 3b 2 2, 4 3b, 4, 7, 15 
3b  2.84, dd (13.0, 14.3) 3a, 4 1, 2, 5  3a, 7, 15 
4 72.5, CH 5.17, dd (5.0, 7.0, 13.0) 3b 3, 5, 6, 16, 1’ 3 3a 
5 144.3, C    16  
6 122.4, CH 5.41, dt (1.3, 9.5) 7, 16 16   
7 73.6, CH 5.78, d (9.5) 6 5, 6, 19  3a, 3b 
8 71.4, C      
9 65.2, CH 5.92, d (3.8) 10 8, 9-OCOCH3  10, 18, 20 
10 44.7, CH 2.47, d (3.8) 9, 11-OH 1, 2, 8, 9, 11, 15, 20  2, 9 
11 72.6, C      
12 73.5, CH 4.75, d  (6.0) 13 10, 11, 13, 14, 12-OCOCH3 13 13, 20 
13 122.1, CH 5.97, dd (6.0, 10.3) 12, 14 1 12 12 
14 141.9, CH 5.89, d (10.3) 13 1, 10, 15  15 
15 14.1, CH3 1.13, s  1, 2, 14  3a, 3b, 14, 20 9-OCOCH3 
16 26.5, CH3 2.05, d (1.3) 6  5 2 
17 64.9, C      
18 9.7, CH3 1.69, s  8, 17, 19  9 
19 170.4, C      
20 21.2, CH3 1.22, s    9, 12, 15 
1’ 173.2, C    2’  
2’ 34.2, CH2 2.32, t (7.5) 23 1’, 3’, 4’ 1’, 3’  
3’ 24.5, CH2 1.64, m 22, 24 1’, 2’, 4’, 5’ 2’, 4’  
4’ 31.2, CH2 1.32, m  5’ 3’, 5’  
5’ 22.3, CH2 1.32, m 26 4’ 4’, 6’  
6’ 13.9, CH3 0.90, t (7.0) 25 4’, 5’ 5’  
9-OCOCH3 168.3, C      
9-OCOCH3 21.6, CH3 2.24, s  9-OCOCH3  15 
12-OCOCH3 169.8, C      
12-OCOCH3 20.9, CH3 2.07, s  11, 12-OCOCH3   
11-OH  2.39, br s 10, 20 20   
2-OH  4.87, br s     
aData determined at 100 MHz 
bDetermined by HSQC experiment at 400 MHz 
cData determined at 400 MHz 
dData determined at 500 MHz 
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 Table A6 NMR Spectroscopic Data (CDCl3) for RAM C (4) 
position δC, a mult.b δH (J in Hz)c COSYd HMBCd NOESYc 
1 48.2, C     
2 77.5, CH 3.26, t (7.5) 3a 15, 3, 10, 1  
3a 40.2, CH2 2.00, m 2, 3b, 4 4, 2 2, 3b, 4, 7, 15 
3b  2.85, dd (12.7, 14.3) 3a, 4 1, 4, 2, 5 2, 3b, 4, 6, 7, 9, 10, 15, 9-OCOCH3 
4 72.5, CH 5.17, ddd (1.0, 5.5, 12.7) 3a, 3b 16, 6, 5 2, 3a, 3b, 7, 16 
5 144.4, C     
6 122.4, CH 5.40, dt (1.5, 9.5) 7, 16 16, 4 10, 16 
7 73.6, CH 5.78, d (9.5) 6 9, 6, 5, 19 3b,  9-OCOCH3 
8 71.4, C     
9 65.2, CH 5.92, d (4.0) 10 8, 9-OCOCH3  
10 44.7, CH 2.47, d (4.0) 9 15, 20, 1, 9, 8, 11, 2 2, 6, 9 
11 72.6, C     
12 73.5, CH 4.74, d (6.0) 13 20, 10, 11, 13, 14, 12-OCOCH3 10, 13, 14, 20, 11-OH 
13 122.0, CH 5.96, dd (6.0, 10.3) 12, 14 1, 4 12, 15, 20 
14 142.0, CH 5.89, d (10.3) 13 15, 10, 1, 12, 2 2, 12, 15, 20, 11-OH 
15 14.1, CH3 1.13, s  10, 1, 2, 14 14, 16, 18, 9-OCOCH3, 12-OCOCH3 
16 26.5, CH3 2.05, d (1.5) 6 4, 5, 6  
17 64.9, C     
18 9.7, CH3 1.68, s  17, 8, 19 9 
19 170.4, C     
20 21.2, CH3 1.22, s 11-OH 10, 11, 12 9, 15 
1’ 173.1, C     
2’ 34.2, CH2 2.32, t (7.5) 3’ 1’, 3’, 4’ 3’, 4’, 7 
3’ 24.8, CH2 1.62, m 2’, 4’ 1’, 2’, 4’  
4’ 29.0, CH2 1.31 3’ 5’  
5’ 28.9, CH2 1.31    
6’ 31.6, CH2 1.29  8’  
7’ 22.6, CH2 1.28 8’   
8’ 14.1, CH3 0.88, t (7.0) 7’ 6’, 7’  
9-OCOCH3 168.3, C     
9-OCOCH3 21.6, CH3 2.24, s  9-OCOCH3 15, 16, 18, 20, 12-OCOCH3, 2-OH 
12-OCOCH3 169.8, C     
12-OCOCH3 20.9, CH3 2.06, s  12-OCOCH3  
11-OH  2.39, br s 20   
2-OH  2.63, br s    
aData determined at 100 MHz 
bDetermined by HSQC experiment at 400 MHz. 
cData determined at 500 MHz 
dData determined at 400 MHz 
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 Table A7 NMR Spectroscopic Data (CDCl3) for RAM A-M1 (5) 
position δC, a mult.b δH (J in Hz)c COSYd HMBCd NOESYc 
1 48.0, C     
2 77.7, CH 3.32, d (7.7) 3a 15 10, 16 
3a 40.1, CH2 2.00 2, 3b, 4 4, 2, 5 3b, 15 
3b  2.83, dd (12.5, 14.0) 3a, 4 1, 4 3a, 7, 15 
4 72.9, CH 5.17, ddd (12.5, 5.5, 1.0) 3a, 3b 16, 3, 6, 5, 4-OCOCH3 16 
5 144.2, C     
6 122.4, CH 5.39, dt (9.5, 1.5) 7, 16 16, 4 7, 16 
7 73.9, CH 5.78, d (9.5) 6 5, 19 3b, 6 
8 71.4, C     
9 65.6, CH 5.92, d (3.4) 10 10, 1, 17, 12, 8, 7, 9-OCOCH3 18, 20, 11-OH 
10 44.0, CH 2.40, d (3.4) 9 15, 20, 1, 9, 8, 7, 2 2, 11-OH 
11 77.2, C     
12 70.6, CH 3.75, d (6.0) 13 10, 13, 14 13, 20 
13 124.4, CH 5.90, dd (10.3, 6.0) 12, 14 1, 12, 7 12 
14 140.0, CH 5.83, d (10.3) 13 15, 10, 1, 12, 2 15 
15 14.1, CH3 1.13, s  10, 1, 2, 14 3a, 3b, 14, 9-OCOCH3 
16 26.6, CH3 2.04, d (1.5) 6 4, 6, 5 2, 4, 6 
17 64.9, C     
18 9.8, CH3 1.71, s  17, 8, 19 9 
19 170.5, C     
20 21.4, CH3 1.17, s  10, 12, 7 9, 12 
4-OCOCH3 170.2, C     
4-OCOCH3 21.1, CH3 2.09, s  4-OCOCH3  
9-OCOCH3 168.3, C     
9-OCOCH3 21.6, CH3 2.25, s  9-OCOCH3 15 
11-OH  2.65, br s  20 9, 10 
aData determined at 100 MHz 
bDetermined by HSQC experiment at 400 MHz. 
cData determined at 500 MHz 
dData determined at 400 MHz 
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 Table A8 NMR Spectroscopic Data (CDCl3) for RAM B-M1 (6) 
position δC,a mult.b δH (J in Hz)c COSYd HMBCc NOESYc 
1 48.0, C     
2 77.6, CH 3.32, d (7.3) 3a 3, 4, 10, 15 10, 16 
3a 40.1, CH2 2.00 m 3b, 2, 4 2, 4, 5 3b 
3b  2.83, dd (12.4, 14.5) 3a, 4 1, 4 3a, 7, 15 
4 72.8, CH 5.17, dd (5.4, 12.4) 3a, 3b 5, 6, 16, 1’ 16 
5 144.3, C     
6 122.3, CH 5.38, dt (9.5, 1.2) 16, 7 4, 16 7, 16 
7 73.8, CH 5.76, d (9.5) 6 5, 6, 19 3b, 6 
8 71.4, C     
9 65.6, CH 5.92, d (3.5) 10 1, 7, 8, 10, 9-OCOCH3 10, 18, 20, 11-OH 
10 44.0, CH 2.40, d (3.5) 20, 9 1, 2, 7, 8, 9, 15, 20 2, 9, 11-OH 
11 73.9, C     
12 70.6, CH 3.75, d (6.0) 13 10, 11, 13, 14, 20 13, 14, 20 
13 124.2, CH 5.90, dd (6.0, 10.2) 12, 14 11, 12 12, 14 
14 140.1, CH 5.84, d (10.2) 13 1, 10, 12, 15 12, 13, 15 
15 14.1, CH3 1.13, s   3b, 14, 9-OCOCH3 
16 26.6, CH3 2.04, d (1.2) 6 4,5,  6 2, 4, 6 
17 64.9, C     
18 9.8, CH3 1.70, s  8, 17, 19 9 
19 170.5, C     
20 21.4, CH3 1.16, s 10 10, 11, 12 9, 12 
1’ 173.1, C     
2’ 34.2, CH2 2.32, t, 7.4 3’ 1’, 3’, 4’ 3’ 
3’ 24.6, CH2 1.63, m, 7.4 2’, 4’ 1’, 2’, 4’, 5’ 2’, 4’ 
4’ 31.2, CH2 1.32, m 3’ 5’ 3’ 
5’ 22.3, CH2 1.32, m 6’ 4’ 6’ 
6’ 13.9, CH3 0.90, t (7.0) 5’ 4’, 5’ 5’ 
9-OCOCH3 168.3, C     
9-OCOCH3 21.6, CH3 2.24, s  9-OCOCH3  
11-OH  2.67, br. s  11, 20 9, 10 
aData determined at 100 MHz 
bDetermined by HSQC experiment at 500 MHz. 
cData determined at 500 MHz 
dData determined at 400 MHz 
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 Table A9 NMR Spectroscopic Data (CDCl3) for RAM C-M1 (7) 
position δC,a mult.b δH (J in Hz)c COSYd HMBCc NOESYc 
1 48.0, C     
2 77.7, CH 3.33, d (7.0) 3a 4, 15 10, 16 
3a 40.1, CH2 2.00, m 2, 3b, 4 2, 4, 5 3b, 15 
3b  2.83, dd (12.5, 14.0) 3a, 4 1, 2, 4 3a, 7, 15 
4 72.7, CH 5.17, dd (5.4, 12.5) 3a, 3b 3a, 5, 6, 16, 1’ 16 
5 144.3, C     
6 122.3, CH 5.38, d (9.4) 7, 16 4, 16 7, 16 
7 73.7, CH 5.76, d (9.4) 6 5, 6, 19 3b, 6 
8 71.4, C     
9 65.6, CH 5.92, d (3.0) 10 8, 11 18, 20, 11-OH 
10 44.0, CH 2.40, d (3.0) 9 1, 2, 8, 11, 15, 20  
11 73.9, C     
12 70.6, CH 3.75, d (6.0) 13 10, 11, 13, 14, 20 20 
13 124.3, CH 5.90, dd (6.0, 10.4) 12, 14 9-OCOCH3 14 
14 140.1, CH 5.84, d (10.4) 13 1, 10, 12 13, 15 
15 14.1, CH3 1.13, s  1, 2, 10, 14 3a, 3b, 14, 9-OCOCH3 
16 26.6, CH3 2.04, s 6 4, 5, 6 2, 4, 6 
17 64.9, C     
18 9.8, CH3 1.71, s  8, 17, 19 9 
19 170.5, C     
20 21.4, CH3 1.17, s  10, 11, 12 9, 12 
1’ 173.1, C     
2’ 34.3, CH2 2.32, t (7.5) 3’ 1’, 3’, 4’ 3’ 
3’ 24.9, CH2 1.63, m 2’,4’ 1’, 2’, 4’ 2’ 
4’ 29.0, CH2 1.31, m 3’ 5’  
5’ 28.9, CH2 1.31, m    
6’ 31.6, CH2 1.27, m    
7’ 22.6, CH2 1.29, m 8’ 8’ 8’ 
8’ 14.07, CH3 0.88, t (7.5) 7’ 6’, 7’ 7’ 
9-OCOCH3 168.3, C     
9-OCOCH3 21.6, CH3 2.24, s  9-OCOCH3  
11-OH  2.67, br. s  11, 20  
aData determined at 100 MHz 
bDetermined by HSQC experiment at 500 MHz. 
cData determined at 500 MHz 
dData determined at 400 MHz 
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Table A10 Crystallographic data and structure refinement for RAM A (2).  Data was 
collected and interpreted by Dr. Douglas Powell in the Department of Chemistry and 
Biochemistry at the University of Oklahoma. 
Empirical formula C26 H34 O11 
Formula weight 522.53 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions 
a = 9.724(2) Å      α= 90° 
b = 14.873(3) Å    β= 115.539(8)° 
c = 10.233(2) Å    γ= 90° 
Volume 1335.3(5) Å3 
Z, Z' 2, 1 
Density (calculated) 1.300 Mg/m3 
Wavelength 0.71073 Å 
Temperature 100(2) K 
F(000) 556 
Absorption coefficient Semi-empirical from equivalents 
Max. and min. transmission 0.979 and 0.961 
Theta range for data collection 2.21 to 26.00° 
Reflections collected 11814 
Independent reflections 5239 [R(int) = 0.0258] 
Data / restraints / parameters 5239 / 1 / 340 
wR(F2 all data) wR2 = 0.0766 
R(F obsd data) R1 = 0.0331 
Goodness-of-fit on F2 1.005 
Observed data [I > 2σ(I)] 4977 
Absolute structure parameter 0.3(6) 
Largest and mean shift / s.u. 0.000and 0.000 
Largest diff. peak and hole 0.177 and -0.175 e/Å3 
wR2 = ( Σ [w(Fo2 - Fc2)2] / Σ [w(Fo 2)2] )1/2  
R1 = Σ ||Fo| - |Fc|| / Σ |Fo| 
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Figure A3 HRESIMS of RAM A (2) 
 
Figure A4 1H-NMR spectrum (500 MHz, CDCl3) of RAM A (2)  
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Figure A5 13C-NMR spectrum (125 MHz, CDCl3) of RAM A (2) 
 
Figure A6 HSQC-NMR spectrum (500 MHz, CDCl3) of RAMA (2)  
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Figure A7 HMBC-NMR spectrum (500 MHz, CDCl3) of RAM A (2) 
 
Figure A8 COSY-NMR spectrum (500 MHz, CDCl3) of RAM A (2)  
Figure A9 NOESY-NMR spectrum (
Figure A10 HRESIMS of 
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500 MHz, CDCl3) of RAM A (2) 
RAM B (3)  
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Figure A11 1H-NMR spectrum (400 MHz, CDCl3) of RAM B (3) 
 
Figure A12 13C-NMR spectrum (100 MHz, CDCl3) of RAM B (3)  
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Figure A13 HSQC-NMR spectrum (400 MHz, CDCl3) of RAM B (3) 
 
Figure A14 HMBC-NMR spectrum (400 MHz, CDCl3) of RAM B (3)  
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Figure A15 COSY-NMR spectrum (400 MHz, CDCl3) of RAM B (3) 
 
Figure A16 NOESY-NMR spectrum (500 MHz, CDCl3) of RAM B (3)  
Figure A17 INADEQUATE
Figure A18 HRESIMS of 
128 
-NMR spectrum (400 MHz, CDCl3) of RAM
RAM C (4)  
 
 B (3) 
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Figure A19 1H-NMR spectrum (500 MHz, CDCl3) of RAM C (4) 
 
Figure A20 13C-NMR (100 MHz, CDCl3) of RAM C (4)  
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Figure A21 HSQC-NMR spectrum (400 MHz, CDCl3) of RAM C (4) 
 
Figure A22 HMBC-NMR spectrum (400 MHz, CDCl3) of RAM  C (4)  
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Figure A23 COSY-NMR spectrum (400 MHz, CDCl3) of RAM C (4) 
 
Figure A24 NOESY-NMR spectrum (500 MHz, CDCl3) of RAM C (4)  
Table A11 Crystallographic data and structure refinement
collected and interpreted by Dr. Douglas Powell in the Department of Chemistry and 
Biochemistry at the University of Oklahoma.
Empirical formula 
Formula weight 
Crystal system 
Space group 
Unit cell dimensions 
Volume 
Z, Z' 
Density (calculated) 
Wavelength 
Temperature 
F(000) 
Absorption coefficient 
Max. and min. transmission
Theta range for data collection
Reflections collected 
Independent reflections 
Data / restraints / parameters
wR(F2 all data) 
R(F obsd data) 
Goodness-of-fit on F2 
Observed data [I > 2σ(I)] 
Absolute structure parameter
Largest and mean shift / s.u.
Largest diff. peak and hole 
wR2 = ( Σ [w(Fo2 - Fc2)2] / 
R1 = Σ ||Fo| - |Fc|| / Σ |Fo 
Figure A25 HRESIMS of 
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 for RAM A-M1
 
(C24 H32 O10) ⋅ (H2 O) 
C24 H34 O11 
498.51 
Orthorhombic 
P212121 
a = 8.0444(16) Å   α= 90° 
b = 16.005(3) Å     β= 90° 
c = 18.919(6) Å     γ= 90° 
2435.8(10) Å3 
4, 1 
1.359 Mg/m3 
0.71073 Å 
100(2) K 
1064 
Semi-empirical from equivalents 
 0.995 and 0.955 
 1.67 to 26.00° 
2721 
2721 [R(int) = 0.0000] 
 2721 / 0 / 316 
wR2 = 0.1950 
R1 = 0.0817 
1.147 
2270 
 0(3) 
 0.000and 0.000 
0.379 and -0.324 e/Å3 
Σ [w(Fo 2)2] )1/2 
 
RAM A-M1 (5) 
 (2).  Data was 
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Figure A26 1H-NMR (500 MHz, CDCl3) of RAM A-M1 (5) 
 
Figure A27 13C-NMR (100 MHz, CDCl3) of RAM A-M1 (5)  
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Figure A28 HSQC-NMR (400 MHz, CDCl3) of RAM A-M1 (5) 
 
Figure A29 HMBC-NMR (400 MHz, CDCl3) of RAM A-M1 (5)  
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Figure A30 COSY-NMR (400 MHz, CDCl3) of RAM A-M1 (5) 
 
Figure A31 NOESY-NMR (400 MHz, CDCl3) of RAM A-M1 (5)   
Figure A32 HRESIMS of 
Figure A33 1H-NMR (500 MHz, CDCl
136 
RAM B-M1 (6) 
3) of RAM B-M1 (6) 
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Figure A34 13C-NMR (100 MHz, CDCl3) of RAM B-M1 (6) 
 
Figure A35 HSQC-NMR (500 MHz, CDCl3) of RAM B-M1 (6)  
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Figure A36 HMBC-NMR (500 MHz, CDCl3) of RAM B-M1 (6) 
 
Figure A37 COSY-NMR (400 MHz, CDCl3) of RAM B-M1 (6)  
Figure A38 NOESY-NMR (500 MHz, CDCl
Figure A39 HRESIMS of 
139 
3) of RAM B-M1 (6) 
RAM C-M1 (7)  
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Figure A40 1H-NMR (500 MHz, CDCl3) of RAM C-M1 (7) 
 
 
Figure A41 13C-NMR (100 MHz, CDCl3) of RAM C-M1 (7) 
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Figure A42 HSQC-NMR (500 MHz, CDCl3) of RAM C-M1 (7) 
 
Figure A43 HMBC-NMR (500 MHz, CDCl3) of RAM C-M1 (7)  
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Figure A44 COSY-NMR (400 MHz, CDCl3) of RAM C-M1 (7) 
 
Figure A45 NOESY-NMR (500 MHz, CDCl3) of RAM C-M1 (7) 
